Comparison of the effectiveness of interferon in chronic myeloproliferative disorders.
\\n\\n
\\n"}]',published:!0,mainMedia:{caption:"Milestone",originalUrl:"/media/original/124"}},components:[{type:"htmlEditorComponent",content:'
Barely three months into the new year and we are happy to announce a monumental milestone reached - 150 million downloads.
\n\nThis achievement solidifies IntechOpen’s place as a pioneer in Open Access publishing and the home to some of the most relevant scientific research available through Open Access.
\n\nWe are so proud to have worked with so many bright minds throughout the years who have helped us spread knowledge through the power of Open Access and we look forward to continuing to support some of the greatest thinkers of our day.
\n\nThank you for making IntechOpen your place of learning, sharing, and discovery, and here’s to 150 million more!
\n\n\n\n\n'}],latestNews:[{slug:"intechopen-supports-asapbio-s-new-initiative-publish-your-reviews-20220729",title:"IntechOpen Supports ASAPbio’s New Initiative Publish Your Reviews"},{slug:"webinar-introduction-to-open-science-wednesday-18-may-1-pm-cest-20220518",title:"Webinar: Introduction to Open Science | Wednesday 18 May, 1 PM CEST"},{slug:"step-in-the-right-direction-intechopen-launches-a-portfolio-of-open-science-journals-20220414",title:"Step in the Right Direction: IntechOpen Launches a Portfolio of Open Science Journals"},{slug:"let-s-meet-at-london-book-fair-5-7-april-2022-olympia-london-20220321",title:"Let’s meet at London Book Fair, 5-7 April 2022, Olympia London"},{slug:"50-books-published-as-part-of-intechopen-and-knowledge-unlatched-ku-collaboration-20220316",title:"50 Books published as part of IntechOpen and Knowledge Unlatched (KU) Collaboration"},{slug:"intechopen-joins-the-united-nations-sustainable-development-goals-publishers-compact-20221702",title:"IntechOpen joins the United Nations Sustainable Development Goals Publishers Compact"},{slug:"intechopen-signs-exclusive-representation-agreement-with-lsr-libros-servicios-y-representaciones-s-a-de-c-v-20211123",title:"IntechOpen Signs Exclusive Representation Agreement with LSR Libros Servicios y Representaciones S.A. de C.V"},{slug:"intechopen-expands-partnership-with-research4life-20211110",title:"IntechOpen Expands Partnership with Research4Life"}]},book:{item:{type:"book",id:"6598",leadTitle:null,fullTitle:"Wearable Technologies",title:"Wearable Technologies",subtitle:null,reviewType:"peer-reviewed",abstract:"This edited volume Wearable Technologies is a collection of reviewed and relevant research chapters, offering a comprehensive overview of recent developments in the field of computer engineering. The book comprises single chapters authored by various researchers and edited by an expert active in the computer engineering research area. All chapters are complete in themselves but united under a common research study topic. This publication aims at providing a thorough overview of the latest research efforts.",isbn:"978-1-78984-004-9",printIsbn:"978-1-78984-003-2",pdfIsbn:"978-1-83881-580-6",doi:"10.5772/intechopen.71472",price:119,priceEur:129,priceUsd:155,slug:"wearable-technologies",numberOfPages:268,isOpenForSubmission:!1,isInWos:null,isInBkci:!1,hash:"90c456078d3c654876b0af2946804b7c",bookSignature:"Jesús Hamilton Ortiz",publishedDate:"October 3rd 2018",coverURL:"https://cdn.intechopen.com/books/images_new/6598.jpg",numberOfDownloads:14893,numberOfWosCitations:18,numberOfCrossrefCitations:24,numberOfCrossrefCitationsByBook:2,numberOfDimensionsCitations:39,numberOfDimensionsCitationsByBook:2,hasAltmetrics:1,numberOfTotalCitations:81,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"October 13th 2017",dateEndSecondStepPublish:"November 3rd 2017",dateEndThirdStepPublish:"January 5th 2018",dateEndFourthStepPublish:"March 23rd 2018",dateEndFifthStepPublish:"May 22nd 2018",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6,7",editedByType:"Edited by",kuFlag:!1,featuredMarkup:null,editors:[{id:"97704",title:"Dr.",name:"Jesús Hamilton",middleName:null,surname:"Ortiz",slug:"jesus-hamilton-ortiz",fullName:"Jesús Hamilton Ortiz",profilePictureURL:"https://mts.intechopen.com/storage/users/97704/images/3096_n.jpg",biography:"Jesus Hamilton Ortiz obtained his bachelor degree in mathematics at the Santiago de Cali University, DEA in Telecommunication engineering in Madrid Technical University, PhD in Computer Engineering in Castilla La Mancha University and PhD (c) in Telecommunication engineering from Madrid Autonomous University. He was previously assistant professor and full researcher at the Castilla La Mancha University, Jesus is CEO Close mobile R&D. In addition to this, Jesus is associate editor in IEEE, author, reviewer, editor in different topics about mobile ad hoc networks, telecommunication networks, wearables, etc. Currently, he is working on R&D projects on swarm of UAVs, swarm AUVs, RPAs, IoT an industry 4.0.",institutionString:"Close mobile R&D",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"0",totalChapterViews:"0",totalEditedBooks:"5",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"758",title:"Sensor Technology",slug:"electrical-and-electronic-engineering-sensor-technology"}],chapters:[{id:"61315",title:"Advances in Wearable Sensing Technologies and Their Impact for Personalized and Preventive Medicine",doi:"10.5772/intechopen.76916",slug:"advances-in-wearable-sensing-technologies-and-their-impact-for-personalized-and-preventive-medicine",totalDownloads:1330,totalCrossrefCites:1,totalDimensionsCites:3,hasAltmetrics:1,abstract:"Recent advances in miniaturized electronics, as well as mobile access to computational power, are fostering a rapid growth of wearable technologies. In particular, the application of such wearable technologies to health care enables to access more information from the patient than standard episodically testing conducted in health provider centres. Clinical, behavioural and self-monitored data collected by wearable devices provide a means for improving the early-stage detection and management of diseases as well as reducing the overall costs over more invasive standard diagnostics approaches. In this chapter, we will discuss some of the ongoing key innovations in materials science and micro/nano-fabrication technologies that are setting the basis for future personalized and preventive medicine devices and approaches. The design of wire- and power-less ultra-thin sensors fabricated on wearable biocompatible materials that can be placed in direct contact with the body tissues such as the skin will be reviewed, focusing on emerging solutions and bottlenecks. The application of nanotechnology for the fabrication of sophisticated miniaturized sensors will be presented. Exemplary sensor designs for the non-invasive measurement of ultra-low concentrations of important biomarkers will be discussed as case studies for the application of these emerging technologies.",signatures:"Noushin Nasiri and Antonio Tricoli",downloadPdfUrl:"/chapter/pdf-download/61315",previewPdfUrl:"/chapter/pdf-preview/61315",authors:[{id:"234150",title:"Dr.",name:"Noushin",surname:"Nasiri",slug:"noushin-nasiri",fullName:"Noushin Nasiri"},{id:"236706",title:"Prof.",name:"Antonio",surname:"Tricoli",slug:"antonio-tricoli",fullName:"Antonio Tricoli"}],corrections:null},{id:"60508",title:"A Proposal for New Algorithm that Defines Gait-Induced Acceleration and Gait Cycle in Daily Parkinsonian Gait Disorders",doi:"10.5772/intechopen.75483",slug:"a-proposal-for-new-algorithm-that-defines-gait-induced-acceleration-and-gait-cycle-in-daily-parkinso",totalDownloads:991,totalCrossrefCites:2,totalDimensionsCites:2,hasAltmetrics:0,abstract:"We developed a new device, the portable gait rhythmogram (PGR), to record up to 70 hrs of movement-induced accelerations. Acceleration values induced by various movements, averaged every 10 min, showed gamma distribution, and the mean value of this distribution was used as an index of the amount of overall movements. Furthermore, the PGR algorithm can specify gait-induced accelerations using the pattern-matching method. Analysis of the relationship between gait-induced accelerations and gait cycle duration makes it possible to quantify Parkinson’s disease (PD)-specific pathophysiological mechanisms underlying gait disorders. Patients with PD showed the following disease-specific patterns: (1) reduced amount of overall movements and (2) low amplitude of gait-induced accelerations in the early stages of the disease, which was compensated by fast stepping. Loss of compensation was associated with slow stepping gait, (3) narrow range of gait-induced acceleration amplitude and gait cycle duration, suggesting monotony, and (4) evident motor fluctuations during the day by tracing changes in the above two parameters. Prominent motor fluctuation was associated with frequent switching between slow stepping mode and active mode. These findings suggest that monitoring various movement- and gait-induced accelerations allows the detection of specific changes in PD. We conclude that continuous long-term monitoring of these parameters can provide accurate quantitative assessment of parkinsonian clinical motor signs.",signatures:"Masahiko Suzuki, Makiko Yogo, Masayo Morita, Hiroo Terashi,\nMutsumi Iijima, Mitsuru Yoneyama, Masato Takada, Hiroya Utsumi,\nYasuyuki Okuma, Akito Hayashi, Satoshi Orimo and Hiroshi Mitoma",downloadPdfUrl:"/chapter/pdf-download/60508",previewPdfUrl:"/chapter/pdf-preview/60508",authors:[{id:"210486",title:"Prof.",name:"Hiroshi",surname:"Mitoma",slug:"hiroshi-mitoma",fullName:"Hiroshi Mitoma"},{id:"227967",title:"Dr.",name:"Masahiko",surname:"Suzuki",slug:"masahiko-suzuki",fullName:"Masahiko Suzuki"},{id:"229488",title:"Prof.",name:"Hiroo",surname:"Terashi",slug:"hiroo-terashi",fullName:"Hiroo Terashi"},{id:"240961",title:"Dr.",name:"Makiko",surname:"Yogo",slug:"makiko-yogo",fullName:"Makiko Yogo"},{id:"240962",title:"Dr.",name:"Masayo",surname:"Morita",slug:"masayo-morita",fullName:"Masayo Morita"},{id:"240964",title:"Prof.",name:"Mutsumi",surname:"Iijima",slug:"mutsumi-iijima",fullName:"Mutsumi Iijima"},{id:"240966",title:"Prof.",name:"Yasuyuki",surname:"Okuma",slug:"yasuyuki-okuma",fullName:"Yasuyuki Okuma"},{id:"240967",title:"Dr.",name:"Satoshi",surname:"Orimo",slug:"satoshi-orimo",fullName:"Satoshi Orimo"},{id:"240968",title:"Prof.",name:"Akito",surname:"Hayashi",slug:"akito-hayashi",fullName:"Akito Hayashi"},{id:"240969",title:"Prof.",name:"Hiroya",surname:"Utsumi",slug:"hiroya-utsumi",fullName:"Hiroya Utsumi"},{id:"240970",title:"BSc.",name:"Mitsuru",surname:"Yoneyama",slug:"mitsuru-yoneyama",fullName:"Mitsuru Yoneyama"},{id:"240971",title:"BSc.",name:"Masato",surname:"Takada",slug:"masato-takada",fullName:"Masato Takada"}],corrections:null},{id:"61336",title:"Wearable Technology as a Tool to Motivate Health Behaviour: A Case Study",doi:"10.5772/intechopen.77002",slug:"wearable-technology-as-a-tool-to-motivate-health-behaviour-a-case-study",totalDownloads:1054,totalCrossrefCites:1,totalDimensionsCites:1,hasAltmetrics:0,abstract:"According to the Scientific Committee on Occupational Exposure Limits, work-related exposures are estimated to account for about 15% of all adult respiratory diseases. Today, the use of personal protective equipment (PPE) is the only way for workers to prevent disease. Nevertheless, its use is highly sparse. Currently, products and systems embedded with wearable technologies are able to protect, motivate and educate users. The authors then suggested the development of a novel wearable system following the beliefs that wearable technology can be persuasive and elicit a conscious behaviour towards the use of the PPEs by consequently improving their health condition. The authors here describe the result of a Transnational Research Project named “P_O_D Plurisensorial Device to prevent Occupational Disease.” The chapter describes the findings achieved so far, the research phase and the new wearable system conceived as a possible example of how to use wearable technology as a useful tool to influence behavioural change.",signatures:"Venere Ferraro, Mila Stepanovic and Silvia Ferraris",downloadPdfUrl:"/chapter/pdf-download/61336",previewPdfUrl:"/chapter/pdf-preview/61336",authors:[{id:"227494",title:"Dr.",name:"Venere",surname:"Ferraro",slug:"venere-ferraro",fullName:"Venere Ferraro"},{id:"240690",title:"MSc.",name:"Mila",surname:"Stepanovic",slug:"mila-stepanovic",fullName:"Mila Stepanovic"},{id:"240691",title:"Dr.",name:"Silvia",surname:"Ferraris",slug:"silvia-ferraris",fullName:"Silvia Ferraris"}],corrections:null},{id:"60918",title:"Wearable Neuromodulators",doi:"10.5772/intechopen.76673",slug:"wearable-neuromodulators",totalDownloads:890,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"In neuromodulation, by delivering a form of stimulus to neural tissue the response of an associated neural circuit may be changed, enhanced or inhibited (i.e., modulated) as desired. This powerful technique may be used to treat various medical conditions as outlined in this chapter. After a brief introduction to the human nervous system, key example applications of electrical neuromodulation such as cardiac pacemakers, devices for pain relief, deep brain stimulation, cochlear implant and visual prosthesis and their respective methods of deployment are discussed. Furthermore, key features of wearable neuromodulators with reference to some existing devices are briefly reviewed. This chapter is concluded by a case study on design and development of a wearable device with non-invasive electrodes for treating lower urinary tract dysfunctions after spinal cord injury.",signatures:"Arsam N. Shiraz, Brian Leaker and Andreas Demosthenous",downloadPdfUrl:"/chapter/pdf-download/60918",previewPdfUrl:"/chapter/pdf-preview/60918",authors:[{id:"231986",title:"Dr.",name:"Arsam",surname:"Shiraz",slug:"arsam-shiraz",fullName:"Arsam Shiraz"},{id:"231987",title:"Prof.",name:"Andreas",surname:"Demosthenous",slug:"andreas-demosthenous",fullName:"Andreas Demosthenous"},{id:"249146",title:"Dr.",name:"Brian",surname:"Leaker",slug:"brian-leaker",fullName:"Brian Leaker"}],corrections:null},{id:"60301",title:"Wearable Dialysis: Current State and Perspectives",doi:"10.5772/intechopen.75552",slug:"wearable-dialysis-current-state-and-perspectives",totalDownloads:1383,totalCrossrefCites:1,totalDimensionsCites:2,hasAltmetrics:0,abstract:"For more than four decades, scientists and engineers are trying to miniaturise dialysis machines to make them wearable. There are many reasons for that—from increased biocompatibility and cost-efficiency to longer life expectancy and higher quality of life. That can be achieved by continuous blood treatment like in natural kidneys, which softly filter blood for 168 h a week when hemodialysis does that quickly—for approximately 20 h a week, which affects the organism in a bad way. Along with that, during hemodialysis, the patient must be near the dialysis machine, in contrary to wearable apparatus that can be carried anywhere. To achieve these advantages, dialysis fluid regeneration system must be developed, and it is a problem to be solved in the next few years. In this chapter, we describe current prototypes of wearable artificial kidneys, their design principles and results of our investigations.",signatures:"Nikolai Bazaev, Nikita Zhilo, Viktor Grinval’d and Sergey Selishchev",downloadPdfUrl:"/chapter/pdf-download/60301",previewPdfUrl:"/chapter/pdf-preview/60301",authors:[{id:"194094",title:"Dr.",name:"Nikolay",surname:"Bazaev",slug:"nikolay-bazaev",fullName:"Nikolay Bazaev"},{id:"242734",title:"BSc.",name:"Nikita",surname:"Zhilo",slug:"nikita-zhilo",fullName:"Nikita Zhilo"},{id:"242735",title:"Prof.",name:"Viktor",surname:"Grinval’d",slug:"viktor-grinval'd",fullName:"Viktor Grinval’d"},{id:"242736",title:"Prof.",name:"Sergey",surname:"Selishchev",slug:"sergey-selishchev",fullName:"Sergey Selishchev"}],corrections:null},{id:"61246",title:"Smart Materials for Wearable Healthcare Devices",doi:"10.5772/intechopen.76604",slug:"smart-materials-for-wearable-healthcare-devices",totalDownloads:1710,totalCrossrefCites:1,totalDimensionsCites:3,hasAltmetrics:0,abstract:"Wearable devices seem to have great potential that could result in a revolutionary non-clinical approach to health monitoring and diagnosing disease. With continued innovation and intensive attention to the materials and fabrication technologies, development of these healthcare devices is progressively encouraged. This chapter gives a concise review of some of the main concepts and approaches related to recent advances and developments in the scope of wearable devices from the perspective of emerging materials. A complementary section of the review linking these advanced materials with wearable device technologies is particularly specified. Some of the strong and weak points in development of each wearable material/device are clearly highlighted and criticized.",signatures:"Han Jin, Qinghui Jin and Jiawen Jian",downloadPdfUrl:"/chapter/pdf-download/61246",previewPdfUrl:"/chapter/pdf-preview/61246",authors:[{id:"230089",title:"Associate Prof.",name:"Han",surname:"Jin",slug:"han-jin",fullName:"Han Jin"}],corrections:null},{id:"61160",title:"Recent Progress in Nanostructured Zinc Oxide Grown on Fabric for Wearable Thermoelectric Power Generator with UV Shielding",doi:"10.5772/intechopen.76672",slug:"recent-progress-in-nanostructured-zinc-oxide-grown-on-fabric-for-wearable-thermoelectric-power-gener",totalDownloads:1284,totalCrossrefCites:1,totalDimensionsCites:2,hasAltmetrics:0,abstract:"Traditional materials for thermoelectric such as bismuth telluride have been studied and utilized commercially for the last half century, but recent advancements in materials selection are one of the principal function of the active thermoelectric device as it determines the reliability of the fabrication regarding technical and economic aspects. Recently, many researcher’s efforts have been made to utilize oxide nanomaterials for wearable thermoelectric power generator (WTPG) applications which may provide environmental stable, mechanical flexibility, and light weight with low cost of manufacturing. In precise, fabric containing oxide metals have shown great promise as P−/N-type materials with improved transport and UV shielding properties. On the other hand, we have focused on ZnO nanostructures as a high-efficiency WTPG material because they are non-toxic to skin, inexpensive and easy to obtain and possess attractive electronic properties, which means that they are available for clothing with low-cost fabrication. To our observation, we are chaptering about the thermoelectric properties of ZnO and their composite nanostructures coated cotton fabric via the solvothermal method for the first time.",signatures:"Pandiyarasan Veluswamy, Suhasini Sathiyamoorthy, Hiroya Ikeda,\nManikandan Elayaperumal and Malik Maaza",downloadPdfUrl:"/chapter/pdf-download/61160",previewPdfUrl:"/chapter/pdf-preview/61160",authors:[{id:"25875",title:"Dr.",name:"Malek",surname:"Maaza",slug:"malek-maaza",fullName:"Malek Maaza"},{id:"185864",title:"Prof.",name:"Manikandan",surname:"Elayaperumal",slug:"manikandan-elayaperumal",fullName:"Manikandan Elayaperumal"},{id:"215388",title:"Dr.",name:"Pandiyarasan",surname:"Veluswamy",slug:"pandiyarasan-veluswamy",fullName:"Pandiyarasan Veluswamy"},{id:"248532",title:"Ms.",name:"Suhasini",surname:"Sathiyamoorthy",slug:"suhasini-sathiyamoorthy",fullName:"Suhasini Sathiyamoorthy"},{id:"248533",title:"Prof.",name:"Ikeda",surname:"Hiroya",slug:"ikeda-hiroya",fullName:"Ikeda Hiroya"}],corrections:null},{id:"60834",title:"Conductive Yarn Embroidered Circuits for System on Textiles",doi:"10.5772/intechopen.76627",slug:"conductive-yarn-embroidered-circuits-for-system-on-textiles",totalDownloads:1428,totalCrossrefCites:3,totalDimensionsCites:5,hasAltmetrics:1,abstract:"With the recent convergence of electronics and textile technology, various kinds of smart wearables are being developed, such as heating clothes, health monitoring clothes, and motion sensing clothes. In this study, the novel conductive embroidery yarns for touch sensing and signal transmission for system on textile (SoT) are introduced. The conductive yarn for touch sensing can be used as a user interface of smart clothes by constructing an embroidery circuit. The conductive yarn for signal transmission can be embroidered on smart clothing and used as a transmission line to transmit power and signal. The conductive yarns and their embroidered circuits were characterized and SoT prototypes using the embroidered circuit of these conductive yarns were presented. These e-textiles based on touch sensing and signal transmission can be comfortably applied for SoT and maintain electrical performance without being damaged by tensile force generated by the movement of the wearer.",signatures:"Jung-Sim Roh",downloadPdfUrl:"/chapter/pdf-download/60834",previewPdfUrl:"/chapter/pdf-preview/60834",authors:[{id:"232246",title:"Associate Prof.",name:"Jung-Sim",surname:"ROh",slug:"jung-sim-roh",fullName:"Jung-Sim ROh"}],corrections:null},{id:"60481",title:"A Wearable Heating System with a Controllable e-Textile- Based Thermal Panel",doi:"10.5772/intechopen.76192",slug:"a-wearable-heating-system-with-a-controllable-e-textile-based-thermal-panel",totalDownloads:1560,totalCrossrefCites:2,totalDimensionsCites:3,hasAltmetrics:0,abstract:"Flexible textile heating systems present great advantage due to their ability to bend and hence could ensure uniform heating for irregular geometries. In cooler outer environment, the user requires his/her body to be kept warm for monitoring vital body functions within realistic thermal body balance constraints. In this chapter, heated vest with controllable e-textile-based thermal panel has been studied. Several e-textile-based thermal panels with different conductive yarns were produced using hot air welding technology under different manufacturing parameters. E-textile-based thermal panels were tested for their heating behaviors at varying direct current (DC) power levels. Based on the experimental results, the optimum e-textile-based thermal panel design was chosen considering its flexibility and uniform heating behavior. Moreover, a control algorithm with electrical circuit and electrical connection network was designed and assembled in an electronic control module. Finally, the electronic module consisting of power control and management system was integrated to attachable e-textile-based thermal panel in order to form a wearable heating vest.",signatures:"Senem Kurşun Bahadir and Umut Kivanc Sahin",downloadPdfUrl:"/chapter/pdf-download/60481",previewPdfUrl:"/chapter/pdf-preview/60481",authors:[{id:"48882",title:"Dr.",name:"Senem",surname:"Kurşun Bahadır",slug:"senem-kursun-bahadir",fullName:"Senem Kurşun Bahadır"},{id:"116271",title:"Dr.",name:"Umut Kivanc",surname:"Sahin",slug:"umut-kivanc-sahin",fullName:"Umut Kivanc Sahin"}],corrections:null},{id:"61357",title:"The Comparison of Wearable Fitness Devices",doi:"10.5772/intechopen.76967",slug:"the-comparison-of-wearable-fitness-devices",totalDownloads:1028,totalCrossrefCites:7,totalDimensionsCites:7,hasAltmetrics:0,abstract:"The wearable devices or wearable trackers help to motivate you during daily exercise or workouts. It gives you information about your daily routine or fitness by using wearable technology in combination with your smart phone to track your daily activities and fitness without the manual calculations or records that can be intrusive. Generally, companies display advertising for these kinds of products and depict them as good, user-friendly, and accurate. However, there are no subjective research results to prove the veracity of their words. Four popular wrist band-style wearable devices currently in the market were selected at the devices which are most popular (Withings Pulse, Misfit Shine, Jawbone Up24, and Fitbit Flex). The accuracy of tracking was one of the key components for fitness tracking, with some devices performing better than others. Accuracy in the tracking of daily activities such as walking, running, and sleeping is important. This research showed subjective and objective experiment results, which were used to compare the accuracy of four wearable devices in conjunction with user-friendliness. Satisfaction levels, the accuracy of tracking, and the opinion of each subject while using wearable device to track their daily activity were compared. The results determined that the cost-effectiveness was the Withings Pulse, followed by the Fitbit Flex, Jawbone Up24, and Misfit Shine.",signatures:"Kanitthika Kaewkannate and Soochan Kim",downloadPdfUrl:"/chapter/pdf-download/61357",previewPdfUrl:"/chapter/pdf-preview/61357",authors:[{id:"228941",title:"Prof.",name:"Soochan",surname:"Kim",slug:"soochan-kim",fullName:"Soochan Kim"},{id:"228943",title:"MSc.",name:"Kanitthika",surname:"Kaewkannate",slug:"kanitthika-kaewkannate",fullName:"Kanitthika Kaewkannate"}],corrections:null},{id:"60448",title:"Bio-Inspired Wearable Antennas",doi:"10.5772/intechopen.75912",slug:"bio-inspired-wearable-antennas",totalDownloads:1258,totalCrossrefCites:5,totalDimensionsCites:11,hasAltmetrics:0,abstract:"Due to the recent miniaturization of wireless devices, the use of wearable antennas is steadily increasing. A wearable antenna is intended to be a part of the clothing used for communication purposes. In this way, a lower visual cost may be achieved. Recently, biologically inspired design, a kind of design by cross-domain analogy is a promising paradigm for innovation as well as low visual cost. The shapes of the plants are structures optimized by nature with the primary goal of light energy capture, transforming it into chemical energy. In this case, they have similar behavior to that of parabolic reflectors; this enables microwave engineers design innovative antennas using bio-inspired concepts. One of the advantages of using bio-inspired plant shapes is the design of antennas with great perimeters in compact structures. Thus, we have small antennas operating in low frequencies. This chapter presents the recent development in bio-inspired wearable antennas, easily integrated to the clothes and accessories used by the body, built in denim, low-cost flexible dielectric, and polyamide flexible dielectric, that is flexible with high resistance to twists and temperatures, for wireless body area network (WBAN) applications, operating in cellular mobile (2G, 3G, and 4G) and wireless local area network (2.4 and 5 GHz) protocols.",signatures:"Paulo Fernandes da Silva Júnior, Alexandre Jean René Serres,\nRaimundo Carlos Silvério Freire, Georgina Karla de Freitas Serres,\nEdmar Candeia Gurjão, Joabson Nogueira de Carvalho and Ewaldo\nEder Carvalho Santana",downloadPdfUrl:"/chapter/pdf-download/60448",previewPdfUrl:"/chapter/pdf-preview/60448",authors:[{id:"199230",title:"Dr.",name:"Alexandre Jean René",surname:"Serres",slug:"alexandre-jean-rene-serres",fullName:"Alexandre Jean René Serres"},{id:"205094",title:"Dr.",name:"Georgina Karla",surname:"Freitas Serres",slug:"georgina-karla-freitas-serres",fullName:"Georgina Karla Freitas Serres"},{id:"205095",title:"Ph.D.",name:"Paulo",surname:"Fernandes da Silva Junior",slug:"paulo-fernandes-da-silva-junior",fullName:"Paulo Fernandes da Silva Junior"},{id:"229216",title:"Dr.",name:"Edmar",surname:"Candeia",slug:"edmar-candeia",fullName:"Edmar Candeia"},{id:"229218",title:"Dr.",name:"Joabson",surname:"Nogueira",slug:"joabson-nogueira",fullName:"Joabson Nogueira"},{id:"229219",title:"Dr.",name:"Raimundo",surname:"Freire",slug:"raimundo-freire",fullName:"Raimundo Freire"},{id:"240706",title:"Dr.",name:"Ewaldo",surname:"Santana",slug:"ewaldo-santana",fullName:"Ewaldo Santana"}],corrections:null},{id:"61567",title:"Middleware-Driven Intelligent Glove for Industrial Applications",doi:"10.5772/intechopen.76382",slug:"middleware-driven-intelligent-glove-for-industrial-applications",totalDownloads:978,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,abstract:"It is estimated that by the year 2020, 700 million wearable technology devices will be sold worldwide. One of the reasons is the industries’ need to increase their productivity. Some of the tools welcomed by industries are handheld devices such as tablets, PDAs and mobile phones. However, handheld devices are not ideal for industrial applications because they often subject users to fatigue during their long working hours. A viable solution to this problem is wearable devices. The advantage of wearable devices is that they become part of the user. Hence, they subject the user to less fatigue, thereby increasing their productivity. This chapter presents the development of an intelligent glove, which is designed to control actuators in an industrial environment. This system utilizes RTI connext data distributed service middleware to facilitate communication over WiFi. Our experiments show very promising results with maximum power consumption of 310 mW and latency as low as 23 ms. These results make the proposed system a perfect fit for most industrial applications.",signatures:"Farouq Muhammad Aliyu and Basem Almadani",downloadPdfUrl:"/chapter/pdf-download/61567",previewPdfUrl:"/chapter/pdf-preview/61567",authors:[{id:"227198",title:"Mr.",name:"Farouq",surname:"Aliyu",slug:"farouq-aliyu",fullName:"Farouq Aliyu"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},subseries:null,tags:null},relatedBooks:[{type:"book",id:"5408",title:"Ad Hoc Networks",subtitle:null,isOpenForSubmission:!1,hash:"3d8f56e9f0b5b530cd132c040fdef6c5",slug:"ad-hoc-networks",bookSignature:"Jesus Hamilton Ortiz and Alvaro Pachon de la Cruz",coverURL:"https://cdn.intechopen.com/books/images_new/5408.jpg",editedByType:"Edited by",editors:[{id:"97704",title:"Dr.",name:"Jesús Hamilton",surname:"Ortiz",slug:"jesus-hamilton-ortiz",fullName:"Jesús Hamilton Ortiz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1636",title:"Telecommunications Networks",subtitle:"Current Status and Future Trends",isOpenForSubmission:!1,hash:"3cd52027cd1f450d5770cede2b712b46",slug:"telecommunications-networks-current-status-and-future-trends",bookSignature:"Jesus Hamilton Ortiz",coverURL:"https://cdn.intechopen.com/books/images_new/1636.jpg",editedByType:"Edited by",editors:[{id:"97704",title:"Dr.",name:"Jesús Hamilton",surname:"Ortiz",slug:"jesus-hamilton-ortiz",fullName:"Jesús Hamilton Ortiz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9426",title:"Industry 4.0",subtitle:"Current Status and Future Trends",isOpenForSubmission:!1,hash:"f9d1cc5119410371683c26acc0239d22",slug:"industry-4-0-current-status-and-future-trends",bookSignature:"Jesús Hamilton Ortiz",coverURL:"https://cdn.intechopen.com/books/images_new/9426.jpg",editedByType:"Edited by",editors:[{id:"97704",title:"Dr.",name:"Jesús Hamilton",surname:"Ortiz",slug:"jesus-hamilton-ortiz",fullName:"Jesús Hamilton Ortiz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1902",title:"Mobile Networks",subtitle:null,isOpenForSubmission:!1,hash:"5351aa9d45ae2f6c117f48979caa469a",slug:"mobile-networks",bookSignature:"Jesus Hamilton Ortiz",coverURL:"https://cdn.intechopen.com/books/images_new/1902.jpg",editedByType:"Edited by",editors:[{id:"97704",title:"Dr.",name:"Jesús Hamilton",surname:"Ortiz",slug:"jesus-hamilton-ortiz",fullName:"Jesús Hamilton Ortiz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2405",title:"Smart Actuation and Sensing Systems",subtitle:"Recent Advances and Future Challenges",isOpenForSubmission:!1,hash:"e0ba43135d522bb9ad308c72f3fc932b",slug:"smart-actuation-and-sensing-systems-recent-advances-and-future-challenges",bookSignature:"Giovanni Berselli, Rocco Vertechy and Gabriele Vassura",coverURL:"https://cdn.intechopen.com/books/images_new/2405.jpg",editedByType:"Edited by",editors:[{id:"122191",title:"Prof.",name:"Giovanni",surname:"Berselli",slug:"giovanni-berselli",fullName:"Giovanni Berselli"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"147",title:"Biosensors",subtitle:"Emerging Materials and Applications",isOpenForSubmission:!1,hash:"506ba7fc7057db3f5a13c57a5ed4a460",slug:"biosensors-emerging-materials-and-applications",bookSignature:"Pier Andrea Serra",coverURL:"https://cdn.intechopen.com/books/images_new/147.jpg",editedByType:"Edited by",editors:[{id:"6091",title:"Prof.",name:"Pier Andrea",surname:"Serra",slug:"pier-andrea-serra",fullName:"Pier Andrea Serra"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3559",title:"Radar Technology",subtitle:null,isOpenForSubmission:!1,hash:"1672be706f8291d33463da05c27e82b3",slug:"radar-technology",bookSignature:"Guy Kouemou",coverURL:"https://cdn.intechopen.com/books/images_new/3559.jpg",editedByType:"Edited by",editors:[{id:"19952",title:"Dr.",name:"Guy",surname:"Kouemou",slug:"guy-kouemou",fullName:"Guy Kouemou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"162",title:"Microsensors",subtitle:null,isOpenForSubmission:!1,hash:"3d48614c970df4eb00d2d1a4e1bb5cda",slug:"microsensors",bookSignature:"Igor Minin",coverURL:"https://cdn.intechopen.com/books/images_new/162.jpg",editedByType:"Edited by",editors:[{id:"3712",title:"Prof.",name:"Oleg",surname:"Minin",slug:"oleg-minin",fullName:"Oleg Minin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3608",title:"Development and Implementation of RFID Technology",subtitle:null,isOpenForSubmission:!1,hash:null,slug:"development_and_implementation_of_rfid_technology",bookSignature:"Cristina Turcu",coverURL:"https://cdn.intechopen.com/books/images_new/3608.jpg",editedByType:"Edited by",editors:[{id:"9302",title:"Dr.",name:"Cristina",surname:"Turcu",slug:"cristina-turcu",fullName:"Cristina Turcu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3150",title:"Advances in Sonar Technology",subtitle:null,isOpenForSubmission:!1,hash:"6129b514b5260b24b59fba38ac402b9e",slug:"advances_in_sonar_technology",bookSignature:"Sergio Rui Silva",coverURL:"https://cdn.intechopen.com/books/images_new/3150.jpg",editedByType:"Edited by",editors:[{id:"252220",title:"Dr.",name:"Sergio",surname:"Silva",slug:"sergio-silva",fullName:"Sergio Silva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"79356",slug:"corrigendum-the-application-of-electric-drive-technologies-i",title:"Corrigendum: Application of Electric Drive Technologies in City Buses",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/79043.pdf",downloadPdfUrl:"/chapter/pdf-download/79043",previewPdfUrl:"/chapter/pdf-preview/79043",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/79043",risUrl:"/chapter/ris/79043",chapter:{id:"41487",slug:"the-application-of-electric-drive-technologies-in-city-buses",signatures:"Zlatomir Živanović and Zoran Nikolic",dateSubmitted:"April 4th 2012",dateReviewed:"July 21st 2012",datePrePublished:null,datePublished:"December 19th 2012",book:{id:"3196",title:"New Generation of Electric Vehicles",subtitle:null,fullTitle:"New Generation of Electric Vehicles",slug:"new-generation-of-electric-vehicles",publishedDate:"December 19th 2012",bookSignature:"Zoran Stevic",coverURL:"https://cdn.intechopen.com/books/images_new/3196.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"30692",title:"Dr.",name:"Zoran",middleName:"M.",surname:"Stevic",slug:"zoran-stevic",fullName:"Zoran Stevic"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"154524",title:"Dr.",name:"Zlatomir",middleName:null,surname:"Zivanovic",fullName:"Zlatomir Zivanovic",slug:"zlatomir-zivanovic",email:"zzivanovic@vinca.rs",position:null,institution:{name:"University of Belgrade",institutionURL:null,country:{name:"Serbia"}}},{id:"164696",title:"Dr.",name:"Zoran",middleName:null,surname:"Nikolic",fullName:"Zoran Nikolic",slug:"zoran-nikolic",email:"zor.nikolic@yahoo.com",position:null,institution:null}]}},chapter:{id:"41487",slug:"the-application-of-electric-drive-technologies-in-city-buses",signatures:"Zlatomir Živanović and Zoran Nikolic",dateSubmitted:"April 4th 2012",dateReviewed:"July 21st 2012",datePrePublished:null,datePublished:"December 19th 2012",book:{id:"3196",title:"New Generation of Electric Vehicles",subtitle:null,fullTitle:"New Generation of Electric Vehicles",slug:"new-generation-of-electric-vehicles",publishedDate:"December 19th 2012",bookSignature:"Zoran Stevic",coverURL:"https://cdn.intechopen.com/books/images_new/3196.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"30692",title:"Dr.",name:"Zoran",middleName:"M.",surname:"Stevic",slug:"zoran-stevic",fullName:"Zoran Stevic"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"154524",title:"Dr.",name:"Zlatomir",middleName:null,surname:"Zivanovic",fullName:"Zlatomir Zivanovic",slug:"zlatomir-zivanovic",email:"zzivanovic@vinca.rs",position:null,institution:{name:"University of Belgrade",institutionURL:null,country:{name:"Serbia"}}},{id:"164696",title:"Dr.",name:"Zoran",middleName:null,surname:"Nikolic",fullName:"Zoran Nikolic",slug:"zoran-nikolic",email:"zor.nikolic@yahoo.com",position:null,institution:null}]},book:{id:"3196",title:"New Generation of Electric Vehicles",subtitle:null,fullTitle:"New Generation of Electric Vehicles",slug:"new-generation-of-electric-vehicles",publishedDate:"December 19th 2012",bookSignature:"Zoran Stevic",coverURL:"https://cdn.intechopen.com/books/images_new/3196.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"30692",title:"Dr.",name:"Zoran",middleName:"M.",surname:"Stevic",slug:"zoran-stevic",fullName:"Zoran Stevic"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"11538",leadTitle:null,title:"Updates on Supercapacitors",subtitle:null,reviewType:"peer-reviewed",abstract:"
\r\n\tSupercapacitors are an important topic of research and development because they are interesting both in terms of energy and environmental aspects. Standard power storage systems are supercapacitors and rechargeable batteries. Recently, more and more attention is paid to supercapacitors as a qualitatively new type of capacitor and fuel cells as sources of electricity. A large number of teams and laboratories around the world are working on the development of supercapacitors, while their ever-improving performance allows for wider use. The goal of this book is to bring readers closer to new supercapacitor technologies that are changing the present and future of electricity storage. The big challenges are to improve the parameters of supercapacitors, primarily energy density and operating voltage, but we are also working on miniaturization, optimization, energy efficiency, and environmental friendliness. The expansion of electric cars brings a new trend in the development of supercapacitors - hybridization with batteries or a complex power supply that contains a battery, supercapacitor, and power electronics for energy management. The economic aspect must also be taken into account.
\r\n\r\n\tThe book hopes to cover the following topics: new achievements in the field of electrode and inter-electrode materials, new models and test methods, new constructions and applications, and the environmental aspect.
",isbn:"978-1-83962-642-5",printIsbn:"978-1-83962-641-8",pdfIsbn:"978-1-83962-688-3",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!0,isSalesforceBook:!1,isNomenclature:!1,hash:"defe620d92b00d7a1b12b939941b7528",bookSignature:"Dr. Zoran M. Stevic",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/11538.jpg",keywords:"Electrode Materials, Electrolytes, Energy Density, Power Density, Modeling and Simulation, Measurement and Testing, High Energy Density, Miniaturization, EV, Hybrid Design, Energy Harvesting, Green Energy",numberOfDownloads:3,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"April 14th 2022",dateEndSecondStepPublish:"June 22nd 2022",dateEndThirdStepPublish:"August 21st 2022",dateEndFourthStepPublish:"November 9th 2022",dateEndFifthStepPublish:"January 8th 2023",dateConfirmationOfParticipation:null,remainingDaysToSecondStep:"2 months",secondStepPassed:!0,areRegistrationsClosed:!1,currentStepOfPublishingProcess:3,editedByType:null,kuFlag:!1,biosketch:"Dr. Stevic is a member of IEEE, IBPSA, SMEITS, and SCS. He published over 350 papers (over 50 refereed full papers in Scientific Journals), 5 books, and 5 chapters. He was the project coordinator and member of working groups on many scientific and technical projects. He is also a professional in thermography (level II acc. ISO 9712).",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"30692",title:"Dr.",name:"Zoran",middleName:"M.",surname:"Stevic",slug:"zoran-stevic",fullName:"Zoran Stevic",profilePictureURL:"https://mts.intechopen.com/storage/users/30692/images/system/30692.jpg",biography:"Zoran M. Stevic (1958), zstevic@etf.rs , zstevic@tfbor.bg.ac.rs , zstevic@live.com is a full professor at the University of Belgrade, Technical Faculty in Bor and School of Electrical Engineering in Belgrade, Serbia. He received his Ph.D. degree from the School of Electrical Engineering in Belgrade, University of Belgrade. His research areas include power electronics, IR thermography, computer measurement, and process control, supercapacitors, energy efficiency, renewable energy sources, system modeling, sensors, optoelectronics, and electrochemistry. He is a member of IEEE, IBPSA, SMEITS, and SCS. He published over 350 papers (over 50 refereed full papers in Scientific Journals), 5 books, and 5 chapters. Also, he was the project coordinator and member of working groups on many scientific and technical projects. He is a professional in thermography (level II acc. ISO 9712).",institutionString:"University of Belgrade",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"University of Belgrade",institutionURL:null,country:{name:"Serbia"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"11",title:"Engineering",slug:"engineering"}],chapters:[{id:"83066",title:"Carbon Nanomaterials Based Supercapacitors: Recent Trends",slug:"carbon-nanomaterials-based-supercapacitors-recent-trends",totalDownloads:3,totalCrossrefCites:0,authors:[null]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"247041",firstName:"Dolores",lastName:"Kuzelj",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/247041/images/7108_n.jpg",email:"dolores@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"3196",title:"New Generation of Electric Vehicles",subtitle:null,isOpenForSubmission:!1,hash:"683b92b692bc7d1e7952cbc7c9f1a98d",slug:"new-generation-of-electric-vehicles",bookSignature:"Zoran Stevic",coverURL:"https://cdn.intechopen.com/books/images_new/3196.jpg",editedByType:"Edited by",editors:[{id:"30692",title:"Dr.",name:"Zoran",surname:"Stevic",slug:"zoran-stevic",fullName:"Zoran Stevic"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10198",title:"Response Surface Methodology in Engineering Science",subtitle:null,isOpenForSubmission:!1,hash:"1942bec30d40572f519327ca7a6d7aae",slug:"response-surface-methodology-in-engineering-science",bookSignature:"Palanikumar Kayaroganam",coverURL:"https://cdn.intechopen.com/books/images_new/10198.jpg",editedByType:"Edited by",editors:[{id:"321730",title:"Prof.",name:"Palanikumar",surname:"Kayaroganam",slug:"palanikumar-kayaroganam",fullName:"Palanikumar Kayaroganam"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophile",surname:"Theophanides",slug:"theophile-theophanides",fullName:"Theophile Theophanides"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2270",title:"Fourier Transform",subtitle:"Materials Analysis",isOpenForSubmission:!1,hash:"5e094b066da527193e878e160b4772af",slug:"fourier-transform-materials-analysis",bookSignature:"Salih Mohammed Salih",coverURL:"https://cdn.intechopen.com/books/images_new/2270.jpg",editedByType:"Edited by",editors:[{id:"111691",title:"Dr.Ing.",name:"Salih",surname:"Salih",slug:"salih-salih",fullName:"Salih Salih"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"117",title:"Artificial Neural Networks",subtitle:"Methodological Advances and Biomedical Applications",isOpenForSubmission:!1,hash:null,slug:"artificial-neural-networks-methodological-advances-and-biomedical-applications",bookSignature:"Kenji Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/117.jpg",editedByType:"Edited by",editors:[{id:"3095",title:"Prof.",name:"Kenji",surname:"Suzuki",slug:"kenji-suzuki",fullName:"Kenji Suzuki"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"872",title:"Organic Pollutants Ten Years After the Stockholm Convention",subtitle:"Environmental and Analytical Update",isOpenForSubmission:!1,hash:"f01dc7077e1d23f3d8f5454985cafa0a",slug:"organic-pollutants-ten-years-after-the-stockholm-convention-environmental-and-analytical-update",bookSignature:"Tomasz Puzyn and Aleksandra Mostrag-Szlichtyng",coverURL:"https://cdn.intechopen.com/books/images_new/872.jpg",editedByType:"Edited by",editors:[{id:"84887",title:"Dr.",name:"Tomasz",surname:"Puzyn",slug:"tomasz-puzyn",fullName:"Tomasz Puzyn"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"23793",title:"Renal Cell Carcinoma in Dialysis Patients with End Stage Renal Disease: Focus on Surgery and Pathology",doi:"10.5772/22855",slug:"renal-cell-carcinoma-in-dialysis-patients-with-end-stage-renal-disease-focus-on-surgery-and-patholog",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/23793.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/23793",previewPdfUrl:"/chapter/pdf-preview/23793",totalDownloads:3319,totalViews:77,totalCrossrefCites:0,totalDimensionsCites:0,totalAltmetricsMentions:0,introChapter:null,impactScore:0,impactScorePercentile:6,impactScoreQuartile:1,hasAltmetrics:0,dateSubmitted:"November 23rd 2010",dateReviewed:"July 11th 2011",datePrePublished:null,datePublished:"November 14th 2011",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/23793",risUrl:"/chapter/ris/23793",book:{id:"1375",slug:"hemodialysis-different-aspects"},signatures:"Hitoshi Masuda, Kazunori Kihara, Yasuhisa Fujii, Fumitaka Koga, Kazutaka Saito, Mizuaki Sakura, Yohei Okada and Satoru Kawakami",authors:[{id:"49521",title:"Dr.",name:"Hitoshi",middleName:null,surname:"Masuda",fullName:"Hitoshi Masuda",slug:"hitoshi-masuda",email:"hi-masu.uro@tmd.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}},{id:"59441",title:"Dr.",name:"Yohei",middleName:null,surname:"Okada",fullName:"Yohei Okada",slug:"yohei-okada",email:"y-okada.uro@tmd.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}},{id:"59442",title:"Dr.",name:"Mizuaki",middleName:null,surname:"Sakura",fullName:"Mizuaki Sakura",slug:"mizuaki-sakura",email:"m-sakura.uro@tmd.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}},{id:"59443",title:"Prof.",name:"Kazunori",middleName:null,surname:"Kihara",fullName:"Kazunori Kihara",slug:"kazunori-kihara",email:"k-kihara.uro@tmd.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}},{id:"103091",title:"Dr.",name:"Yasuhisa",middleName:null,surname:"Fujii",fullName:"Yasuhisa Fujii",slug:"yasuhisa-fujii",email:"y-fujii.uro@tmd.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}},{id:"103104",title:"Dr.",name:"Fumitaka",middleName:null,surname:"Koga",fullName:"Fumitaka Koga",slug:"fumitaka-koga",email:"f-koga.uro@tmd.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}},{id:"103106",title:"Dr.",name:"Kazutaka",middleName:null,surname:"Saito",fullName:"Kazutaka Saito",slug:"kazutaka-saito",email:"kz-saito.uro@tmd.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}},{id:"103108",title:"Dr.",name:"Satoru",middleName:null,surname:"Kawakami",fullName:"Satoru Kawakami",slug:"satoru-kawakami",email:"kawakami@saitama-med.ac.jp",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",institution:{name:"Saitama Medical University",institutionURL:null,country:{name:"Japan"}}}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"1375",type:"book",title:"Hemodialysis",subtitle:"Different Aspects",fullTitle:"Hemodialysis - Different Aspects",slug:"hemodialysis-different-aspects",publishedDate:"November 14th 2011",bookSignature:"Maria Goretti Penido",coverURL:"https://cdn.intechopen.com/books/images_new/1375.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",isbn:null,printIsbn:"978-953-307-315-6",pdfIsbn:"978-953-51-6569-9",reviewType:"peer-reviewed",numberOfWosCitations:10,isAvailableForWebshopOrdering:!0,editors:[{id:"75822",title:"Prof.",name:"Maria Goretti",middleName:"Moreira Guimaraes",surname:"Penido",slug:"maria-goretti-penido",fullName:"Maria Goretti Penido"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1163"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"23791",type:"chapter",title:"Acute Renal Failure Induced by Adenovirus After Stem Cell Transplantation",slug:"acute-renal-failure-induced-by-adenovirus-after-stem-cell-transplantation",totalDownloads:2319,totalCrossrefCites:1,signatures:"Takashi Abe, Shinichi Nishi, Tatsuo Furukawa, Yoichi Ajioka, Masayoshi Masuko and Ichiro Fuse",reviewType:"peer-reviewed",authors:[{id:"45800",title:"Dr.",name:"Takashi",middleName:null,surname:"Abe",fullName:"Takashi Abe",slug:"takashi-abe"},{id:"58768",title:"Dr.",name:"Tatsuo",middleName:null,surname:"Furukawa",fullName:"Tatsuo Furukawa",slug:"tatsuo-furukawa"},{id:"58769",title:"Dr.",name:"Masayoshi",middleName:null,surname:"Masuko",fullName:"Masayoshi Masuko",slug:"masayoshi-masuko"},{id:"58770",title:"Dr.",name:"Ichiro",middleName:null,surname:"Fuse",fullName:"Ichiro Fuse",slug:"ichiro-fuse"},{id:"95076",title:"Prof.",name:"Shinichi",middleName:null,surname:"Nishi",fullName:"Shinichi Nishi",slug:"shinichi-nishi"},{id:"105463",title:"Prof.",name:"Yoichi",middleName:null,surname:"Ajioka",fullName:"Yoichi Ajioka",slug:"yoichi-ajioka"}]},{id:"23792",type:"chapter",title:"Plasma Total Nitric Oxide and Endothelial Constitutive Nitric Oxide Synthase (ecNOS) Inron 4 Gene Polymorphism: A Study in Children with Chronic Kidney Disease",slug:"plasma-total-nitric-oxide-and-endothelial-constitutive-nitric-oxide-synthase-ecnos-inron-4-gene-poly",totalDownloads:1954,totalCrossrefCites:0,signatures:"Manal F. Elshamaa, Samar Sabry, Ahmed Badr, Eman A. Elghoroury, Soulaf Kamel and Gamila Elsaied",reviewType:"peer-reviewed",authors:[{id:"44521",title:"Dr.",name:"Manal",middleName:null,surname:"Elshamaa",fullName:"Manal Elshamaa",slug:"manal-elshamaa"},{id:"56773",title:"Dr.",name:"Samar",middleName:null,surname:"Sabry",fullName:"Samar Sabry",slug:"samar-sabry"},{id:"56775",title:"Prof.",name:"Eman",middleName:null,surname:"Elghoroury",fullName:"Eman Elghoroury",slug:"eman-elghoroury"},{id:"56779",title:"Dr.",name:"Solaf",middleName:null,surname:"Kamel",fullName:"Solaf Kamel",slug:"solaf-kamel"},{id:"56992",title:"Dr.",name:"Gamila",middleName:null,surname:"Elsaied",fullName:"Gamila Elsaied",slug:"gamila-elsaied"},{id:"62823",title:"Dr.",name:"Ahmed",middleName:null,surname:"Badr",fullName:"Ahmed Badr",slug:"ahmed-badr"}]},{id:"23793",type:"chapter",title:"Renal Cell Carcinoma in Dialysis Patients with End Stage Renal Disease: Focus on Surgery and Pathology",slug:"renal-cell-carcinoma-in-dialysis-patients-with-end-stage-renal-disease-focus-on-surgery-and-patholog",totalDownloads:3319,totalCrossrefCites:0,signatures:"Hitoshi Masuda, Kazunori Kihara, Yasuhisa Fujii, Fumitaka Koga, Kazutaka Saito, Mizuaki Sakura, Yohei Okada and Satoru Kawakami",reviewType:"peer-reviewed",authors:[{id:"49521",title:"Dr.",name:"Hitoshi",middleName:null,surname:"Masuda",fullName:"Hitoshi Masuda",slug:"hitoshi-masuda"},{id:"59441",title:"Dr.",name:"Yohei",middleName:null,surname:"Okada",fullName:"Yohei Okada",slug:"yohei-okada"},{id:"59442",title:"Dr.",name:"Mizuaki",middleName:null,surname:"Sakura",fullName:"Mizuaki Sakura",slug:"mizuaki-sakura"},{id:"59443",title:"Prof.",name:"Kazunori",middleName:null,surname:"Kihara",fullName:"Kazunori Kihara",slug:"kazunori-kihara"},{id:"103091",title:"Dr.",name:"Yasuhisa",middleName:null,surname:"Fujii",fullName:"Yasuhisa Fujii",slug:"yasuhisa-fujii"},{id:"103104",title:"Dr.",name:"Fumitaka",middleName:null,surname:"Koga",fullName:"Fumitaka Koga",slug:"fumitaka-koga"},{id:"103106",title:"Dr.",name:"Kazutaka",middleName:null,surname:"Saito",fullName:"Kazutaka Saito",slug:"kazutaka-saito"},{id:"103108",title:"Dr.",name:"Satoru",middleName:null,surname:"Kawakami",fullName:"Satoru Kawakami",slug:"satoru-kawakami"}]},{id:"23794",type:"chapter",title:"Methylene Blue and Dialysis-Related Hypotension",slug:"methylene-blue-and-dialysis-related-hypotension",totalDownloads:3035,totalCrossrefCites:0,signatures:"Wisler J. R. and Stawicki S. P. A.",reviewType:"peer-reviewed",authors:[{id:"44943",title:"Prof.",name:"Stanislaw P. A.",middleName:null,surname:"Stawicki",fullName:"Stanislaw P. A. Stawicki",slug:"stanislaw-p.-a.-stawicki"},{id:"59801",title:"Prof.",name:"Johathan",middleName:null,surname:"Wisler",fullName:"Johathan Wisler",slug:"johathan-wisler"}]},{id:"23795",type:"chapter",title:"Identification of Hemodialysis Patients’ Physical and Psychosocial Problems Using the International Classification of Functioning, Disability and Health (ICF)",slug:"identification-of-hemodialysis-patients-physical-and-psychosocial-problems-using-the-international-c",totalDownloads:2173,totalCrossrefCites:0,signatures:"Hideyo Tsutsui, Teruhiko Koike and Yoshiharu Oshida",reviewType:"peer-reviewed",authors:[{id:"50860",title:"Dr.",name:"Hideyo",middleName:null,surname:"Tsutsui",fullName:"Hideyo Tsutsui",slug:"hideyo-tsutsui"},{id:"58821",title:"Prof.",name:"Teruhiko",middleName:null,surname:"Koike",fullName:"Teruhiko Koike",slug:"teruhiko-koike"},{id:"58822",title:"Prof.",name:"Yoshiharu",middleName:null,surname:"Oshida",fullName:"Yoshiharu Oshida",slug:"yoshiharu-oshida"}]},{id:"23796",type:"chapter",title:"Selenium (Se), Blood Glutathione Peroxidases and DNA Damage in Chronic Kidney Disease Patients on Hemodialysis and After Kidney Transplantation - The Effect of Se Supplementation",slug:"selenium-se-blood-glutathione-peroxidases-and-dna-damage-in-chronic-kidney-disease-patients-on-hemod",totalDownloads:2298,totalCrossrefCites:0,signatures:"Bronislaw A. Zachara",reviewType:"peer-reviewed",authors:[{id:"47879",title:"Prof.",name:"Bronislaw",middleName:null,surname:"Zachara",fullName:"Bronislaw Zachara",slug:"bronislaw-zachara"}]},{id:"23797",type:"chapter",title:"A Systematic Review of the Effect of Vitamin C Infusion and Vitamin E-Coated Membrane on Hemodialysis-Induced Oxidative Stress",slug:"a-systematic-review-of-the-effect-of-vitamin-c-infusion-and-vitamin-e-coated-membrane-on-hemodialysi",totalDownloads:2081,totalCrossrefCites:2,signatures:"Malecka-Massalska Teresa, Wladysiuk Magdalena and Ksiazek Andrzej",reviewType:"peer-reviewed",authors:[{id:"48125",title:"Dr.",name:"Teresa",middleName:"Jadwiga",surname:"Malecka-Massalska",fullName:"Teresa Malecka-Massalska",slug:"teresa-malecka-massalska"},{id:"57912",title:"Prof.",name:"Andrzej",middleName:null,surname:"Ksiazek",fullName:"Andrzej Ksiazek",slug:"andrzej-ksiazek"},{id:"57913",title:"Mrs.",name:"Magdalena",middleName:null,surname:"Wladysiuk",fullName:"Magdalena Wladysiuk",slug:"magdalena-wladysiuk"}]},{id:"23798",type:"chapter",title:"The Role of Ultrasonographic Monitoring for Hip Joint Changes in Patients with Chronic Renal Failure",slug:"the-role-of-ultrasonographic-monitoring-for-hip-joint-changes-in-patients-with-chronic-renal-failure",totalDownloads:1892,totalCrossrefCites:0,signatures:"Damir Matoković, Miroslav Hašpl, Petar Petrić, Sanja Škorvaga, Vlado Drkulec and Goran Šantak",reviewType:"peer-reviewed",authors:[{id:"52779",title:"PhD.",name:"Damir",middleName:null,surname:"Matokovic",fullName:"Damir Matokovic",slug:"damir-matokovic"},{id:"53124",title:"Prof.",name:"Miroslav",middleName:null,surname:"Haspl",fullName:"Miroslav Haspl",slug:"miroslav-haspl"},{id:"53125",title:"Mr",name:"Petar",middleName:null,surname:"Petric",fullName:"Petar Petric",slug:"petar-petric"},{id:"53126",title:"Ms",name:"Sanja",middleName:null,surname:"Skovraga",fullName:"Sanja Skovraga",slug:"sanja-skovraga"},{id:"53127",title:"MSc",name:"Vlado",middleName:null,surname:"Drkulec",fullName:"Vlado Drkulec",slug:"vlado-drkulec"}]},{id:"23799",type:"chapter",title:"Modulation of Iron Metabolism and Hepcidin Release by HFE Mutations in Chronic Hemodialysis Patients: Pathophysiological and Therapeutic Implications",slug:"modulation-of-iron-metabolism-and-hepcidin-release-by-hfe-mutations-in-chronic-hemodialysis-patients",totalDownloads:2280,totalCrossrefCites:0,signatures:"Elena Canavesi and Luca Valenti",reviewType:"peer-reviewed",authors:[{id:"48991",title:"Dr.",name:"Luca",middleName:null,surname:"Valenti",fullName:"Luca Valenti",slug:"luca-valenti"},{id:"58719",title:"Dr.",name:"Elena",middleName:null,surname:"Canavesi",fullName:"Elena Canavesi",slug:"elena-canavesi"}]},{id:"23800",type:"chapter",title:"Micronutrient Metabolism in Hemodialysis Patients",slug:"micronutrient-metabolism-in-hemodialysis-patients",totalDownloads:2601,totalCrossrefCites:2,signatures:"Chih-Hung Guo, Chia-Liang Wang and Pei-Chung Chen",reviewType:"peer-reviewed",authors:[{id:"49194",title:"Prof.",name:"Chih-Hung",middleName:null,surname:"Guo",fullName:"Chih-Hung Guo",slug:"chih-hung-guo"},{id:"59628",title:"Prof.",name:"Pei-Chung",middleName:null,surname:"Chen",fullName:"Pei-Chung Chen",slug:"pei-chung-chen"},{id:"59629",title:"Dr.",name:"Chia-Liang",middleName:null,surname:"Wang",fullName:"Chia-Liang Wang",slug:"chia-liang-wang"}]},{id:"23801",type:"chapter",title:"Differences in Erythrocyte Index and Hyporesponsiveness to Erythropoiesis in Hemodialysis Patients Treated with Different Erythropoiesis-Stimulating Agents",slug:"differences-in-erythrocyte-index-and-hyporesponsiveness-to-erythropoiesis-in-hemodialysis-patients-t",totalDownloads:2108,totalCrossrefCites:0,signatures:"Osamu Saito, Yoichi Furusawa, Kousuke Okuda and Eiji Kusano",reviewType:"peer-reviewed",authors:[{id:"55474",title:"Dr.",name:"Osamu",middleName:null,surname:"Saito",fullName:"Osamu Saito",slug:"osamu-saito"}]},{id:"23802",type:"chapter",title:"Focal Dental Diagnostic in Patients with Replaced Renal Function-One New Method in Dentistry",slug:"focal-dental-diagnostic-in-patients-with-replaced-renal-function-one-new-method-in-dentistry",totalDownloads:2762,totalCrossrefCites:0,signatures:"Maria Dencheva, Angelina Kisselova, Assya Krasteva, Tsvetelina Georgieva, Iliyana Stoeva and Teodora Bolyarova",reviewType:"peer-reviewed",authors:[{id:"32422",title:"Dr.",name:"Asya",middleName:"Zaharieva",surname:"Krasteva",fullName:"Asya Krasteva",slug:"asya-krasteva"},{id:"48928",title:"Prof.",name:"Angelina",middleName:null,surname:"Kisselova",fullName:"Angelina Kisselova",slug:"angelina-kisselova"},{id:"49455",title:"Dr.",name:"Maria",middleName:"Stoyanova",surname:"Dencheva-Garova",fullName:"Maria Dencheva-Garova",slug:"maria-dencheva-garova"},{id:"50207",title:"Dr.",name:"Tzvetelina",middleName:null,surname:"Georgieva",fullName:"Tzvetelina Georgieva",slug:"tzvetelina-georgieva"},{id:"57228",title:"Dr.",name:"Iliana",middleName:null,surname:"Stoeva",fullName:"Iliana Stoeva",slug:"iliana-stoeva"},{id:"94198",title:"Dr.",name:"Teodora",middleName:null,surname:"Bolyarova",fullName:"Teodora Bolyarova",slug:"teodora-bolyarova"}]},{id:"23803",type:"chapter",title:"Renal Aspects and Enzyme Replacement Therapy of Fabry Disease",slug:"renal-aspects-and-enzyme-replacement-therapy-of-fabry-disease",totalDownloads:1871,totalCrossrefCites:0,signatures:"Ane Cláudia Fernandes Nunes, Elvino José Guardão Barros, Virgílio Pimentel Delgado and Alvimar Gonçalves Delgado",reviewType:"peer-reviewed",authors:[{id:"55270",title:"Prof.",name:"Ane",middleName:null,surname:"Claudia Fernandes Nunes",fullName:"Ane Claudia Fernandes Nunes",slug:"ane-claudia-fernandes-nunes"},{id:"55283",title:"Prof.",name:"Elvino",middleName:"J G",surname:"Barros",fullName:"Elvino Barros",slug:"elvino-barros"},{id:"55284",title:"Prof.",name:"Alvimar",middleName:null,surname:"Delgado",fullName:"Alvimar Delgado",slug:"alvimar-delgado"},{id:"90025",title:"Dr.",name:"Virgilio Pimentel",middleName:null,surname:"Delgado",fullName:"Virgilio Pimentel Delgado",slug:"virgilio-pimentel-delgado"}]},{id:"23804",type:"chapter",title:"Chronic Inflammation and S100A12/ Receptor for Advanced Glycation Endproducts Axis: A Novel Risk Factor for Cardiovascular Disease in Patients with Chronic Kidney Disease?",slug:"chronic-inflammation-and-s100a12-receptor-for-advanced-glycation-endproducts-axis-a-novel-risk-facto",totalDownloads:1822,totalCrossrefCites:0,signatures:"Yasukiyo Mori, Yayoi Shiotsu, Eiko Matsuoka, Hiroshi Kado, Ryo Ishida and Hiroaki Matsubara",reviewType:"peer-reviewed",authors:[{id:"54967",title:"Dr.",name:"Yasukiyo",middleName:null,surname:"Mori",fullName:"Yasukiyo Mori",slug:"yasukiyo-mori"},{id:"58806",title:"Dr.",name:"Yayoi",middleName:null,surname:"Shiotsu",fullName:"Yayoi Shiotsu",slug:"yayoi-shiotsu"},{id:"58807",title:"Dr.",name:"Eiko",middleName:null,surname:"Matsuoka",fullName:"Eiko Matsuoka",slug:"eiko-matsuoka"},{id:"95105",title:"Dr.",name:"Hiroshi",middleName:null,surname:"Kado",fullName:"Hiroshi Kado",slug:"hiroshi-kado"},{id:"95106",title:"Dr.",name:"Ryo",middleName:null,surname:"Ishida",fullName:"Ryo Ishida",slug:"ryo-ishida"},{id:"95107",title:"Prof.",name:"Hiroaki",middleName:null,surname:"Matsubara",fullName:"Hiroaki Matsubara",slug:"hiroaki-matsubara"}]},{id:"23805",type:"chapter",title:"Choice of Renal Replacement Therapy and Role of Haemodialysis in the Intensive Care Unit",slug:"choice-of-renal-replacement-therapy-and-role-of-haemodialysis-in-the-intensive-care-unit",totalDownloads:2456,totalCrossrefCites:0,signatures:"Marlies Ostermann",reviewType:"peer-reviewed",authors:[{id:"39346",title:"Dr.",name:"Marlies",middleName:null,surname:"Ostermann",fullName:"Marlies Ostermann",slug:"marlies-ostermann"}]},{id:"23806",type:"chapter",title:"Dry Weight and Measurements Methods",slug:"dry-weight-and-measurements-methods",totalDownloads:18970,totalCrossrefCites:1,signatures:"Fansan Zhu and Nathan W. Levin",reviewType:"peer-reviewed",authors:[{id:"54177",title:"Dr.",name:"Fansan",middleName:null,surname:"Zhu",fullName:"Fansan Zhu",slug:"fansan-zhu"},{id:"58545",title:"Dr.",name:"Nathan W.",middleName:null,surname:"Levin",fullName:"Nathan W. Levin",slug:"nathan-w.-levin"}]},{id:"23807",type:"chapter",title:"Current Status of Synthetic and Biological Grafts for Hemodialysis",slug:"current-status-of-synthetic-and-biological-grafts-for-hemodialysis",totalDownloads:6351,totalCrossrefCites:0,signatures:"Purav P. Patel, Maria Altieri, Tarun R. Jindal, Steven R. Guy, Edward M. Falta, Eric A. Elster, Frank P. Hurst, Anton N. Sidawy and Rahul M. Jindal",reviewType:"peer-reviewed",authors:[{id:"44948",title:"Dr.",name:"Rahul",middleName:null,surname:"Jindal",fullName:"Rahul Jindal",slug:"rahul-jindal"}]}]},relatedBooks:[{type:"book",id:"1377",title:"Technical Problems in Patients on Hemodialysis",subtitle:null,isOpenForSubmission:!1,hash:"af6137ecadd693ee44dd2077bf997c05",slug:"technical-problems-in-patients-on-hemodialysis",bookSignature:"Maria Goretti Penido",coverURL:"https://cdn.intechopen.com/books/images_new/1377.jpg",editedByType:"Edited by",editors:[{id:"75822",title:"Prof.",name:"Maria Goretti",surname:"Penido",slug:"maria-goretti-penido",fullName:"Maria Goretti Penido"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"24609",title:"Bedside Linear Regression Equations to Estimate Equilibrated Blood Urea",slug:"bedside-linear-regression-equations-to-estimate-equilibrated-blood-urea",signatures:"Elmer A. Fernández, Mónica Balzarini and Rodolfo Valtuille",authors:[{id:"50757",title:"Prof.",name:"Elmer",middleName:"Andres",surname:"Fernandez",fullName:"Elmer Fernandez",slug:"elmer-fernandez"},{id:"59434",title:"Prof.",name:"Monica",middleName:null,surname:"Balzarini",fullName:"Monica Balzarini",slug:"monica-balzarini"},{id:"59435",title:"Prof.",name:"Rodolfo",middleName:"Amilcar",surname:"Valtuille",fullName:"Rodolfo Valtuille",slug:"rodolfo-valtuille"}]},{id:"24610",title:"Hemodialysis Access: The Fistula",slug:"hemodialysis-access-the-fistula",signatures:"Mary Hammes",authors:[{id:"44541",title:"Dr.",name:"Mary",middleName:null,surname:"Hammes",fullName:"Mary Hammes",slug:"mary-hammes"}]},{id:"24611",title:"The Brachio-Brachial Arteriovenous Fistula",slug:"the-brachio-brachial-arteriovenous-fistula",signatures:"Lucian Florin Dorobanţu, Ovidiu Ştiru, Cristian Bulescu, Şerban Bubenek and Vlad Anton Iliescu",authors:[{id:"48397",title:"Dr.",name:"Lucian Florin",middleName:null,surname:"Dorobantu",fullName:"Lucian Florin Dorobantu",slug:"lucian-florin-dorobantu"},{id:"110315",title:"Dr.",name:"Ovidiu",middleName:null,surname:"Stiru",fullName:"Ovidiu Stiru",slug:"ovidiu-stiru"},{id:"110317",title:"Dr.",name:"Cristian",middleName:null,surname:"Bulescu",fullName:"Cristian Bulescu",slug:"cristian-bulescu"},{id:"110318",title:"Dr.",name:"Serban",middleName:null,surname:"Bubenek",fullName:"Serban Bubenek",slug:"serban-bubenek"},{id:"110319",title:"Prof.",name:"Vlad Anton",middleName:null,surname:"Iliescu",fullName:"Vlad Anton Iliescu",slug:"vlad-anton-iliescu"}]},{id:"24612",title:"Vascular Access for Hemodialysis",slug:"vascular-access-for-hemodialysis",signatures:"Konstantinos Pantelias and Eirini Grapsa",authors:[{id:"49421",title:"Prof.",name:"Eirini",middleName:null,surname:"Grapsa",fullName:"Eirini Grapsa",slug:"eirini-grapsa"},{id:"52276",title:"Dr.",name:"Konstantinos",middleName:null,surname:"Pantelias",fullName:"Konstantinos Pantelias",slug:"konstantinos-pantelias"}]},{id:"24613",title:"Subjective Well-Being Measures of Hemodialysis Patients",slug:"subjective-well-being-measures-of-hemodialysis-patients",signatures:"Paulo Roberto Santos",authors:[{id:"46690",title:"Ph.D.",name:"Paulo",middleName:"Roberto",surname:"Santos",fullName:"Paulo Santos",slug:"paulo-santos"}]},{id:"24614",title:"Hemodialysis Access Infections, Epidemiology, Pathogenesis and Prevention",slug:"hemodialysis-access-infections-epidemiology-pathogenesis-and-prevention",signatures:"Nirosha D. Gunatillake, Elizabeth M. Jarvis and David W. Johnson",authors:[{id:"50425",title:"Prof.",name:"David",middleName:null,surname:"Johnson",fullName:"David Johnson",slug:"david-johnson"},{id:"50700",title:"Dr.",name:"Nirosha",middleName:null,surname:"Gunatillake",fullName:"Nirosha Gunatillake",slug:"nirosha-gunatillake"},{id:"50701",title:"Dr.",name:"Elizabeth",middleName:null,surname:"Jarvis",fullName:"Elizabeth Jarvis",slug:"elizabeth-jarvis"}]},{id:"24615",title:"Acute and Chronic Catheter in Hemodialysis",slug:"acute-and-chronic-catheter-in-hemodialysis",signatures:"Andrew S. H. Lai and Kar Neng Lai",authors:[{id:"52922",title:"Prof.",name:"Kar Neng",middleName:null,surname:"Lai",fullName:"Kar Neng Lai",slug:"kar-neng-lai"},{id:"52998",title:"Dr.",name:"Andrew S.H.",middleName:null,surname:"Lai",fullName:"Andrew S.H. Lai",slug:"andrew-s.h.-lai"}]},{id:"24616",title:"Complex Wounds in Patients Receiving Hemodialysis",slug:"complex-wounds-in-patients-receiving-hemodialysis",signatures:"Masaki Fujioka",authors:[{id:"53197",title:"Prof.",name:"Masaki",middleName:null,surname:"Fujioka",fullName:"Masaki Fujioka",slug:"masaki-fujioka"}]},{id:"24617",title:"Specifications of the Quality of Granulated Activated Charcoal Used in Water Systems Treatment in Hemodialysis Centers in Brazil",slug:"specifications-of-the-quality-of-granulated-activated-charcoal-used-in-water-systems-treatment-in-he",signatures:"Eden Cavalcanti Albuquerque Júnior, Marcos Antonio de Souza Barros, Manoel O. Mendez, Aparecido R. Coutinho and Telma T. Franco",authors:[{id:"54345",title:"PhD.",name:"Eden",middleName:"Cavalcanti",surname:"Albuquerque Jr",fullName:"Eden Albuquerque Jr",slug:"eden-albuquerque-jr"},{id:"61500",title:"Prof.",name:"Manoel",middleName:null,surname:"Orlando A. Mendez",fullName:"Manoel Orlando A. Mendez",slug:"manoel-orlando-a.-mendez"},{id:"61501",title:"Prof.",name:"Aparecido",middleName:null,surname:"Reis Coutinho",fullName:"Aparecido Reis Coutinho",slug:"aparecido-reis-coutinho"},{id:"61502",title:"Prof.",name:"Telma",middleName:null,surname:"Teixeira Franco",fullName:"Telma Teixeira Franco",slug:"telma-teixeira-franco"},{id:"93680",title:"BSc.",name:"Marcos Antonio",middleName:null,surname:"Barros",fullName:"Marcos Antonio Barros",slug:"marcos-antonio-barros"}]},{id:"24618",title:"Bioimpedance Measurement in the Kidney Disease Patient",slug:"bioimpedance-measurement-in-the-kidney-disease-patient",signatures:"Joëlle Cridlig, Mustapha Nadi and Michèle Kessler",authors:[{id:"62297",title:"Prof.",name:"Mustapha",middleName:null,surname:"Nadi",fullName:"Mustapha Nadi",slug:"mustapha-nadi"},{id:"62827",title:"Dr.",name:"Joëlle",middleName:null,surname:"J. Cridlig",fullName:"Joëlle J. Cridlig",slug:"joelle-j.-cridlig"},{id:"62828",title:"Ms.",name:"Michčle",middleName:null,surname:"Kessler",fullName:"Michčle Kessler",slug:"michcle-kessler"}]},{id:"24619",title:"Management of Fluid Status in Haemodialysis Patients: The Roles of Technology and Dietary Advice",slug:"management-of-fluid-status-in-haemodialysis-patients-the-roles-of-technology-and-dietary-advice",signatures:"Elizabeth Lindley, Lynne Aspinall, Claire Gardiner and Elizabeth Garthwaite",authors:[{id:"62467",title:"Dr.",name:"Elizabeth",middleName:null,surname:"Lindley",fullName:"Elizabeth Lindley",slug:"elizabeth-lindley"},{id:"103006",title:"Ms.",name:"Claire",middleName:null,surname:"Gardiner",fullName:"Claire Gardiner",slug:"claire-gardiner"},{id:"103008",title:"Ms.",name:"Lynne",middleName:null,surname:"Aspinall",fullName:"Lynne Aspinall",slug:"lynne-aspinall"},{id:"103009",title:"Dr.",name:"Elizabeth",middleName:null,surname:"Garthwaite",fullName:"Elizabeth Garthwaite",slug:"elizabeth-garthwaite"}]},{id:"24620",title:"Cell-Free Nucleic Acids as Biomarkers of Biocompatibility in Dialytic Process",slug:"cell-free-nucleic-acids-as-biomarkers-of-biocompatibility-in-dialytic-process",signatures:"Marie Korabečná and Aleš Hořínek",authors:[{id:"55927",title:"Dr.",name:"Marie",middleName:null,surname:"Korabecna",fullName:"Marie Korabecna",slug:"marie-korabecna"},{id:"57157",title:"Dr.",name:"Ales",middleName:null,surname:"Horinek",fullName:"Ales Horinek",slug:"ales-horinek"}]},{id:"24621",title:"Measuring System of Urea in Blood by Application in Recirculation for Hemodialysis Treatment",slug:"measuring-system-of-urea-in-blood-by-application-in-recirculation-for-hemodialysis-treatment",signatures:"G.A. Martinez",authors:[{id:"59796",title:"Dr.",name:"Gustavo Adolfo",middleName:null,surname:"Martinez Chavez",fullName:"Gustavo Adolfo Martinez Chavez",slug:"gustavo-adolfo-martinez-chavez"}]},{id:"24622",title:"Acetate Free Biofiltration with Potassium Profiled Dialysate (AFB-K)",slug:"acetate-free-biofiltration-with-potassium-profiled-dialysate-afb-k-",signatures:"R.I. Muñoz, I. Gallardo and J. Montenegro",authors:[{id:"43950",title:"Dr.",name:"Jesús",middleName:null,surname:"Montenegro",fullName:"Jesús Montenegro",slug:"jesus-montenegro"}]},{id:"24623",title:"Blood Volume Regulation",slug:"blood-volume-regulation",signatures:"Roland E. Winkler, Fabio Grandi and Antonio Santoro",authors:[{id:"43902",title:"Dr.",name:"Roland",middleName:"E.",surname:"Winkler, M.B.A.",fullName:"Roland Winkler, M.B.A.",slug:"roland-winkler-m.b.a."},{id:"50721",title:"Dr",name:"Fabio",middleName:null,surname:"Grandi",fullName:"Fabio Grandi",slug:"fabio-grandi"},{id:"50722",title:"Prof.",name:"Antonio",middleName:null,surname:"Santoro",fullName:"Antonio Santoro",slug:"antonio-santoro"}]},{id:"24624",title:"Acute Complications of Hemodialysis",slug:"acute-complications-of-hemodialysis",signatures:"Gülsüm Özkan and Şükrü Ulusoy",authors:[{id:"48454",title:"Dr.",name:"Gülsüm",middleName:null,surname:"Özkan",fullName:"Gülsüm Özkan",slug:"gulsum-ozkan"},{id:"51497",title:"Prof.",name:"Şükrü",middleName:null,surname:"Ulusoy",fullName:"Şükrü Ulusoy",slug:"sukru-ulusoy"}]},{id:"24625",title:"Review of the Effectiveness of Cellulose- and Polysulfone-Based Vitamin E-Bonded Dialysis Membranes",slug:"review-of-the-effectiveness-of-cellulose-and-polysulfone-based-vitamin-e-bonded-dialysis-membranes",signatures:"Masaharu Aritomi and Francesco Galli",authors:[{id:"54429",title:"Dr.",name:"Masaharu",middleName:null,surname:"Aritomi",fullName:"Masaharu Aritomi",slug:"masaharu-aritomi"},{id:"76370",title:"Prof.",name:"Francesco",middleName:null,surname:"Galli",fullName:"Francesco Galli",slug:"francesco-galli"}]}]}],publishedBooks:[{type:"book",id:"2075",title:"Diseases of Renal Parenchyma",subtitle:null,isOpenForSubmission:!1,hash:"2f0f00e88ec0f84bcefa06ddd6b1b888",slug:"diseases-of-renal-parenchyma",bookSignature:"Manisha Sahay",coverURL:"https://cdn.intechopen.com/books/images_new/2075.jpg",editedByType:"Edited by",editors:[{id:"65130",title:"Prof.",name:"Manisha",surname:"Sahay",slug:"manisha-sahay",fullName:"Manisha Sahay"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2076",title:"Chronic Kidney Disease and Renal Transplantation",subtitle:null,isOpenForSubmission:!1,hash:"98fa21235bd6030e806911316308ea85",slug:"chronic-kidney-disease-and-renal-transplantation",bookSignature:"Manisha Sahay",coverURL:"https://cdn.intechopen.com/books/images_new/2076.jpg",editedByType:"Edited by",editors:[{id:"65130",title:"Prof.",name:"Manisha",surname:"Sahay",slug:"manisha-sahay",fullName:"Manisha Sahay"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3257",title:"Current Issues and Future Direction in Kidney Transplantation",subtitle:null,isOpenForSubmission:!1,hash:"32aaeaf9eae59e0b53029c221285c846",slug:"current-issues-and-future-direction-in-kidney-transplantation",bookSignature:"Thomas Rath",coverURL:"https://cdn.intechopen.com/books/images_new/3257.jpg",editedByType:"Edited by",editors:[{id:"67436",title:"Dr.",name:"Thomas",surname:"Rath",slug:"thomas-rath",fullName:"Thomas Rath"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3258",title:"The Latest in Peritoneal Dialysis",subtitle:null,isOpenForSubmission:!1,hash:"2ad689203925cdc49dd44bdfeb3e9f0f",slug:"the-latest-in-peritoneal-dialysis",bookSignature:"Abelardo Aguilera Peralta",coverURL:"https://cdn.intechopen.com/books/images_new/3258.jpg",editedByType:"Edited by",editors:[{id:"159084",title:"Dr.",name:"Abelardo",surname:"Aguilera Peralta",slug:"abelardo-aguilera-peralta",fullName:"Abelardo Aguilera Peralta"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3267",title:"Hemodialysis",subtitle:null,isOpenForSubmission:!1,hash:"960f1c2998be5bdb86d0b9412f13fb0b",slug:"hemodialysis",bookSignature:"Hiromichi Suzuki",coverURL:"https://cdn.intechopen.com/books/images_new/3267.jpg",editedByType:"Edited by",editors:[{id:"156403",title:"Prof.",name:"Hiromichi",surname:"Suzuki",slug:"hiromichi-suzuki",fullName:"Hiromichi Suzuki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],publishedBooksByAuthor:[{type:"book",id:"1375",title:"Hemodialysis",subtitle:"Different Aspects",isOpenForSubmission:!1,hash:"3989e961b6cf011ae00f297f1f47eb0d",slug:"hemodialysis-different-aspects",bookSignature:"Maria Goretti Penido",coverURL:"https://cdn.intechopen.com/books/images_new/1375.jpg",editedByType:"Edited by",editors:[{id:"75822",title:"Prof.",name:"Maria Goretti",surname:"Penido",slug:"maria-goretti-penido",fullName:"Maria Goretti Penido"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"789",title:"Emerging Research and Treatments in Renal Cell Carcinoma",subtitle:null,isOpenForSubmission:!1,hash:"616688465519d2b5bcb1d867a3806714",slug:"emerging-research-and-treatments-in-renal-cell-carcinoma",bookSignature:"Robert J. Amato",coverURL:"https://cdn.intechopen.com/books/images_new/789.jpg",editedByType:"Edited by",editors:[{id:"73752",title:"Dr.",name:"Robert",surname:"Amato",slug:"robert-amato",fullName:"Robert Amato"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},onlineFirst:{chapter:{type:"chapter",id:"81569",title:"Impact of Interferon Alpha/Beta in the Management of Chronic Myeloproliferative Disorders",doi:"10.5772/intechopen.104501",slug:"impact-of-interferon-alpha-beta-in-the-management-of-chronic-myeloproliferative-disorders",body:'Chronic myeloproliferative disorders are a group of clonal diseases of the stem cell. It is a group of several diseases with some common features. They derive from a multipotential hematopoietic stem cell. A clone of neoplastic cells in all these neoplams is characterized by a lower proliferative activity than that of acute myeloproliferative diseases. In each of these diseases, leukocytosis, thrombocythemia, and polyglobulia may appear at some stage, depending on the diagnosis [1, 2].
The research on interferon has been going on since the 1950s [3]. Then, the attention was paid to its influence on the immune system. It has been noted that it can exert an antiproliferative effect by stimulating cells of the immune system [4]. In 1987, a publication by Ludwig et al. was published, which reported the effectiveness of interferon alpha in the treatment of chronic myeloproliferative disorders [5].
More and more new studies have been showing the effectiveness of interferon alpha in reducing the number of platelets, reducing the need for phlebotomies in patients with polycythemia vera and also in reducing the number of leukocytes. Moreover, interferon reduced the symptoms of myeloproliferative disorders such as redness and itching of the skin. Additionally, it turned out to be effective in reducing the size of the spleen.
Further studies on the assessment of remission using molecular-level response assessments indicate that the interferon action in chronic myeloproliferation diseases targets cells from the mutant clone with no effect on normal bone marrow cells [6].
Over the years, interferon alpha-2a and interferon alpha-2b have been introduced into the treatment of chronic myeloproliferation, followed by their pegylated forms. The introduction of pegylated forms allowed for a reduction in the number of side effects and less frequent administration of the drug to patients. In recent years, monopegylated interferon alpha-2b has been used to further increase the interval between drug administrations while maintaining its antiproliferative efficacy.
The exact mechanism of action of interferon alpha in the treatment of chronic myeloproliferative disease is still not fully understood, but it has an impact on JAK2 (Janus Kinase) signal transducers and activates the STAT signal pathway (Janus Kinase/SignalTransducer and Activator of Transcription).
Interferon alpha binds to IFNAR1 and IFNAR2c, which are type I interferon receptors. Interferon alpha has an impact on JAK2(Janus Kinase) signal transducers and activates the STAT signal pathway. The disturbances in this signaling pathway are observed in chronic myeloproliferative disorders [7].
Interferon inhibits the JAK-STAT signaling pathway by directly inhibiting the action of thrombopoietin in this pathway [8].
So far, three driver mutations have been described in the course of chronic myeloproliferative diseases that affect the functioning of the JAK-STAT pathway.
JAK2 kinase and JAK1, JAK3, and TYK2 kinases belong to the family of non-receptor tyrosine kinases. They are involved in the intracellular signal transduction of the JAK-STAT pathway. It is a system of intracellular proteins used by growth factors and cytokines to express genes that regulate cell activation, proliferation, and differentiation. The mechanism of JAK activation is based on the autophosphorylation of tyrosine residues that occurs after ligand binds to the receptor. JAK2 kinase transmits signals from the hematopoietic cytokine receptors of the myeloid lineage (erythropoietin, granulocyte-colony stimulating factor thrombopoietin, and lymphoid lineage [9].
A somatic G/T point mutation in exon 14 of the JAK2 kinase gene converts valine to phenylalanine at position 617 (V617F) in the JAK2 pseudokinase domain, which allows constitutive, ligand-independent activation of the receptor to trigger a proliferative signal [10].
Mutation of the MPL gene, which encodes the receptor for thrombopoietin, increases the sensitivity of magekaryocytes to the action of thrombopoietin, which stimulates their proliferation [11].
Malfunction of calreticulin as a result of mutation of the CARL gene leads to the activation of the MPL-JAK/STAT signaling pathway, which is independent of the ligand, as calreticulin is responsible, for the proper formation of the MPL receptor. Consequently, there is a clonal proliferation of hematopoietic stem cells [12].
Below, we provide an overview of some clinical studies on the efficacy of interferon in chronic myeloproliferative disorders.
Polycythemia vera (PV) is characterized by an increase in the number of erythrocytes in the peripheral blood.
Polycythemia vera is caused by a clonal mutation in the multipotential hematopoietic stem cell of the bone marrow. The mutation leads to an uncontrolled proliferation of the mutated cell clone, independent of erythropoietin and other regulatory factors. As the mutation takes place at an early stage of hematopoiesis, an increase of the number of erythrocytes as well as of leukocytes and platelets is observed in the peripheral blood. The cause of proliferation in PV independent from external factors is a mutation in the Janus 2 (JAK2) tyrosine kinase gene. The V617F point mutation in the JAK2 gene is responsible for about 96% mutation, and in the remaining cases the mutation arises in exon 12. Both mutations lead to constitutive activation of the JAK-STAT signaling pathway [13].
As a result of the uncontrolled proliferation, blood viscosity increases, which generates symptoms such as headaches and dizziness, visual disturbances, or erythromelalgia. As the number of all hematopoietic cells, including the granulocytes ones, increases, the difficult to control symptoms of their hyperdegranulation may appear, among which gastric ulcer or skin itching is often observed. During the disease progression, the spleen and liver become enlarged.
The most common complication of the disease is episodes of thrombosis, especially arterial one. During the course of the disease, it can also evolve into myelofibrosis or acute myeloid leukemia.
The treatment of PV is aimed at preventing thromboembolic complications, relieving the general symptoms, the appearance of hepatosplenomegaly as well as preventing its progression.
Each patient should receive an antiplatelet drug chronically, and usually acetylsalicylic acid is the choice. Most often, the treatment is started with phlebotomy in order to rapidly lower the hematocrit level. If cytoreductive therapy is necessary, the drugs of first choice are hydroxycarbamide and interferon [2].
However, the research on the mechanism of the action of interferons is still ongoing. In vitro studies with CD34+ cells from peripheral blood of patients diagnosed with polycythemia vera showed that interferon inhibits clonal changed cells selectively. It was found that interferon alpha-2b and pegylated interferon alpha-2a reduce the percentage of cells with JAK2 V617F mutation by about 40%. Pegylated interferon alpha-2a works by activating mitogen-activated protein kinase P38. It affects CD34+ cells of patients with polycythemia vera by increasing the rate of their apoptosis [6].
A case of a patient with PV with a confirmed chromosomal translocation t(6;8) treated with interferon alpha-2b, which resulted in a reduction of the clone with translocation by 50% from the baseline value, was also described [14].
In 2019, the results of a phase II multicenter study were published, which aimed at assessing the effectiveness of recombinant pegylated interferon alpha-2a in cases of refractory to previously hydroxycarbamide therapy. The study included 65 patients with essential thrombocythemia (ET) and 50 patients with polycythemia vera. All patients had previously been treated with hydroxycarbamide and showed resistance to this drug or its intolerance.
The assessment of the response was performed after 12 months of treatment. Overall response rate to interferon was higher in patients diagnosed with ET than in patients with polycythemia vera. In essential thrombocythemia, the percentage of achieved complete remissions was 43 and 26% of partial remissions. The remission rate in ET patients was higher if calreticulin CALR gene mutation was present. Patients with polycythemia vera achieved complete remission in 22% of cases and partial remission in 38% of cases.
Treatment-related side effects that follow to discontinuation of treatment were reported in almost 14% of patients [15].
The duration of response to treatment with pegylated interferon alpha-2a and the assessment of its safety in long-term use in patients with chronic myeloproliferative disorders was the goal of a phase II of the single-center study. Forty-three adult patients with polycythemia vera and 40 patients with essential thrombocythemia were enrolled in the study. The complete hematological response was defined as a decrease in hemoglobin concentration below 15.0 g/l, without phlebotomies, a resolution of splenomegaly, and no thrombotic episodes in the case of PV, and for essential thrombocythemia—a decrease platelet count below 440,000/μl and two other conditions as above. The assessment of the hematological response was performed every 3–6 months. The median follow-up was 83 months.
The hematological response was obtained in 80% of cases for the entire group. In patients with polycythemia vera, 77% of patients achieved a complete response (CR) while 7% a partial response (PR). The duration of response averaged 65 months for CR and 35 months for PR. In the group of patients diagnosed with essential thrombocythemia, CR was achieved in 73% and PR in 3%. The durance of CR was 58 months and PR was 25 months.
The molecular response for the entire group was achieved in 63% of cases.
The overall analysis showed that the duration of hematological remission and its achievement with pegylated interferon alpha-2a treatment is not affected neither by baseline disease characteristics nor JAK2 allele burden and disease molecular status. There was also no effect on age, sex, or the presence of splenomegaly.
During the course of the study, 22% of patients discontinued the treatment, because of toxicity. Toxicity was the greatest at the beginning of treatment. The starting dose was 450 μg per week and was gradually tapered off.
Thus, on the basis of the above observations, the researchers established that pegylated interferon alpha-2a may give long-term hematological and molecular remissions [16].
The assessment of pegylated interferon alpha-2a in group of patients diagnosed with polycythemia vera only was performed. The evaluation was carried out on a group of 27 patients. Interferon decreased the JAK2 V617F allele burden in 89% of cases. In three patients who were JAK2 homozygous at baseline, after the interferon alpha-2a treatment wild-type of JAK2 reappeared. The reduction of the JAK2 allele burden was estimated from 49% to an average 27%, and additional in one patient the mutant JAK2 allele was not detectable after treatment. It can therefore be postulated that the action of pegylated interferon alpha-2a is directed to cells of the polycythemia vera clone [17].
In 2005, the results of treatment by pegylated interferon alpha-2b of 21 patients diagnosed with polycythemia vera and 21 patients diagnosed with essential thrombocythemia were published. In the case of polycythemia vera in 14 patients, PRV-1 gene mutation was initially detected. In 36% of cases, PRV-1 expression normalized after treatment with pegylated interferon alpha-2b. For the entire group of 42 patients, the remission assessment showed that complete remission was achieved in 69% cases after 6 months of treatment. However, only in 19 patients remission was still maintained 2 years after the start of the study. Pegylated interferon alpha-2b was equally effective in patients with PV and ET. The use and the type of prior therapy did not affect the achievement of remission [18].
Another study with enrolled only PV patients included 136 patients. They were divided into two arms. One group received interferon alpha-2b and the other group received hydroxycarbamide. Interferon dosage was administered in 3 million units three times a week for 2 years and then 5 million units two times a week. Hydroxycarbamide was administered at a dose between 15 and 20 mg/kg/day.
In the group of patients treated with interferon, a significantly lower percentage of patients developed erythromelalgia (9.4%) and distal parasthesia (14%) compared with the group treated with hydroxycarbamide, for whom these percentages were respectively: 29 and 37.5%. Interferon alpha-2b was found to be more effective in inducing a molecular response, which was achieved in 54.7% of cases, in comparison with hydroxycarbamide—19.4% of cases, despite the fact that the percentage of achieved general hematological responses did not differ between the groups and amounted about 70%. The 5-year progression free period in the interferon group was achieved in a higher percentage (66%) than in the hydroxycarbamide group (46.7%) [19].
The most recent form of interferon approved by the
Thanks to these changes to the structure of the molecule, it was possible to achieve a significant increase in its half-life. Ropeginterferon can be administered subcutaneously to patients every 14 days. The clinical trials conducted so far have assessed the ropeginterferon dose from 50 micrograms to a maximum dose of 500 microgams administered as standard every 2 weeks. The possible dose change in case of side effects includes not only the reduction of the drug dose itself, but also the extension of the interval between doses. The extension of the dosing interval up to 4 weeks was assessed.
Ropeginterforn was approved in 2019 by the EMA for the use in patients diagnosed with polycythemia vera without splenomegaly, as monotherapy.
Ropeginterferon, like the previous forms of interferons used in treatment, is contraindicated in patients with severe mental disorders, such as severe depression. It is also a contraindication in patients with noncompensatory standard treatment of disorders of the thyroid gland as well as severe forms of autoimmune diseases. The safety profile of ropeginterferon is similar to that of other forms of alpha interferons. The most common side effects are flu-like symptoms [20].
Ropeginterferon has been shown to exhibit in vitro activity against JAK2-mutant cells. The activity of ropeginterferon against JAK2-positive cells is similar to that of other forms of interferons used actually for standard therapy. Ropeginterferon has an inhibitory effect on erythroid progenitor cells with a mutant JAK2 gene. At the same time, it has almost no effect on progenitor cells without the mutated allele (JAK2-wile-type) and normal CD34+ cells. A gradual decrease of JAK2-positive cells was observed in patients with PV during ropeginterferon treatment. The examination was performed after 6 and 12 months of treatment. In comparison, the reduction in the percentage of JAK2 positive cells in patients treated with hydroxycarbamide was significantly lower.
These results may suggest that ropeginterferon may cause elimination of the mutant clone, but further prospective clinical trials are needed to confirm this theory. The evaluation was performed on a group of patients enrolled in the PROUD-PV study who were treated in France [21].
In 2017, a multicenter study was opened in Italy. The study was of the second phase. In total, 127 patients with polycythemia vera were included in the study. All patients enrolled on the study had low-risk PV. The clinical trial consisted of two arms. Patients received phlebotomies and low-dose aspirin in one arm and ropeginterferon in the other arm. The aim of the study was to achieve a hematocrit of 45% or lower without any evidence of disease progression. Ropeginterferon was administered every 2 weeks at a constant dose of 100 μg.
The response to the treatment was assessed after 12 months. The reduction of hematocrit to the assumed level was achieved in significantly higher percentage of patients in the ropeginterferon group than of patients who received only phlebotomies and aspirin. In addition, none of the patients treated with ropeginterferon experienced disease progression during the course of the study, while among those treated with phlebotomies, 8% of patients progressed.
Grade 4 or 5 adverse events were not observed in patients treated with ropeginterferon, and the incidence of remaining adverse event (AE) was small and comparable in both arms. The most common side effects in the ropeginterferon group were flu-like symptoms and neutropenia; however, the third-grade neutropenia was the most common (8% of cases) [22].
One of the most important clinical studies on the use of ropeginterferon was the PROUD-PV study and its continuation: the CONTINUATION-PV study. These were three-phase, multicenter studies. The aim of the study was to compare the effectiveness of ropeginterferon in relation to hydroxycarbamide. The study included adult patients diagnosed with polycythemia vera treated with hydroxycarbamide for less than 3 years and no cytoreductive treatment at all. In total, 257 patients received this treatment. The patients were divided into two groups: those receiving ropeginterferon or the other being given hydroxycarbamide.
During the PROUD-study, drug doses were increased until the hematocrit was achieved below 45% without the use of phlebotomies, and the normalization of the number of leukocytes and platelets was reached.
The PROUD-PV study lasted 12 months. After this time, the patients continued the treatment under the CONTINUATION-PV study for further 36 months. After the final analysis performed in the 12th month at the end of PROUD study, it was found that the hematological response rates did not differ between the ropeginterferon and hydroxycarbamide treatment groups. These were consecutively 43% in the ropeginterferon arm and 46% in the control arm.
However, after analyzing the CONTINUATION- PV study, it turned out that after 36 months of treatment, the rates of hematological responses begin to prevail in the group of patients receiving ropeginterferon, 53% versus 38% in the control group. Thus, from the above data, it can be seen that the response rate to ropeginterferon increases with the duration of treatment [23].
Another analysis of patients participating in the PROUD and CONTINUATION studies was based on the assessment of treatment results after 24 months, dividing patients into two groups according to age (under and over 60 years).
The initial comparison of both groups of patients showed that older patients had a more aggressive course of the disease. Patients over 60 years of age had a higher percentage of cells with a mutant JAK2 allele. They experienced both general symptoms and some complications, such as thrombosis, more frequently. Both patients under 60 years of age and over 60 years of age in the ropeginterferon arm had a higher rate of molecular response, namely 77.1 and 58.7% compared with the HU remission: 33.3 and 36.1%, respectively. Significantly higher reductions in the JAK2 allele were observed in both groups of patients after ropeginterferon treatment: it was 54.8% for younger patients and 35.1% for elderly patients. For comparison, this difference in the group of patients treated with HU was 4.5 and 18.4%, respectively.
What is more, the age did not affect the frequency of ropeginterferon side effects. In addition, the incidence of adverse ropeginterferon disorders was similar to that observed in the hydroxycarbamide group [24].
Essential thrombocythemia is a clonal growth of multipotential stem cells in the bone marrow. The consequence of this is increased proliferation of megakaryocytes in the bone marrow and an increase in the number of platelets in the peripheral blood. The level of platelets above 450,000/μl is considered a diagnostic criterion.
Essential thrombocythemia may progress over time to a more aggressive form of myeloproliferation, i.e., myelofibrosis. The disease can also evolve into acute myeloid leukemia or myelodysplastic syndrome, both with very poor prognosis. Thromboembolic complications are serious, and they concern over 20% of patients. Thrombosis occurs in the artery and venous area. Moreover, in patients with a very high platelet count, above 1,000,000/μl, bleeding may occur as a result of secondary von Willebrand syndrome [1, 2].
The treatment of ET is primarily aimed to prevent thrombotic complications.
In low-risk patients, only acetylsalicylic acid is used. In cases of high-risk patients, hydroxycarbamide is the first-line drug for most patients. Anagrelide and interferon are commonly used as second-line drugs.
Due to the possible effects of hydroxycarbamide of cytogenetic changes in the bone marrow cells after long-lasting usage, some experts recommend the use of interferon in younger patients in the first line. Interferon is also used as the drug of choice in patients planning a pregnancy [25].
The efficacy of pegylated interferon alpha-2a was assessed on the basis of the group of 39 patients with essential thrombocythemia and 40 patients with polycythemia vera.
Of the overall group, 81% of patients were previously treated prior to the study entry. The patients received pegylated interferon alpha-2a in a dose of 90 μg once a week. The dose of 450 μg was associated with a high percentage of intolerance.
In patients with essential thrombocythemia, the complete remission was achieved in 76%, while the overall hematological response rate brought 81%. Moreover, the molecular remission was achieved in 38%, in 14% of cases, JAK2 transcript became not detectable.
Patients diagnosed with polycythemia vera achieved 70% complete hematological remission and 80% general hematological response to treatment. JAK2 transcript was undetectable in 6% of patients. Molecular remission was achieved in 54% of cases.
Pegylated interferon alpha-2a at the dose of 90 μg per week was very well tolerated. In total, 20% of patients experienced a grade of 3 or 4 of adverse reaction, which was neutropenia. In addition, an increase in liver function tests was observed. Grade 4 of AE was not observed among patients who started the treatment with 90 μg/week while grade 3 neutropenia was an adverse event in only 7% of cases [26].
The effect of interferon alpha-2b treatment in patients with ET and PV was investigated. The study was prospective. Some of the results concerning the group of patients with polycythemia vera are presented in the subsection on polycythemia vera. In total, 123 patients with diagnosed essential thrombocythemia participated in the study. All of them received interferon alpha-2b. The patients were divided into two groups depending on the presence of the JAK2 V617F mutation. The enrolled patients were between 18 and 65 years of age. The treatment they received was, sequentially, interferon alpha-2b in the dose of 3 million units three times a week for the first 2 years, after which time the dose was changed into a maintenance dose, which amounted to 5 million units two times a week.
The analysis showed that the patients with the JAK2 V617F mutation present in a higher percentage achieved an overall hematological response as well as a complete hematological response. The overall hematological response was achieved in 83% of patients with JAK2 mutation, and the complete hematological remission was achieved in 23 cases. In the group of ET patients without the JAK2 V617F mutation, overall hematological response was achieved in 61.4%, while the complete hematological remission was achieved in 12 patients. The 5-year progression-free survival was obtained in 75.9% in the JAKV617F group and only in 47.6% without the mutation.
A significant proportion of patients experienced mild side effects. Grade 3 and 4 of adverse events were severe, most of them being a fever. The isolated cases of elevated liver tests and nausea have also been reported [19].
Pegylated interferon alpha-2b in patients with essential thrombocythemia who were previously treated with hydroxycarbamide, anagrelide, and other forms of interferon alpha, however, due to the lack of efficacy or toxicity, the patients required a change of treatment, was assessed. Pegylated interferon alpha-2b turned out to be effective in these cases. It led to the complete hematological remission in 91% of patients after 2 months of therapy, and in 100% of patients after 4 months. However, merely 11 patients participated in the study. Also only two patients required treatment discontinuation due to the side effects such as depression and general fatigue grade 3 [27].
In case of pregnant patients, interferon is currently considered the only safe cytoreductive drug. Over the years, several analyses of the results of interferon treatment during pregnancy have been carried out.
The assessment of 34 pregnancies in 23 women diagnosed with ET was performed retrospectively. All the pregnancies included in the analysis were of high risk. This high risk was associated with a high platelet count above 1,500,000/μl, a history of thrombotic episode, severe microcirculation disorders, or a history of major hemorrhage.
It turned out that the use of interferon allowed the birth of an alive child in 73.5% of cases. There was no difference in efficacy between the basic and pegylated forms of interferon alpha. In pregnancies without interferon treatment, the percentage of live births was only 60%. Moreover, it was not found if the presence of the JAK2 V617F mutation had any influence on the course of pregnancy [28].
An analysis of the course of pregnancy in patients with ET was assessed in Italy. Data from 17 centers were taken into account. Data from 122 pregnancies were collected from 92 women. In patients diagnosed with essential thrombocythemia, the risk of the spontaneous loss of pregnancy is about 2.5 times higher than among the general population. In the contrary to the study quoted above, it was found that the presence of the JAK2 mutation increases the risk of pregnancy loss. The proportion of live births in patients exposed to interferon during pregnancy was 95%, compared with 71.6% in the group of patients not treated with interferon.
The multivariate analysis also showed that the use of acetylsalicylic acid during pregnancy had no effect on the live birth rate of patients with ET [29].
Whatever its form, interferon is the drug of first choice in pregnancy. Hydroxycarbamide and anagrelide should be withdrawn for about 6 months, and at least for 3 months, before the planned conception. Experts recommend the use of interferon in high-risk pregnancies [30]. A Japanese analysis of 10 consecutive pregnancies in ET patients showed 100% live births in patients who received interferon [31].
In myelofibrosis (MF), monoclonal megakaryocytes produce cytokines that stimulate the proliferation of normal, non-neoplastic fibroblasts and stimulate angiogenesis. The consequence of this is the gradual fibrosis of the bone marrow, impaired hematopoiesis in the bone marrow, and the formation of extramedullary location mainly in the sites of fetal hematopoiesis, i.e., in the spleen and the liver.
The production of various cytokines by neoplastic megakaryocytes leads to the proliferation of normal, noncancerous fibroblasts as well as to increased angiogenesis.
Progressive bone marrow fibrosis leads to worsening anemia and thrombocytopenia. On the other hand, the production of proinflammatory cytokines by megakaryoblasts leads to the general symptoms such as weight loss, fever, joint pain, night sweats, and consequently, progressive worsening of general condition.
The prognosis for myelofibrosis is poor. In about 20% of patients, myelofibrosis evolves into acute myeloid leukemia with poor prognosis.
Currently, the only effective method of treatment that gives a chance to prolong the life is allogeneic bone marrow transplantation. However, this method is only available to younger patients.
The goal of treatment of patients who have not been qualified for allotranspalntation is to reduce the symptoms and to improve the patient’s quality of life. In case of leukocytosis cytoreducing drugs, such as hydroxycarbamide, melphalan, or cladribine can be used. They cause a reduction in the number of leukocytes and may, to some extent, inhibit splenomegaly. Interferon alpha has been used successfully for the treatment of myelofibrosis for many years. The results of its effectiveness will be presented below [2].
Currently, the JAK2 inhibitor ruxolitinib is approved for the treatment of myelofibrosis with enlarged spleen in intermediate and high-risk patients. Ruxolitinib reduces the size of the spleen, reduces general symptoms, and improves the quality of life; however, it does not prolong the overall survival of patients [32].
In 2015, the results of a retrospective study were published to compare the histological parameters of the bone marrow before and after interferon treatment. Twelve patients diagnosed with primary myelofibrosis as well as post-PV MF and post-ET MF were enrolled in the study. Patients were treated with pegylated recombinant interferon alpha-2a or recombinant interferon alpha-2b in standard doses. The time of treatment was from 1 to 10 years. Some patients had previously been treated with hydroxycarbamide or anagrelide. In all cases, karyotype was normal. The prognostic factor of Dynamic International Prognostic Scoring System (DIPSS) was assessed at the beginning as well as during the treatment.
Bone marrow cellularity decreased in cases with increased bone marrow cellularity before the treatment. After the interferon treatment, a reduction in the degree of bone marrow fibrosis was found. The parameters, such as the density of naked nuclei and the density of megakaryocytes in the bone marrow, also improved.
It proves that if the JAK2 V617F mutation had been present, DIPSS was decreased after interferon treatment. This relationship was not observed in patients without the JAK2 V617F mutation. The improvement in peripheral blood morphological parameters and the overall clinical improvement correlated with the improvement in the assessed histological parameters of the bone marrow.
Before the initiation of interferon, seven patients had splenomegaly. During the treatment with interferon, the complete resolution of splenomegaly was achieved in 17% of patients (two cases), and its size decreased in 25% (three cases). A good clinical response was achieved in 83% during interferon therapy. There was no significant difference in response between the two types of interferon used [33].
A prospective study was also conducted in patients with low and intermediate-1 risk group myelofibrosis. Seventeen patients were enrolled. Patients received interferon alpha-2b (0.5–3 milion units/three times a week) or pegylated interferon alpha-2a (45–90 μg/week). The duration of therapy was on average 3.3 years.
Most of the patients responded to the treatment. Partial remission was found in seven patients and complete remission in two patients. Moreover, in four cases, the disease was stabilized and in one case the clinical improvement was achieved. Three patients did not respond to treatment at all and progressed to myelofibrosis. Additionally, the assessment in reducing spleen size was performed. At baseline, 15 patients have splenomegaly, nine of them achieved the compete regression of spleen size [34].
However, the efficacy of interferon in the treatment of myelofibrosis appears to be limited only to a less advanced form, when the bone marrow still has an adequate percentage of normal hemopoiesis and the marrow stroma is not significantly fibrotic. In more advanced stages, interferon was not shown to have any significant effect on the regression of the fibrosis process [35].
In 2020, the results of the COMBI study were published. That was a two-phase, multicenter, single-arm study that investigated the efficacy and safety of the combination of ruxolitinib and pegylated interferon alpha. Thirty-two patients with PV and 18 patients with primary and secondary myelofibrosis participated in the study. The patients were at age 18 and older. Remission was achieved in 44% of myelofibrosis cases, including 28% (5 patients) of complete remission. In patients with PV, the results were slightly worse: 31% of remissions, including 9% of complete remissions. Patients received pegylated interferon alpha-2a (45 μg/week) or pegylated interferon alpha-2b (35 μg/week) in low doses and ruxolitinib in doses of 5–20 mg twice a day.
For the entire group of patients (with PV and MF), the initial JAK2 allele burden was 47% at baseline, and after 2 years of treatment with interferon and ruxolitinib, it decreased to 12%.
The treatment toxicity was low. The highest incidence of side effects occurred at initiation of therapy. It was mostly anemia and thrombocytopenia.
The observations from the COMBI study show that, for the combination of interferon in lower doses with ruxolitinib, it may be effective and well tolerated even in the group of patients who had intolerance to interferon used as the only drug in higher doses. The combined treatment improved the bone marrow in terms of fibrosis and its cellularity. It also allowed to improve the value of peripheral blood counts [36].
It is currently known that some of the additional mutations are associated with a worse prognosis in patients with myelorpoliferation, including patients with myelofibrosis. Some of these mutations have been identified as high-risk molecular mutations. These are ASXL1, EZH2, IDH1/2, or SRSF2. Earlier studies have shown their association with a more aggressive course of the disease, worse prognosis, and shorter survival of patients, as well as a poorer response to treatment. Due to their importance, they have been included in the diagnostic criteria of myelofibrosis [37].
It is also known that the presence of driver mutations, i.e., JAK2, CALR, and MPL or triple negativity, may affect the course of myeloproliferation, including the incidence of thromboembolic complications.
The assessment of the influence of driver mutations and a panel of selected additional mutations on the effectiveness of interferon treatment in patients with myelofibrosis was performed on a group of 30 patients. Only the patients with low- and intermediate-1-risk were enrolled in the study. The treatment with pegylated interferon alpha-2a or interferon alpha-2b resulted in a complete remission in two patients and partial remission in nine patients. The disease progressed in three cases. One patient relapsed and four died. The remaining patients achieved a clinical improvement or disease stabilization. In the studied group, it was not found if the effectiveness of interferon treatment was influenced by the lack of driver mutations. Among the group of four patients with additional mutations, two died and one had disease progression. It was a mutation of ASXL1 and SRSF2. The treatment with interferon in patients without additional molecular mutations in the early stages of the disease may prevent further progression of the disease [38].
The side effects of interferon in the group of patients with myelofibrosis are similar to those occurring after the treatment of other chronic myeloproliferative diseases. The most frequently described are hematological toxicity- anemia and thrombocytopenia, less often is the appearance of leukopenia. Hematological toxicity usually resolves with dose reduction or extension of the dose interval. The most frequently nonhematological toxicity was fatigue, muscle pain, weakness, and depression symptoms. All symptoms are usually mild and do not exceed grade 2 [38].
However, the use of interferon in the treatment of myelofibrosis has not been recommended as a standard therapy. Interferon is still being evaluated in clinical trials, or it is used in selected patients as a nonstandard therapy in this diagnosis.
Mastocytosis is characterized by an excessive proliferation of abnormal mast cells and their accumulation in various organs.
The basis for the development of mastocytosis is ligand-independent activation of the KIT receptor, resulting from mutations in the KIT proto-oncogene. The KIT receptor is a trans membrane receptor with tyrosine kinase’s activity. Its activation stimulates the proliferation of mast cells. That excessive numbers of mast cells infiltrate tissues and organs and release mediators such as histamine, interleukine-6, tryptase, heparin, and others, which are responsible for the appearance of symptoms typical of mastocytosis. In addition, the infiltration of tissues for mast cells itself causes damage to the affected organs.
The prognosis of mastocytosis depends on the type of the disease. In the case of cutaneous mastocytosis (CM), in the majority of cases prognosis is good and the disease does not shorten the patient’s life, but in aggressive systemic mastocytosis (ASM), the average follow-up is about 40 months. Mast cell leukemia has a poor prognosis with a median follow-up of approximately 1 year.
Systemic mastocytosis usually requires the implementation of cytoreductive therapy. The first line of therapy is interferon alone or its combination with corticosteroids. In aggressive systemic mastocytosis, the first line in addition to interferon 2-CdA can be used. An effective drug turned out to be midostaurin in the case of the present KIT mutation. In patients without the KIT D816V mutation, treatment with imatinib may be effective. In the case of mast cell leukemia, multidrug chemotherapy is most often required, as in acute leukemias, followed by bone marrow transplantation [39].
Systemic mastocytosis requiring treatment is a rare disease, this is why the studies available in the literature evaluating various therapies concern mostly small groups of patients.
In 2002, the French authors presented their experiences on the use of interferon in patients with systemic mastocytosis. They included 20 patients. The patients received interferon alpha-2b in gradually increased doses.
The patients were assessed after 6 months. In cases in which bone marrow was infiltrated for mast cells at baseline, it still remained infiltrated after 6 months of treatment.
However, the responses were obtained in terms of symptoms related to mast cell degranulation. Partial remission was achieved in 35% of patients and minor remission in 30%. It concerns mainly skin lesions and vascular congestion. Moreover, the assessment of the histamine level in the plasma revealed a decrease of it in patients who previously presented symptoms related to the degranulation of mast cells, such as gastrointestinal disorders and flushing.
A high percentage of side effects were found during treatment. They concerned 35% of patients. Depression and cytopenia were most frequent ones [40].
Another analysis was a report of five patients with systemic mastocytosis treated with interferon and prednisolone. All patients received interferon alpha-2b in a dose of 3 million units three times a week and four patients additionally received prednisolone. Four patients responded to interferon treatment at varying degrees. One patient, who at baseline had bone marrow involvement by mast cells in above 10%, progressed to mast cell leukemia. In two patients, the symptoms C resolved completely and in one of them they partially disappeared. In one case, stabilizing disease was achieved [41].
In 2009, a retrospective analysis of patients treated with cytoreductive therapy due to mastocytosis was published. The authors collected data from 108 patients treated at the Mayo Clinic. This analysis allowed for the comparison of the efficacy of four drugs used in systemic mastocytosis. There were interferon alpha alone or in the combination with prednisone—among 40 patients, hydroxycarbamide—among 26 ones, imatinib—among 22 persons, and 2-chlorodeoxyadenosine (2-CdA)—among 22 patients.
After dividing the patients into three additional groups on the basis of the type of mastocytosis—indolent systemic mastocytosis, aggressive systemic mastocytosis, and systemic mastocytosis associated with another clonal hematological nonmast cell lineage disease (SM-AHNMD)—the effectiveness of each of type of therapy was assessed.
The highest response rates in indolent and aggressive mastocytosis were achieved with interferon treatment. They were 60% of the responses in both groups, and in the SM-AHNMD group of patients, the percentage was also one of the highest and amounted to 45%. The second most effective drug was 2-CdA. The response rates were 56% for indolent MS, 50% for aggressive MS, and 55% for SM-AHNMD. The patients treated with imatinib achieved response in 14, 50, and 9% by following groups, respectively. In contrast, patients with indolent and aggressive systemic mastocytosis did not respond to hydroxycarbamide treatment at all. The response rate in both groups was 0%. However, patients with MS associated with another clonal hematological nonmast cell lineage disease achieved 21% response to hydroxycarbamide. Additionally, it was found that only interferon relieved symptoms caused by the release of inflammatory mediators by mast cells.
The additional analysis showed no influence of the TET 2 mutation on the response to treatment [42].
In the literature, there are also single cases of mastocytosis presenting trials of nonstandard treatment. That is description of a patient with systemic mastocytosis with mast cell bone marrow involvement. Mutation of c-kit Asp816Val was present. Patient progressed despite treatment with dasatinib and 2-chlorodeoxyadenosine. The patient developed symptoms related to the degranulation of mast cells and increased ascites.
The patient was treated with pranlukast, which is an anti-leukotriene receptor antagonist due to an asthma episode. The rate of ascites growth decreased significantly after one administration. The patient required paracentesis every 10 days and not every 3 days, as before starting to take the drug. After 15 days of treatment with pranlukast, the patient received interferon alpha, which resulted in complete regression of ascites, resolution of pancytopenia, and complete disappearance of the c-kit mutation clone. The infiltration of mast cells in the bone marrow significantly decreased [43].
Interferon alpha was also effective in a patient with systemic mastocytosis associated with myelodysplastic syndrome with the c-kit D816V mutation, which was refractory to imatinib treatment [44].
Interferon alpha also proved to be effective in the treatment of osteoporotic lesions appearing in the course of mastocytosis.
The series of 10 cases with resolved mastocytosis and osteoporosis-related fractures was presented in 2011. The patients received interferon alpha in a dose of 1.5 million units three times a week as well as pamindronic acid. The patients were treated for an average of 60 months. For the first 2 years, pamindronate was given at a dose of 1 mg/kg every month, and then every 3 months.
During the course of the study, no patient had a new-bone fracture. The level of alkaline phosphatase decreased by 25% in relation to the value before treatment and tryptase by 34%. Bone density increased during treated with interferon and pamindronate. The increase was on average 12% in the spine bones and 1.9% in the hip bones. At the same time, there was no increase in the density of the hip bone and a minimal increase in the density of the spine in patients treated with pamindronate alone.
The results of this observation suggest that it is beneficial to add low doses of interferon alpha to pamindronate treatment in terms of bone density increase [45].
That experiences show that interferon used in systemic mastocytosis significantly improves the quality of life of patients by inhibiting the symptoms caused by degranulation of mast cells. They prevent bone fractures and, in some patients, they cause remission of bone marrow infiltration by mast cells.
Chronic neutrophilic leukemia (CNL) is a very rare disease. It is characterized by the clonal proliferation of mature neutrophils.
The diagnostic criteria proposed by the World Health Organization (WHO) comprise leukocyte counts above 25,000/μl (including more than 80% of rod and segmented
Physical examination often shows enlargement of the liver and spleen, moreover, patients complain on weight loss and weakness [1].
The prognosis varies. The average survival time for patients with CNL is less than 2 years.
Only few descriptions of chronic neutrophilic leukemia are available in the literature, and these are mostly single case reports.
Because it is an extremely rare disease, there are no established and generally accepted treatment standards. In most cases, patients are given hydroxycarbamide or interferon. Patients who are eligible for a bone marrow transplant may benefit from this treatment. Bone marrow allotransplantation remains the only method that gives a chance for a significant extension of life.
The German authors presented a series of 14 cases of chronic neutrophilic leukemia. The group of patients consisted of eight women and six men. The average age was 64.7 years. From the entire group of patients, longer survival was achieved only in three cases. One of these patients was treated with interferon alpha and achieved hematological remission, the other underwent bone marrow allotransplantation from a family donor, and the third one was treated with hydroxycarbamide and transfusions as needed. The follow-up period of the patient after allogeneic matched related donor transplantation (allo-MRD) was 73 months, and for the patient after interferon treatment it was 41 months.
The remaining patients died within 2 years of diagnosis. Six patients, the largest group, died due to intracranial bleeding, three patients died because of leukemia cell tissue infiltration, one patient because of the disease transformation into leukemia, and one patient because of pneumonia [46].
It can be seen from these experiences that treatment with interferon alpha can significantly extend the survival time of patients.
The case of a 40-year-old woman diagnosed with chronic neutrophilic leukemia is presented by Yassin and coauthors. Initially, the patient had almost 41,000 leukocytes in the peripheral blood. In a physical examination, splenomegaly and hepatomegaly were not present. Patient received pegylated interferon alpha-2a. The initially dose was 50 μg once a week for the first 2 weeks, then the dose was increased to 135 μg weekly for 6 weeks, and then the dose interval was extended to another 2 weeks. As a result of the treatment, the general condition of the patient improved and the parameters of peripheral blood counts were normalized [47].
Another case report presented in the literature describes a 41-year-old woman diagnosed with CNL accompanied by focal segmental glomerulosclerosis (FSGS). The patient had increasing leukocytosis for several months. On the admission to the hospital, leukocytosis was 94,000/μl. Moreover, the number of platelets in the morphology exceeded 1,000,000/μl. More than a year earlier, the patient had splenectomy due to splenomegaly and spleen infraction.
Additionally, JAK2 V617F mutation was found. Some authors suggest that the presence of JAK2 mutation may be associated with longer survival in CNL.
The patient received hydroxycarbamide for 3 months and reduction in the number of leukocytes was achieved. After this time, interferon alpha-2b was added to hydroxycarbamide. As a result, focal segmental glomerulosclerosis disappeared and the renal tests improved [48].
Another case of chronic neutrophilic leukemia with a JAK2 gene mutation concerns a 53-year-old man. The patient’s baseline leukocytosis was 33,500/μl, including the neutrophil count of 29,700/μl. The patient also had splenomegaly.
The treatment with interferon alpha-2b at a dose of 3 million units every other day was started. After a month of treatment, the number of leukocytes was reduced to less than 10,000/μl. Then the patient was treated chronically with interferon alpha-2b in doses of 3 million units every 2 weeks. As a result of the therapy, the number of leukocytes remains between 8 and 10,000/μl. The patient remains in general good condition [49].
A series of two CNL cases are also shown. The first patient was a 70-year-old woman with stable leukocytosis of about 35,000/μl and the remaining morphology parameters in normal range. The patient was only observed for 5 years until hepasplenomegaly progressed rapidly. Then, interferon alpha-2b was included. Due to the treatment, the rapid regression of hepatosplenomegaly was achieved.
The second case is a 68-year-old woman with baseline leukocytosis of almost 14,000/μl. In this case, the treatment with hydroxycarbamide was started immediately. However, no improvement was achieved. After 6 weeks of HU treatment, interferon alpha-2b 3 million units 3 times a week was implemented and leukocytosis decreased. Due to the interferon treatment, the disease stabilized for a long time. Because the patient experienced an adverse reaction, a severe flu-like syndrome, interferon was discontinued. After interferon withdrawal, the disease progressed gradually and the treatment attempts by busulfan and 6-mercaptopurine were unsuccessful. Therefore, interferon was readministered and the disease went into remission. Interferon treatment was continued at a reduced dose. The disease regression was achieved again.
Additionally, the patient showed an improvement in the function of granulocytes in terms of phagocytosis and an improvement in neutral killer (NK) cell function after treatment with interferon [50].
The above examples show that interferon alpha is effective in the treatment of chronic neutrophilic leukemia. The side effects are rare and can be managed with dose reductions. Moreover, in these cases, interferon is also effective in a reduced dose. Disease remission or regression can be achieved without typical of CNL complications, such as intracranial bleeding.
Interferon has been used in the past to treat chronic myeloid leukemia. The treatment with tyrosine kinase inhibitors is now a standard practice. However, in a small number of patients, they are ineffective or exhibit unmanageable toxicity. Therefore, the attempts are underway to use interferon in combination with TKI in lower doses, which is to ensure the enhancement of the antiproliferative effect while reducing the toxicity.
There are ongoing attempts to use ropeginterferon in patients diagnosed with chronic myeloid leukemia, in whom treatment with imatinib alone has not led to deep molecular response (DMR). The first phase study was conducted in a small group of patients with chronic myeloid leukemia. The patients in first chronic phase treated with imatinib who did not achieve DMR, but in complete hematologic remission and complete cytogenetic remission, were included in the study. Patients have been treated with imatinib for at least 18 months. Twelve patients were enrolled in the study, and they completed the study according to the protocol. These patients received additional ropeginterferon to imatinib and four achieved DMR. Low toxicity was observed during the treatment. Among the hematological toxicities, neutropenia was the most common. There was no nonhematological toxicity with a degree higher than 1/2 during the treatment. Moreover, it has been found that better effects and fewer side effects are obtained when ropeginterferon is administered for a longer time, but in lower doses. The comparison of the effectiveness of interferon in chronic myeloproliferative disorders based on selected articles is presented in Table 1 [51].
Source | Type of trial | Interferon | Diagnosis | No. | Prior treatment status | Response rate |
---|---|---|---|---|---|---|
Yacoubet al. [15] | Phase II, multicenter | Pegylated IFN alfa-2a | PV | 50 | Resistance to HU or HU intolerance | CR:22% PR:38% |
ET | 65 | CR:43% PR:26% | ||||
Masarova et al. [16] | Phase II, single-center | Pegylated IFN alfa-2a | PV | 43 | Untreated or previously treated with cytoreductive therapy | CR:77% PR:7% |
ET | 40 | CR:73% PR:3% | ||||
Samuelsson et al. [18] | Phase II | Pegylated IFN alfa-2b | PV | 21 | Untreated or previously treated with cytoreductive therapy | CR: 69% for the entire group |
ET | 21 | |||||
Huang BT et al. [19] | Open label, multicenter | IFN alfa-2b | PV | 136 | Untreated or previously treated with cytoreductive therapy | OHR:70% Molecular response:54.7% |
ET | 123 | OHR (JAK2+ patients):83% CHR:23 cases OHR (JAK2-patients): 61.4% CHR:12 cases | ||||
Gisslinger et al. [23] | phase III, multicenter | Ropeginterferon | PV | 257 | Previously treated | OHR:53% |
Quintás-Cardama et al. [26] | phase II | Pegylated IFN alfa-2a | PV | 40 | Untreated or previously treated with cytoreductive therapy | OHR:80% CR:70% Molecular remission:54% |
ET | 39 | OHR:81% CR:76% Molecular remission:38% | ||||
Sørensen et al. [36] | Phase III, multicenter, COMBI | Pegylated IFN alfa-2a with ruxolitinib or Pegylated IFN alfa-2b with ruxolitinib | PV | 32 | Untreated or previously treated with cytoreductive therapy | OHR:44% CR:28% |
MF | 18 | OHR:31% CR:9% | ||||
Casassus et al. [40] | Open label, multicenter | IFN alpha-2b | Mastocytosis | 20 | Untreated and previously treated | PR:35% Minor remission: 30% |
Comparison of the effectiveness of interferon in chronic myeloproliferative disorders.
PV: polycythemia vera; ET: essential thrombocythemia; MF: myelofibrosis; HU: hydroxycarbamide/hydroxyurea; CR: complete remission; PR: partial remission; and OHR: overall hematological response.
Interferon alpha appears to be an effective and safe drug in the most type of chronic myeloproliferative disorders. Nowadays, all forms of its using have similar effectiveness. Interferon alpha can be effective even in cases of resistance for first-line treatment. Trial research is currently underway to combine it with some new drugs, such as ruxolitinib, and to add it to the already well-established therapy, it is a promising option for patients with refractory disease.
From time to time, new forms of interferon, such as ropeginterferon, are introduced, which gives hope for better effectiveness, better safety profile, and greater comfort in its use for patients who have to be treated for many years. In the case of the use of interferons alpha in the treatment of chronic myeloproliferative diseases, there are still opportunities to extend its use and to study its combination with newly introduced drugs.
We believe financial barriers should not prevent researchers from publishing their findings. With the need to make scientific research more publicly available and support the benefits of Open Access, more and more institutions and funders are dedicating resources to assist faculty members and researchers cover Open Access Publishing Fees (OAPFs). In addition, IntechOpen provides several further options presented below, all of which are available to researchers, and could secure the financing of your Open Access publication.
",metaTitle:"Waiver Policy",metaDescription:"We feel that financial barriers should never prevent researchers from publishing their research. With the need to make scientific research more publically available and support the benefits of Open Access, more institutions and funders have dedicated funds to assist their faculty members and researchers cover the APCs associated with publishing in Open Access. Below we have outlined several options available to secure financing for your Open Access publication.",metaKeywords:null,canonicalURL:"/page/waiver-policy",contentRaw:'[{"type":"htmlEditorComponent","content":"At IntechOpen, the majority of OAPFs are paid by an Author’s institution or funding agency - Institutions (73%) vs. Authors (23%).
\\n\\nThe first step in obtaining funds for your Open Access publication begins with your institution or library. IntechOpen’s publishing standards align with most institutional funding programs. Our advice is to petition your institution for help in financing your Open Access publication.
\\n\\nHowever, as Open Access becomes a more commonly used publishing option for the dissemination of scientific and scholarly content, in addition to institutions, there are a growing number of funders who allow the use of grants for covering OA publication costs, or have established separate funds for the same purpose.
\\n\\nPlease consult our Open Access Funding page to explore some of these funding opportunities and learn more about how you could finance your IntechOpen publication. Keep in mind that this list is not definitive, and while we are constantly updating and informing our Authors of new funding opportunities, we recommend that you always check with your institution first.
\\n\\nFor Authors who are unable to obtain funding from their institution or research funding bodies and still need help in covering publication costs, IntechOpen offers the possibility of applying for a Waiver.
\\n\\nOur mission is to support Authors in publishing their research and making an impact within the scientific community. Currently, 14% of Authors receive full waivers and 6% receive partial waivers.
\\n\\nWhile providing support and advice to all our international Authors, waiver priority will be given to those Authors who reside in countries that are classified by the World Bank as low-income economies. In this way, we can help ensure that the scientific work being carried out can make an impact within the worldwide scientific community, no matter where an Author might live.
\\n\\nThe application process is open after your submitted manuscript has been accepted for publication. To apply, please fill out a Waiver Request Form and send it to your Author Service Manager. If you have an official letter from your university or institution showing that funds for your OA publication are unavailable, please attach that as well. The Waiver Request will normally be addressed within one week from the application date. All chapters that receive waivers or partial waivers will be designated as such online.
\\n\\nDownload Waiver Request Form
\\n\\nFeel free to contact us at funders@intechopen.com if you have any questions about Funding options or our Waiver program. If you have already begun the process and require further assistance, please contact your Author Service Manager, who is there to assist you!
\\n\\nNote: All data represented above was collected by IntechOpen from 2013 to 2017.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'At IntechOpen, the majority of OAPFs are paid by an Author’s institution or funding agency - Institutions (73%) vs. Authors (23%).
\n\nThe first step in obtaining funds for your Open Access publication begins with your institution or library. IntechOpen’s publishing standards align with most institutional funding programs. Our advice is to petition your institution for help in financing your Open Access publication.
\n\nHowever, as Open Access becomes a more commonly used publishing option for the dissemination of scientific and scholarly content, in addition to institutions, there are a growing number of funders who allow the use of grants for covering OA publication costs, or have established separate funds for the same purpose.
\n\nPlease consult our Open Access Funding page to explore some of these funding opportunities and learn more about how you could finance your IntechOpen publication. Keep in mind that this list is not definitive, and while we are constantly updating and informing our Authors of new funding opportunities, we recommend that you always check with your institution first.
\n\nFor Authors who are unable to obtain funding from their institution or research funding bodies and still need help in covering publication costs, IntechOpen offers the possibility of applying for a Waiver.
\n\nOur mission is to support Authors in publishing their research and making an impact within the scientific community. Currently, 14% of Authors receive full waivers and 6% receive partial waivers.
\n\nWhile providing support and advice to all our international Authors, waiver priority will be given to those Authors who reside in countries that are classified by the World Bank as low-income economies. In this way, we can help ensure that the scientific work being carried out can make an impact within the worldwide scientific community, no matter where an Author might live.
\n\nThe application process is open after your submitted manuscript has been accepted for publication. To apply, please fill out a Waiver Request Form and send it to your Author Service Manager. If you have an official letter from your university or institution showing that funds for your OA publication are unavailable, please attach that as well. The Waiver Request will normally be addressed within one week from the application date. All chapters that receive waivers or partial waivers will be designated as such online.
\n\nDownload Waiver Request Form
\n\nFeel free to contact us at funders@intechopen.com if you have any questions about Funding options or our Waiver program. If you have already begun the process and require further assistance, please contact your Author Service Manager, who is there to assist you!
\n\nNote: All data represented above was collected by IntechOpen from 2013 to 2017.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{},profiles:[],filtersByRegion:[{group:"region",caption:"North America",value:1,count:13389},{group:"region",caption:"Middle and South America",value:2,count:11662},{group:"region",caption:"Africa",value:3,count:4168},{group:"region",caption:"Asia",value:4,count:22333},{group:"region",caption:"Australia and Oceania",value:5,count:2019},{group:"region",caption:"Europe",value:6,count:33644}],offset:0,limit:12,total:null},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"1390"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:22},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:6},{group:"topic",caption:"Business, Management and Economics",value:7,count:4},{group:"topic",caption:"Chemistry",value:8,count:15},{group:"topic",caption:"Computer and Information Science",value:9,count:18},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:8},{group:"topic",caption:"Engineering",value:11,count:37},{group:"topic",caption:"Environmental Sciences",value:12,count:5},{group:"topic",caption:"Immunology and Microbiology",value:13,count:8},{group:"topic",caption:"Materials Science",value:14,count:15},{group:"topic",caption:"Mathematics",value:15,count:8},{group:"topic",caption:"Medicine",value:16,count:62},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:2},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:7},{group:"topic",caption:"Physics",value:20,count:5},{group:"topic",caption:"Psychology",value:21,count:5},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:8},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:0},popularBooks:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3737",title:"MATLAB",subtitle:"Modelling, Programming and Simulations",isOpenForSubmission:!1,hash:null,slug:"matlab-modelling-programming-and-simulations",bookSignature:"Emilson Pereira Leite",coverURL:"https://cdn.intechopen.com/books/images_new/3737.jpg",editors:[{id:"12051",title:"Prof.",name:"Emilson",middleName:null,surname:"Pereira Leite",slug:"emilson-pereira-leite",fullName:"Emilson Pereira Leite"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"1770",title:"Gel Electrophoresis",subtitle:"Principles and Basics",isOpenForSubmission:!1,hash:"279701f6c802cf02deef45103e0611ff",slug:"gel-electrophoresis-principles-and-basics",bookSignature:"Sameh Magdeldin",coverURL:"https://cdn.intechopen.com/books/images_new/1770.jpg",editors:[{id:"123648",title:"Dr.",name:"Sameh",middleName:null,surname:"Magdeldin",slug:"sameh-magdeldin",fullName:"Sameh Magdeldin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:4797},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",publishedDate:"July 27th 2022",numberOfDownloads:7175,editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1981,editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10796",title:"Extracellular Vesicles",subtitle:"Role in Diseases, Pathogenesis and Therapy",isOpenForSubmission:!1,hash:"eb5407fcf93baff7bca3fae5640153a2",slug:"extracellular-vesicles-role-in-diseases-pathogenesis-and-therapy",bookSignature:"Manash K. Paul",coverURL:"https://cdn.intechopen.com/books/images_new/10796.jpg",publishedDate:"July 20th 2022",numberOfDownloads:2308,editors:[{id:"319365",title:"Assistant Prof.",name:"Manash K.",middleName:null,surname:"Paul",slug:"manash-k.-paul",fullName:"Manash K. Paul"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",publishedDate:"July 27th 2022",numberOfDownloads:1473,editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"95",title:"Applications and Experiences of Quality Control",subtitle:null,isOpenForSubmission:!1,hash:"4bcb22b1eee68210a977a97d5a0f363a",slug:"applications-and-experiences-of-quality-control",bookSignature:"Ognyan Ivanov",coverURL:"https://cdn.intechopen.com/books/images_new/95.jpg",publishedDate:"April 26th 2011",numberOfDownloads:318571,editors:[{id:"22230",title:"Prof.",name:"Ognyan",middleName:null,surname:"Ivanov",slug:"ognyan-ivanov",fullName:"Ognyan Ivanov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",publishedDate:"September 26th 2012",numberOfDownloads:271836,editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3560",title:"Advances in Landscape Architecture",subtitle:null,isOpenForSubmission:!1,hash:"a20614517ec5f7e91188fe8e42832138",slug:"advances-in-landscape-architecture",bookSignature:"Murat Özyavuz",coverURL:"https://cdn.intechopen.com/books/images_new/3560.jpg",publishedDate:"July 1st 2013",numberOfDownloads:243450,editors:[{id:"93073",title:"Dr.",name:"Murat",middleName:null,surname:"Ozyavuz",slug:"murat-ozyavuz",fullName:"Murat Ozyavuz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10739",title:"Global Decline of Insects",subtitle:null,isOpenForSubmission:!1,hash:"543783652b9092962a8fa4bed38eeb17",slug:"global-decline-of-insects",bookSignature:"Hamadttu Abdel Farag El-Shafie",coverURL:"https://cdn.intechopen.com/books/images_new/10739.jpg",publishedDate:"July 20th 2022",numberOfDownloads:1582,editors:[{id:"192142",title:"Dr.",name:"Hamadttu",middleName:null,surname:"Abdel Farag El-Shafie",slug:"hamadttu-abdel-farag-el-shafie",fullName:"Hamadttu Abdel Farag El-Shafie"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10911",title:"Higher Education",subtitle:"New Approaches to Accreditation, Digitalization, and Globalization in the Age of Covid",isOpenForSubmission:!1,hash:"223a02337498e535e967174c1f648fbc",slug:"higher-education-new-approaches-to-accreditation-digitalization-and-globalization-in-the-age-of-covid",bookSignature:"Lee Waller and Sharon Waller",coverURL:"https://cdn.intechopen.com/books/images_new/10911.jpg",publishedDate:"July 13th 2022",numberOfDownloads:2082,editors:[{id:"263301",title:"Dr.",name:"Lee",middleName:null,surname:"Waller",slug:"lee-waller",fullName:"Lee Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"3568",title:"Recent Advances in Plant in vitro Culture",subtitle:null,isOpenForSubmission:!1,hash:"830bbb601742c85a3fb0eeafe1454c43",slug:"recent-advances-in-plant-in-vitro-culture",bookSignature:"Annarita Leva and Laura M. R. Rinaldi",coverURL:"https://cdn.intechopen.com/books/images_new/3568.jpg",publishedDate:"October 17th 2012",numberOfDownloads:256294,editors:[{id:"142145",title:"Dr.",name:"Annarita",middleName:null,surname:"Leva",slug:"annarita-leva",fullName:"Annarita Leva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"10808",title:"Current Concepts in Dental Implantology",subtitle:"From Science to Clinical Research",isOpenForSubmission:!1,hash:"4af8830e463f89c57515c2da2b9777b0",slug:"current-concepts-in-dental-implantology-from-science-to-clinical-research",bookSignature:"Dragana Gabrić and Marko Vuletić",coverURL:"https://cdn.intechopen.com/books/images_new/10808.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"26946",title:"Prof.",name:"Dragana",middleName:null,surname:"Gabrić",slug:"dragana-gabric",fullName:"Dragana Gabrić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11328",title:"Botulinum Toxin",subtitle:"Recent Topics and Applications",isOpenForSubmission:!1,hash:"7dd05a316001cef143e209eda51387a7",slug:"botulinum-toxin-recent-topics-and-applications",bookSignature:"Suna Sabuncuoglu",coverURL:"https://cdn.intechopen.com/books/images_new/11328.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"270856",title:"Associate Prof.",name:"Suna",middleName:null,surname:"Sabuncuoglu",slug:"suna-sabuncuoglu",fullName:"Suna Sabuncuoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11085",title:"Polycystic Ovary Syndrome",subtitle:"Functional Investigation and Clinical Application",isOpenForSubmission:!1,hash:"3066dd3ff29e1fac072fd60b08d4d3e7",slug:"polycystic-ovary-syndrome-functional-investigation-and-clinical-application",bookSignature:"Zhengchao Wang",coverURL:"https://cdn.intechopen.com/books/images_new/11085.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"204883",title:"Dr.",name:"Zhengchao",middleName:null,surname:"Wang",slug:"zhengchao-wang",fullName:"Zhengchao Wang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10833",title:"Tumor Angiogenesis and Modulators",subtitle:null,isOpenForSubmission:!1,hash:"f29b575c46128b2da061ef7f9bd1070b",slug:"tumor-angiogenesis-and-modulators",bookSignature:"Ke Xu",coverURL:"https://cdn.intechopen.com/books/images_new/10833.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"59529",title:"Dr.",name:"Ke",middleName:null,surname:"Xu",slug:"ke-xu",fullName:"Ke Xu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11356",title:"Molecular Cloning",subtitle:null,isOpenForSubmission:!1,hash:"671c629dd86e97f0fb467b9e70e92296",slug:"molecular-cloning",bookSignature:"Sadık Dincer, Hatice Aysun Mercimek Takcı and Melis Sumengen Ozdenef",coverURL:"https://cdn.intechopen.com/books/images_new/11356.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"188141",title:"Prof.",name:"Sadik",middleName:null,surname:"Dincer",slug:"sadik-dincer",fullName:"Sadik Dincer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7827",title:"Interpersonal Relationships",subtitle:null,isOpenForSubmission:!1,hash:"ebf41f4d17c75010eb3294cc8cac3d47",slug:"interpersonal-relationships",bookSignature:"Martha Peaslee Levine",coverURL:"https://cdn.intechopen.com/books/images_new/7827.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"186919",title:"Dr.",name:"Martha",middleName:null,surname:"Peaslee Levine",slug:"martha-peaslee-levine",fullName:"Martha Peaslee Levine"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10908",title:"Advances in Decision Making",subtitle:null,isOpenForSubmission:!1,hash:"126486f7f91e18e2e3539a32c38be7b1",slug:"advances-in-decision-making",bookSignature:"Fausto Pedro García Márquez",coverURL:"https://cdn.intechopen.com/books/images_new/10908.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"22844",title:"Prof.",name:"Fausto Pedro",middleName:null,surname:"García Márquez",slug:"fausto-pedro-garcia-marquez",fullName:"Fausto Pedro García Márquez"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10669",title:"Corrosion",subtitle:"Fundamentals and Protection Mechanisms",isOpenForSubmission:!1,hash:"4a76d54f8a40fc2e7002a8d13fd617c1",slug:"corrosion-fundamentals-and-protection-mechanisms",bookSignature:"Fahmina Zafar, Anujit Ghosal and Eram Sharmin",coverURL:"https://cdn.intechopen.com/books/images_new/10669.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"89672",title:"Dr.",name:"Fahmina",middleName:null,surname:"Zafar",slug:"fahmina-zafar",fullName:"Fahmina Zafar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10677",title:"Advanced Topics of Topology",subtitle:null,isOpenForSubmission:!1,hash:"bf964c52f9e653fac20a7fcab58070e5",slug:"advanced-topics-of-topology",bookSignature:"Francisco Bulnes",coverURL:"https://cdn.intechopen.com/books/images_new/10677.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"92918",title:"Dr.",name:"Francisco",middleName:null,surname:"Bulnes",slug:"francisco-bulnes",fullName:"Francisco Bulnes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"11195",title:"Recent Advances in Biometrics",subtitle:null,isOpenForSubmission:!1,hash:"2d32e33e0f499cb5241734bb75dd2a83",slug:"recent-advances-in-biometrics",bookSignature:"Muhammad Sarfraz",coverURL:"https://cdn.intechopen.com/books/images_new/11195.jpg",editedByType:"Edited by",publishedDate:"July 27th 2022",editors:[{id:"215610",title:"Prof.",name:"Muhammad",middleName:null,surname:"Sarfraz",slug:"muhammad-sarfraz",fullName:"Muhammad Sarfraz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"209",title:"Cognitive Neuroscience",slug:"cognitive-neuroscience",parent:{id:"18",title:"Neuroscience",slug:"life-sciences-neuroscience"},numberOfBooks:11,numberOfSeries:0,numberOfAuthorsAndEditors:313,numberOfWosCitations:261,numberOfCrossrefCitations:189,numberOfDimensionsCitations:447,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicId:"209",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"6819",title:"Prefrontal Cortex",subtitle:null,isOpenForSubmission:!1,hash:"903b3a38d3c8196f6a865526c124a6de",slug:"prefrontal-cortex",bookSignature:"Ana Starcevic and Branislav Filipovic",coverURL:"https://cdn.intechopen.com/books/images_new/6819.jpg",editedByType:"Edited by",editors:[{id:"182584",title:"Dr.",name:"Ana",middleName:null,surname:"Starcevic",slug:"ana-starcevic",fullName:"Ana Starcevic"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6614",title:"Alzheimer's Disease",subtitle:"The 21st Century Challenge",isOpenForSubmission:!1,hash:"91df6c15517737c8fb91543f870d484d",slug:"alzheimer-s-disease-the-21st-century-challenge",bookSignature:"Jolanta Dorszewska and Wojciech Kozubski",coverURL:"https://cdn.intechopen.com/books/images_new/6614.jpg",editedByType:"Edited by",editors:[{id:"31962",title:"Dr.",name:"Jolanta",middleName:null,surname:"Dorszewska",slug:"jolanta-dorszewska",fullName:"Jolanta Dorszewska"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6167",title:"Cognitive and Computational Neuroscience",subtitle:"Principles, Algorithms and Applications",isOpenForSubmission:!1,hash:"828beb18d956dedaf19b5a87c8bfb828",slug:"cognitive-and-computational-neuroscience-principles-algorithms-and-applications",bookSignature:"Seyyed Abed Hosseini",coverURL:"https://cdn.intechopen.com/books/images_new/6167.jpg",editedByType:"Edited by",editors:[{id:"86475",title:"Dr.",name:"Seyyed Abed",middleName:null,surname:"Hosseini",slug:"seyyed-abed-hosseini",fullName:"Seyyed Abed Hosseini"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6144",title:"High-Resolution Neuroimaging",subtitle:"Basic Physical Principles and Clinical Applications",isOpenForSubmission:!1,hash:"505b513060f90e61167b5e46e8cd9fea",slug:"high-resolution-neuroimaging-basic-physical-principles-and-clinical-applications",bookSignature:"Ahmet Mesrur Halefoğlu",coverURL:"https://cdn.intechopen.com/books/images_new/6144.jpg",editedByType:"Edited by",editors:[{id:"51736",title:"Prof.",name:"Ahmet Mesrur",middleName:null,surname:"Halefoğlu",slug:"ahmet-mesrur-halefoglu",fullName:"Ahmet Mesrur Halefoğlu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5947",title:"Mechanisms of Neuroinflammation",subtitle:null,isOpenForSubmission:!1,hash:"e4ade830cd06a3aebc5eae0dae96aff2",slug:"mechanisms-of-neuroinflammation",bookSignature:"Gonzalo Emiliano Aranda Abreu",coverURL:"https://cdn.intechopen.com/books/images_new/5947.jpg",editedByType:"Edited by",editors:[{id:"72314",title:"Dr.",name:"Gonzalo Emiliano",middleName:null,surname:"Aranda Abreu",slug:"gonzalo-emiliano-aranda-abreu",fullName:"Gonzalo Emiliano Aranda Abreu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5313",title:"Update on Dementia",subtitle:null,isOpenForSubmission:!1,hash:"6b264ef130a59fe71274c3811750e6c3",slug:"update-on-dementia",bookSignature:"Davide Vito Moretti",coverURL:"https://cdn.intechopen.com/books/images_new/5313.jpg",editedByType:"Edited by",editors:[{id:"147154",title:"Dr.",name:"Davide",middleName:"Vito",surname:"Moretti",slug:"davide-moretti",fullName:"Davide Moretti"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2604",title:"Basal Ganglia",subtitle:"An Integrative View",isOpenForSubmission:!1,hash:"76d19f809182eea657ce36eb4817c5b8",slug:"basal-ganglia-an-integrative-view",bookSignature:"Fernando A. Barrios and Clemens Bauer",coverURL:"https://cdn.intechopen.com/books/images_new/2604.jpg",editedByType:"Edited by",editors:[{id:"147924",title:"Dr.",name:"Fernando A.",middleName:null,surname:"Barrios",slug:"fernando-a.-barrios",fullName:"Fernando A. Barrios"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2599",title:"The Amygdala",subtitle:"A Discrete Multitasking Manager",isOpenForSubmission:!1,hash:"429fa5522790c0837406fd1fed1280bd",slug:"the-amygdala-a-discrete-multitasking-manager",bookSignature:"Barbara Ferry",coverURL:"https://cdn.intechopen.com/books/images_new/2599.jpg",editedByType:"Edited by",editors:[{id:"139945",title:"Dr.",name:"Barbara",middleName:null,surname:"Ferry",slug:"barbara-ferry",fullName:"Barbara Ferry"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2646",title:"Visual Cortex",subtitle:"Current Status and Perspectives",isOpenForSubmission:!1,hash:"8a5632344dfe9b3f0153eeee84a6ea83",slug:"visual-cortex-current-status-and-perspectives",bookSignature:"Stephane Molotchnikoff and Jean Rouat",coverURL:"https://cdn.intechopen.com/books/images_new/2646.jpg",editedByType:"Edited by",editors:[{id:"145800",title:"Prof.",name:"Stephane",middleName:null,surname:"Molotchnikoff",slug:"stephane-molotchnikoff",fullName:"Stephane Molotchnikoff"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"673",title:"Dyslexia",subtitle:"A Comprehensive and International Approach",isOpenForSubmission:!1,hash:"9a88d127d035ab53de96a00f9ed407ba",slug:"dyslexia-a-comprehensive-and-international-approach",bookSignature:"Taeko N. Wydell and Liory Fern-Pollak",coverURL:"https://cdn.intechopen.com/books/images_new/673.jpg",editedByType:"Edited by",editors:[{id:"87489",title:"Prof.",name:"Taeko",middleName:"N.",surname:"Wydell",slug:"taeko-wydell",fullName:"Taeko Wydell"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1069",title:"Paresthesia",subtitle:null,isOpenForSubmission:!1,hash:"c0225cd8274b4384cd1c91e586645958",slug:"paresthesia",bookSignature:"Luiz E. Imbelloni and Marildo A. Gouveia",coverURL:"https://cdn.intechopen.com/books/images_new/1069.jpg",editedByType:"Edited by",editors:[{id:"80284",title:"Dr.",name:"Luiz Eduardo",middleName:null,surname:"Imbelloni",slug:"luiz-eduardo-imbelloni",fullName:"Luiz Eduardo Imbelloni"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:11,seriesByTopicCollection:[],seriesByTopicTotal:0,mostCitedChapters:[{id:"58070",doi:"10.5772/intechopen.72427",title:"MRI Medical Image Denoising by Fundamental Filters",slug:"mri-medical-image-denoising-by-fundamental-filters",totalDownloads:2618,totalCrossrefCites:20,totalDimensionsCites:32,abstract:"Nowadays Medical imaging technique Magnetic Resonance Imaging (MRI) plays an important role in medical setting to form high standard images contained in the human brain. MRI is commonly used once treating brain, prostate cancers, ankle and foot. The Magnetic Resonance Imaging (MRI) images are usually liable to suffer from noises such as Gaussian noise, salt and pepper noise and speckle noise. So getting of brain image with accuracy is very extremely task. An accurate brain image is very necessary for further diagnosis process. During this chapter, a median filter algorithm will be modified. Gaussian noise and Salt and pepper noise will be added to MRI image. A proposed Median filter (MF), Adaptive Median filter (AMF) and Adaptive Wiener filter (AWF) will be implemented. The filters will be used to remove the additive noises present in the MRI images. The noise density will be added gradually to MRI image to compare performance of the filters evaluation. The performance of these filters will be compared exploitation the applied mathematics parameter Peak Signal-to-Noise Ratio (PSNR).",book:{id:"6144",slug:"high-resolution-neuroimaging-basic-physical-principles-and-clinical-applications",title:"High-Resolution Neuroimaging",fullTitle:"High-Resolution Neuroimaging - Basic Physical Principles and Clinical Applications"},signatures:"Hanafy M. Ali",authors:[{id:"213318",title:"Dr.",name:"Hanafy",middleName:"M.",surname:"Ali",slug:"hanafy-ali",fullName:"Hanafy Ali"}]},{id:"41589",doi:"10.5772/50323",title:"The Role of the Amygdala in Anxiety Disorders",slug:"the-role-of-the-amygdala-in-anxiety-disorders",totalDownloads:9758,totalCrossrefCites:4,totalDimensionsCites:28,abstract:null,book:{id:"2599",slug:"the-amygdala-a-discrete-multitasking-manager",title:"The Amygdala",fullTitle:"The Amygdala - A Discrete Multitasking Manager"},signatures:"Gina L. Forster, Andrew M. Novick, Jamie L. Scholl and Michael J. Watt",authors:[{id:"145620",title:"Dr.",name:"Gina",middleName:null,surname:"Forster",slug:"gina-forster",fullName:"Gina Forster"},{id:"146553",title:"BSc.",name:"Andrew",middleName:null,surname:"Novick",slug:"andrew-novick",fullName:"Andrew Novick"},{id:"146554",title:"MSc.",name:"Jamie",middleName:null,surname:"Scholl",slug:"jamie-scholl",fullName:"Jamie Scholl"},{id:"146555",title:"Dr.",name:"Michael",middleName:null,surname:"Watt",slug:"michael-watt",fullName:"Michael Watt"}]},{id:"39300",doi:"10.5772/51914",title:"Visual Field Map Organization in Human Visual Cortex",slug:"visual-field-map-organization-in-human-visual-cortex",totalDownloads:4246,totalCrossrefCites:5,totalDimensionsCites:22,abstract:null,book:{id:"2646",slug:"visual-cortex-current-status-and-perspectives",title:"Visual Cortex",fullTitle:"Visual Cortex - Current Status and Perspectives"},signatures:"Alyssa A. Brewer and Brian Barton",authors:[{id:"115304",title:"Dr.",name:"Alyssa",middleName:"A",surname:"Brewer",slug:"alyssa-brewer",fullName:"Alyssa Brewer"},{id:"149246",title:"Dr.",name:"Brian",middleName:null,surname:"Barton",slug:"brian-barton",fullName:"Brian Barton"}]},{id:"35807",doi:"10.5772/39042",title:"Sequential Versus Simultaneous Processing Deficits in Developmental Dyslexia",slug:"sequential-versus-simultaneous-processing-deficits-in-developmental-dyslexia",totalDownloads:4445,totalCrossrefCites:9,totalDimensionsCites:21,abstract:null,book:{id:"673",slug:"dyslexia-a-comprehensive-and-international-approach",title:"Dyslexia",fullTitle:"Dyslexia - A Comprehensive and International Approach"},signatures:"Marie Lallier and Sylviane Valdois",authors:[{id:"131402",title:"Dr.",name:"Marie",middleName:null,surname:"Lallier",slug:"marie-lallier",fullName:"Marie Lallier"},{id:"138756",title:"Dr.",name:"Sylviane",middleName:null,surname:"Valdois",slug:"sylviane-valdois",fullName:"Sylviane Valdois"}]},{id:"56407",doi:"10.5772/intechopen.70099",title:"Roles of Pro- and Anti-inflammatory Cytokines in Traumatic Brain Injury and Acute Ischemic Stroke",slug:"roles-of-pro-and-anti-inflammatory-cytokines-in-traumatic-brain-injury-and-acute-ischemic-stroke",totalDownloads:2342,totalCrossrefCites:9,totalDimensionsCites:19,abstract:"This chapter will introduce the reader to the pathophysiology of two devastating neurologic events, traumatic brain injury (TBI) and acute ischemic stroke (AIS). Here we focus on the role of key pro-inflammatory and anti-inflammatory cytokines. Several experimental interventions have been found to modulate cytokine production and brain injury after AIS or TBI. Here minocycline, biological response modifiers, hormonal therapies, omega-3 fatty acids, N-acetylcysteine, and cannabinoids will be discussed. In addition, the role of cytokine-induced inflammasomes in both TBI and AIS will be addressed and followed by discussion of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-18, and IFN-γ). Finally, the main anti-inflammatory cytokines, IL-33, IL-10, IL-6, and IL-4, will be discussed in the context of both TBI and AIS. It should be noted that the role of these cytokines is diverse and the dichotomization of classically pro-versus anti-inflammatory cytokines is being re-examined, as many of these cytokines have been found to play dual roles in TBI and AIS brain injury.",book:{id:"5947",slug:"mechanisms-of-neuroinflammation",title:"Mechanisms of Neuroinflammation",fullTitle:"Mechanisms of Neuroinflammation"},signatures:"Rachelle Dugue, Manan Nath, Andrew Dugue and Frank C. Barone",authors:[{id:"204548",title:"Ph.D.",name:"Rachelle",middleName:null,surname:"Dugue",slug:"rachelle-dugue",fullName:"Rachelle Dugue"},{id:"204658",title:"Prof.",name:"Frank",middleName:null,surname:"Barone",slug:"frank-barone",fullName:"Frank Barone"},{id:"204810",title:"Dr.",name:"Manan",middleName:null,surname:"Nath",slug:"manan-nath",fullName:"Manan Nath"},{id:"208689",title:"Mr.",name:"Andrew",middleName:null,surname:"Dugue",slug:"andrew-dugue",fullName:"Andrew Dugue"}]}],mostDownloadedChaptersLast30Days:[{id:"29764",title:"Underlying Causes of Paresthesia",slug:"underlying-causes-of-paresthesia",totalDownloads:193349,totalCrossrefCites:3,totalDimensionsCites:7,abstract:null,book:{id:"1069",slug:"paresthesia",title:"Paresthesia",fullTitle:"Paresthesia"},signatures:"Mahdi Sharif-Alhoseini, Vafa Rahimi-Movaghar and Alexander R. Vaccaro",authors:[{id:"91165",title:"Prof.",name:"Vafa",middleName:null,surname:"Rahimi-Movaghar",slug:"vafa-rahimi-movaghar",fullName:"Vafa Rahimi-Movaghar"}]},{id:"35802",title:"Cross-Cultural/Linguistic Differences in the Prevalence of Developmental Dyslexia and the Hypothesis of Granularity and Transparency",slug:"cross-cultural-linguistic-differences-in-the-prevalence-of-developmental-dyslexia-and-the-hypothesis",totalDownloads:3622,totalCrossrefCites:2,totalDimensionsCites:7,abstract:null,book:{id:"673",slug:"dyslexia-a-comprehensive-and-international-approach",title:"Dyslexia",fullTitle:"Dyslexia - A Comprehensive and International Approach"},signatures:"Taeko N. Wydell",authors:[{id:"87489",title:"Prof.",name:"Taeko",middleName:"N.",surname:"Wydell",slug:"taeko-wydell",fullName:"Taeko Wydell"}]},{id:"63179",title:"Development Period of Prefrontal Cortex",slug:"development-period-of-prefrontal-cortex",totalDownloads:3728,totalCrossrefCites:6,totalDimensionsCites:13,abstract:"This chapter outlines the issues associated with the development of prefrontal cortex in children and adolescents, and describes the developmental profile of executive processes across childhood. The prefrontal cortex plays an essential role in various cognitive functions and little is known about how such neural mechanisms develop during childhood yet. To better understand this issue, we focus the literature on the development of the prefrontal cortex during early childhood, the changes in structural architecture, neural activity, and cognitive abilities. The prefrontal cortex undergoes maturation during childhood with a reduction of synaptic and neuronal density, a growth of dendrites, and an increase in white matter volume. With these neuroanatomical changes, neural networks construct appropriate for complex cognitive processing. The organization of prefrontal cortical circuitry may have been critical to the occurrence of human-specific executive and social-emotional functions, and developmental pathology in these same systems underlies many psychiatric disorders; therefore, if we understand these developmental process well, we could better analyze the development of psychiatric disorders.",book:{id:"6819",slug:"prefrontal-cortex",title:"Prefrontal Cortex",fullTitle:"Prefrontal Cortex"},signatures:"Merve Cikili Uytun",authors:[{id:"163607",title:"Dr.",name:"Merve",middleName:null,surname:"Cikili",slug:"merve-cikili",fullName:"Merve Cikili"}]},{id:"41594",title:"Amygdala, Childhood Adversity and Psychiatric Disorders",slug:"amygdala-childhood-adversity-and-psychiatric-disorders",totalDownloads:6021,totalCrossrefCites:0,totalDimensionsCites:0,abstract:null,book:{id:"2599",slug:"the-amygdala-a-discrete-multitasking-manager",title:"The Amygdala",fullTitle:"The Amygdala - A Discrete Multitasking Manager"},signatures:"Xiaodan Yan",authors:[{id:"144657",title:"Dr.",name:"X",middleName:null,surname:"Yan",slug:"x-yan",fullName:"X Yan"}]},{id:"58070",title:"MRI Medical Image Denoising by Fundamental Filters",slug:"mri-medical-image-denoising-by-fundamental-filters",totalDownloads:2618,totalCrossrefCites:20,totalDimensionsCites:32,abstract:"Nowadays Medical imaging technique Magnetic Resonance Imaging (MRI) plays an important role in medical setting to form high standard images contained in the human brain. MRI is commonly used once treating brain, prostate cancers, ankle and foot. The Magnetic Resonance Imaging (MRI) images are usually liable to suffer from noises such as Gaussian noise, salt and pepper noise and speckle noise. So getting of brain image with accuracy is very extremely task. An accurate brain image is very necessary for further diagnosis process. During this chapter, a median filter algorithm will be modified. Gaussian noise and Salt and pepper noise will be added to MRI image. A proposed Median filter (MF), Adaptive Median filter (AMF) and Adaptive Wiener filter (AWF) will be implemented. The filters will be used to remove the additive noises present in the MRI images. The noise density will be added gradually to MRI image to compare performance of the filters evaluation. The performance of these filters will be compared exploitation the applied mathematics parameter Peak Signal-to-Noise Ratio (PSNR).",book:{id:"6144",slug:"high-resolution-neuroimaging-basic-physical-principles-and-clinical-applications",title:"High-Resolution Neuroimaging",fullTitle:"High-Resolution Neuroimaging - Basic Physical Principles and Clinical Applications"},signatures:"Hanafy M. Ali",authors:[{id:"213318",title:"Dr.",name:"Hanafy",middleName:"M.",surname:"Ali",slug:"hanafy-ali",fullName:"Hanafy Ali"}]}],onlineFirstChaptersFilter:{topicId:"209",limit:6,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},subscriptionForm:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[],offset:8,limit:8,total:0},allSeries:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:141,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:124,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],testimonialsList:[{id:"13",text:"The collaboration with and support of the technical staff of IntechOpen is fantastic. The whole process of submitting an article and editing of the submitted article goes extremely smooth and fast, the number of reads and downloads of chapters is high, and the contributions are also frequently cited.",author:{id:"55578",name:"Antonio",surname:"Jurado-Navas",institutionString:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRisIQAS/Profile_Picture_1626166543950",slug:"antonio-jurado-navas",institution:{id:"720",name:"University of Malaga",country:{id:null,name:"Spain"}}}},{id:"6",text:"It is great to work with the IntechOpen to produce a worthwhile collection of research that also becomes a great educational resource and guide for future research endeavors.",author:{id:"259298",name:"Edward",surname:"Narayan",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/259298/images/system/259298.jpeg",slug:"edward-narayan",institution:{id:"3",name:"University of Queensland",country:{id:null,name:"Australia"}}}}]},series:{item:{id:"10",title:"Physiology",doi:"10.5772/intechopen.72796",issn:"2631-8261",scope:"Modern physiology requires a comprehensive understanding of the integration of tissues and organs throughout the mammalian body, including the cooperation between structure and function at the cellular and molecular levels governed by gene and protein expression. While a daunting task, learning is facilitated by identifying common and effective signaling pathways mediated by a variety of factors employed by nature to preserve and sustain homeostatic life. \r\nAs a leading example, the cellular interaction between intracellular concentration of Ca+2 increases, and changes in plasma membrane potential is integral for coordinating blood flow, governing the exocytosis of neurotransmitters, and modulating gene expression and cell effector secretory functions. Furthermore, in this manner, understanding the systemic interaction between the cardiovascular and nervous systems has become more important than ever as human populations' life prolongation, aging and mechanisms of cellular oxidative signaling are utilised for sustaining life. \r\nAltogether, physiological research enables our identification of distinct and precise points of transition from health to the development of multimorbidity throughout the inevitable aging disorders (e.g., diabetes, hypertension, chronic kidney disease, heart failure, peptic ulcer, inflammatory bowel disease, age-related macular degeneration, cancer). With consideration of all organ systems (e.g., brain, heart, lung, gut, skeletal and smooth muscle, liver, pancreas, kidney, eye) and the interactions thereof, this Physiology Series will address the goals of resolving (1) Aging physiology and chronic disease progression (2) Examination of key cellular pathways as they relate to calcium, oxidative stress, and electrical signaling, and (3) how changes in plasma membrane produced by lipid peroxidation products can affect aging physiology, covering new research in the area of cell, human, plant and animal physiology.",coverUrl:"https://cdn.intechopen.com/series/covers/10.jpg",latestPublicationDate:"July 20th, 2022",hasOnlineFirst:!0,numberOfPublishedBooks:14,editor:{id:"35854",title:"Prof.",name:"Tomasz",middleName:null,surname:"Brzozowski",slug:"tomasz-brzozowski",fullName:"Tomasz Brzozowski",profilePictureURL:"https://mts.intechopen.com/storage/users/35854/images/system/35854.jpg",biography:"Prof. Dr. Thomas Brzozowski works as a professor of Human Physiology and is currently Chairman at the Department of Physiology and is V-Dean of the Medical Faculty at Jagiellonian University Medical College, Cracow, Poland. His primary area of interest is physiology and pathophysiology of the gastrointestinal (GI) tract, with the major focus on the mechanism of GI mucosal defense, protection, and ulcer healing. He was a postdoctoral NIH fellow at the University of California and the Gastroenterology VA Medical Center, Irvine, Long Beach, CA, USA, and at the Gastroenterology Clinics Erlangen-Nuremberg and Munster in Germany. He has published 290 original articles in some of the most prestigious scientific journals and seven book chapters on the pathophysiology of the GI tract, gastroprotection, ulcer healing, drug therapy of peptic ulcers, hormonal regulation of the gut, and inflammatory bowel disease.",institutionString:null,institution:{name:"Jagiellonian University",institutionURL:null,country:{name:"Poland"}}},editorTwo:null,editorThree:null},subseries:{paginationCount:4,paginationItems:[{id:"10",title:"Animal Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/10.jpg",isOpenForSubmission:!0,editor:{id:"202192",title:"Dr.",name:"Catrin",middleName:null,surname:"Rutland",slug:"catrin-rutland",fullName:"Catrin Rutland",profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",biography:"Catrin Rutland is an Associate Professor of Anatomy and Developmental Genetics at the University of Nottingham, UK. She obtained a BSc from the University of Derby, England, a master’s degree from Technische Universität München, Germany, and a Ph.D. from the University of Nottingham. She undertook a post-doctoral research fellowship in the School of Medicine before accepting tenure in Veterinary Medicine and Science. Dr. Rutland also obtained an MMedSci (Medical Education) and a Postgraduate Certificate in Higher Education (PGCHE). She is the author of more than sixty peer-reviewed journal articles, twelve books/book chapters, and more than 100 research abstracts in cardiovascular biology and oncology. She is a board member of the European Association of Veterinary Anatomists, Fellow of the Anatomical Society, and Senior Fellow of the Higher Education Academy. Dr. Rutland has also written popular science books for the public. https://orcid.org/0000-0002-2009-4898. www.nottingham.ac.uk/vet/people/catrin.rutland",institutionString:null,institution:{name:"University of Nottingham",institutionURL:null,country:{name:"United Kingdom"}}},editorTwo:null,editorThree:null},{id:"11",title:"Cell Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/11.jpg",isOpenForSubmission:!0,editor:{id:"133493",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala",profilePictureURL:"https://mts.intechopen.com/storage/users/133493/images/3091_n.jpg",biography:"Prof. Dr. Angel Catalá \r\nShort Biography Angel Catalá was born in Rodeo (San Juan, Argentina). He studied \r\nchemistry at the Universidad Nacional de La Plata, Argentina, where received aPh.D. degree in chemistry (Biological Branch) in 1965. From\r\n1964 to 1974, he worked as Assistant in Biochemistry at the School of MedicineUniversidad Nacional de La Plata, Argentina. From 1974 to 1976, he was a Fellowof the National Institutes of Health (NIH) at the University of Connecticut, Health Center, USA. From 1985 to 2004, he served as a Full Professor oBiochemistry at the Universidad Nacional de La Plata, Argentina. He is Member ofthe National Research Council (CONICET), Argentina, and Argentine Society foBiochemistry and Molecular Biology (SAIB). His laboratory has been interested for manyears in the lipid peroxidation of biological membranes from various tissues and different species. Professor Catalá has directed twelve doctoral theses, publishedover 100 papers in peer reviewed journals, several chapters in books andtwelve edited books. Angel Catalá received awards at the 40th InternationaConference Biochemistry of Lipids 1999: Dijon (France). W inner of the Bimbo PanAmerican Nutrition, Food Science and Technology Award 2006 and 2012, South AmericaHuman Nutrition, Professional Category. 2006 award in pharmacology, Bernardo\r\nHoussay, in recognition of his meritorious works of research. Angel Catalá belongto the Editorial Board of Journal of lipids, International Review of Biophysical ChemistryFrontiers in Membrane Physiology and Biophysics, World Journal oExperimental Medicine and Biochemistry Research International, W orld Journal oBiological Chemistry, Oxidative Medicine and Cellular Longevity, Diabetes and thePancreas, International Journal of Chronic Diseases & Therapy, International Journal oNutrition, Co-Editor of The Open Biology Journal.",institutionString:null,institution:{name:"National University of La Plata",institutionURL:null,country:{name:"Argentina"}}},editorTwo:null,editorThree:null},{id:"12",title:"Human Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/12.jpg",isOpenForSubmission:!0,editor:{id:"195829",title:"Prof.",name:"Kunihiro",middleName:null,surname:"Sakuma",slug:"kunihiro-sakuma",fullName:"Kunihiro Sakuma",profilePictureURL:"https://mts.intechopen.com/storage/users/195829/images/system/195829.jpg",biography:"Professor Kunihiro Sakuma, Ph.D., currently works in the Institute for Liberal Arts at the Tokyo Institute of Technology. He is a physiologist working in the field of skeletal muscle. He was awarded his sports science diploma in 1995 by the University of Tsukuba and began his scientific work at the Department of Physiology, Aichi Human Service Center, focusing on the molecular mechanism of congenital muscular dystrophy and normal muscle regeneration. His interest later turned to the molecular mechanism and attenuating strategy of sarcopenia (age-related muscle atrophy). His opinion is to attenuate sarcopenia by improving autophagic defects using nutrient- and pharmaceutical-based treatments.",institutionString:null,institution:{name:"Tokyo Institute of Technology",institutionURL:null,country:{name:"Japan"}}},editorTwo:{id:"331519",title:"Dr.",name:"Kotomi",middleName:null,surname:"Sakai",slug:"kotomi-sakai",fullName:"Kotomi Sakai",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000031QtFXQA0/Profile_Picture_1637053227318",biography:"Senior researcher Kotomi Sakai, Ph.D., MPH, works at the Research Organization of Science and Technology in Ritsumeikan University. She is a researcher in the geriatric rehabilitation and public health field. She received Ph.D. from Nihon University and MPH from St.Luke’s International University. Her main research interest is sarcopenia in older adults, especially its association with nutritional status. Additionally, to understand how to maintain and improve physical function in older adults, to conduct studies about the mechanism of sarcopenia and determine when possible interventions are needed.",institutionString:null,institution:{name:"Ritsumeikan University",institutionURL:null,country:{name:"Japan"}}},editorThree:null},{id:"13",title:"Plant Physiology",coverUrl:"https://cdn.intechopen.com/series_topics/covers/13.jpg",isOpenForSubmission:!0,editor:{id:"332229",title:"Prof.",name:"Jen-Tsung",middleName:null,surname:"Chen",slug:"jen-tsung-chen",fullName:"Jen-Tsung Chen",profilePictureURL:"https://mts.intechopen.com/storage/users/332229/images/system/332229.png",biography:"Dr. Jen-Tsung Chen is currently a professor at the National University of Kaohsiung, Taiwan. He teaches cell biology, genomics, proteomics, medicinal plant biotechnology, and plant tissue culture. Dr. Chen\\'s research interests include bioactive compounds, chromatography techniques, in vitro culture, medicinal plants, phytochemicals, and plant biotechnology. He has published more than ninety scientific papers and serves as an editorial board member for Plant Methods, Biomolecules, and International Journal of Molecular Sciences.",institutionString:"National University of Kaohsiung",institution:{name:"National University of Kaohsiung",institutionURL:null,country:{name:"Taiwan"}}},editorTwo:null,editorThree:null}]},overviewPageOFChapters:{paginationCount:16,paginationItems:[{id:"82135",title:"Carotenoids in Cassava (Manihot esculenta Crantz)",doi:"10.5772/intechopen.105210",signatures:"Lovina I. Udoh, Josephine U. Agogbua, Eberechi R. Keyagha and Itorobong I. Nkanga",slug:"carotenoids-in-cassava-manihot-esculenta-crantz",totalDownloads:15,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Carotenoids - New Perspectives and Application",coverURL:"https://cdn.intechopen.com/books/images_new/10836.jpg",subseries:{id:"13",title:"Plant Physiology"}}},{id:"82112",title:"Comparative Senescence and Lifespan",doi:"10.5772/intechopen.105137",signatures:"Hassan M. Heshmati",slug:"comparative-senescence-and-lifespan",totalDownloads:17,totalCrossrefCites:0,totalDimensionsCites:0,authors:[{name:"Hassan M.",surname:"Heshmati"}],book:{title:"Mechanisms and Management of Senescence",coverURL:"https://cdn.intechopen.com/books/images_new/10935.jpg",subseries:{id:"11",title:"Cell Physiology"}}},{id:"81796",title:"Apoptosis-Related Diseases and Peroxisomes",doi:"10.5772/intechopen.105052",signatures:"Meimei Wang, Yakun Liu, Ni Chen, Juan Wang and Ye Zhao",slug:"apoptosis-related-diseases-and-peroxisomes",totalDownloads:11,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"The Metabolic Role of Peroxisome in Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/10837.jpg",subseries:{id:"11",title:"Cell Physiology"}}},{id:"81723",title:"Peroxisomal Modulation as Therapeutic Alternative for Tackling Multiple Cancers",doi:"10.5772/intechopen.104873",signatures:"Shazia Usmani, Shadma Wahab, Abdul Hafeez, Shabana Khatoon and Syed Misbahul Hasan",slug:"peroxisomal-modulation-as-therapeutic-alternative-for-tackling-multiple-cancers",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"The Metabolic Role of Peroxisome in Health and Disease",coverURL:"https://cdn.intechopen.com/books/images_new/10837.jpg",subseries:{id:"11",title:"Cell Physiology"}}}]},overviewPagePublishedBooks:{paginationCount:14,paginationItems:[{type:"book",id:"7264",title:"Calcium and Signal Transduction",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/7264.jpg",slug:"calcium-and-signal-transduction",publishedDate:"October 24th 2018",editedByType:"Edited by",bookSignature:"John N. Buchholz and Erik J. Behringer",hash:"e373a3d1123dbd45fddf75d90e3e7c38",volumeInSeries:1,fullTitle:"Calcium and Signal Transduction",editors:[{id:"89438",title:"Dr.",name:"John N.",middleName:null,surname:"Buchholz",slug:"john-n.-buchholz",fullName:"John N. Buchholz",profilePictureURL:"https://mts.intechopen.com/storage/users/89438/images/6463_n.jpg",biography:"Full Professor and Vice Chair, Division of Pharmacology, Loma Linda University, School of Medicine. He received his B.S. Degree in Biology at La Sierra University, Riverside California (1980) and a PhD in Pharmacology from Loma Linda University School of Medicine (1988). Post-Doctoral Fellow at University of California, Irvine, College of Medicine 1989-1992 with a focus on autonomic nerve function in blood vessels and the impact of aging on the function of these nerves and overall blood vessel function. Twenty years of research funding and served on NIH R01 review panels, Editor-In-Chief of Edorium Journal of Aging Research. Serves as a peer reviewer for biomedical journals. Military Reserve Officer serving with the 100 Support Command, 100 Troop Command, 40 Infantry Division, CA National Guard.",institutionString:null,institution:{name:"Loma Linda University",institutionURL:null,country:{name:"United States of America"}}}]},{type:"book",id:"6925",title:"Endoplasmic Reticulum",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6925.jpg",slug:"endoplasmic-reticulum",publishedDate:"April 17th 2019",editedByType:"Edited by",bookSignature:"Angel Català",hash:"a9e90d2dbdbc46128dfe7dac9f87c6b4",volumeInSeries:2,fullTitle:"Endoplasmic Reticulum",editors:[{id:"196544",title:"Prof.",name:"Angel",middleName:null,surname:"Catala",slug:"angel-catala",fullName:"Angel Catala",profilePictureURL:"https://mts.intechopen.com/storage/users/196544/images/system/196544.jpg",biography:"Angel Catalá studied chemistry at Universidad Nacional de La Plata, Argentina, where he received a Ph.D. in Chemistry (Biological Branch) in 1965. From 1964 to 1974, he worked as an Assistant in Biochemistry at the School of Medicine at the same university. From 1974 to 1976, he was a fellow of the National Institutes of Health (NIH) at the University of Connecticut, Health Center, USA. From 1985 to 2004, he served as a Full Professor of Biochemistry at the Universidad Nacional de La Plata. He is a member of the National Research Council (CONICET), Argentina, and the Argentine Society for Biochemistry and Molecular Biology (SAIB). His laboratory has been interested for many years in the lipid peroxidation of biological membranes from various tissues and different species. Dr. Catalá has directed twelve doctoral theses, published more than 100 papers in peer-reviewed journals, several chapters in books, and edited twelve books. He received awards at the 40th International Conference Biochemistry of Lipids 1999 in Dijon, France. He is the winner of the Bimbo Pan-American Nutrition, Food Science and Technology Award 2006 and 2012, South America, Human Nutrition, Professional Category. In 2006, he won the Bernardo Houssay award in pharmacology, in recognition of his meritorious works of research. Dr. Catalá belongs to the editorial board of several journals including Journal of Lipids; International Review of Biophysical Chemistry; Frontiers in Membrane Physiology and Biophysics; World Journal of Experimental Medicine and Biochemistry Research International; World Journal of Biological Chemistry, Diabetes, and the Pancreas; International Journal of Chronic Diseases & Therapy; and International Journal of Nutrition. He is the co-editor of The Open Biology Journal and associate editor for Oxidative Medicine and Cellular Longevity.",institutionString:"Universidad Nacional de La Plata",institution:{name:"National University of La Plata",institutionURL:null,country:{name:"Argentina"}}}]},{type:"book",id:"6924",title:"Adenosine Triphosphate in Health and Disease",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/6924.jpg",slug:"adenosine-triphosphate-in-health-and-disease",publishedDate:"April 24th 2019",editedByType:"Edited by",bookSignature:"Gyula Mozsik",hash:"04106c232a3c68fec07ba7cf00d2522d",volumeInSeries:3,fullTitle:"Adenosine Triphosphate in Health and Disease",editors:[{id:"58390",title:"Dr.",name:"Gyula",middleName:null,surname:"Mozsik",slug:"gyula-mozsik",fullName:"Gyula Mozsik",profilePictureURL:"https://mts.intechopen.com/storage/users/58390/images/system/58390.png",biography:"Gyula Mózsik MD, Ph.D., ScD (med), is an emeritus professor of Medicine at the First Department of Medicine, Univesity of Pécs, Hungary. He was head of this department from 1993 to 2003. His specializations are medicine, gastroenterology, clinical pharmacology, clinical nutrition, and dietetics. His research fields are biochemical pharmacological examinations in the human gastrointestinal (GI) mucosa, mechanisms of retinoids, drugs, capsaicin-sensitive afferent nerves, and innovative pharmacological, pharmaceutical, and nutritional (dietary) research in humans. He has published about 360 peer-reviewed papers, 197 book chapters, 692 abstracts, 19 monographs, and has edited 37 books. He has given about 1120 regular and review lectures. He has organized thirty-eight national and international congresses and symposia. He is the founder of the International Conference on Ulcer Research (ICUR); International Union of Pharmacology, Gastrointestinal Section (IUPHAR-GI); Brain-Gut Society symposiums, and gastrointestinal cytoprotective symposiums. He received the Andre Robert Award from IUPHAR-GI in 2014. Fifteen of his students have been appointed as full professors in Egypt, Cuba, and Hungary.",institutionString:"University of Pécs",institution:{name:"University of Pecs",institutionURL:null,country:{name:"Hungary"}}}]},{type:"book",id:"8008",title:"Antioxidants",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/8008.jpg",slug:"antioxidants",publishedDate:"November 6th 2019",editedByType:"Edited by",bookSignature:"Emad Shalaby",hash:"76361b4061e830906267933c1c670027",volumeInSeries:5,fullTitle:"Antioxidants",editors:[{id:"63600",title:"Prof.",name:"Emad",middleName:null,surname:"Shalaby",slug:"emad-shalaby",fullName:"Emad Shalaby",profilePictureURL:"https://mts.intechopen.com/storage/users/63600/images/system/63600.png",biography:"Dr. Emad Shalaby is a professor of biochemistry on the Biochemistry Department Faculty of Agriculture, Cairo University. He\nreceived a short-term scholarship to carry out his post-doctoral\nstudies abroad, from Japan International Cooperation Agency\n(JICA), in coordination with the Egyptian government. Dr.\nShalaby speaks fluent English and his native Arabic. He has 77\ninternationally published research papers, has attended 15 international conferences, and has contributed to 18 international books and chapters.\nDr. Shalaby works as a reviewer on over one hundred international journals and is\non the editorial board of more than twenty-five international journals. He is a member of seven international specialized scientific societies, besides his local one, and\nhe has won seven prizes.",institutionString:"Cairo University",institution:{name:"Cairo University",institutionURL:null,country:{name:"Egypt"}}}]}]},openForSubmissionBooks:{paginationCount:2,paginationItems:[{id:"11474",title:"Quality of Life Interventions - Magnitude of Effect and Transferability",coverURL:"https://cdn.intechopen.com/books/images_new/11474.jpg",hash:"5a6bcdaf5ee144d043bcdab893ff9e1c",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"July 7th 2022",isOpenForSubmission:!0,editors:[{id:"245319",title:"Ph.D.",name:"Sage",surname:"Arbor",slug:"sage-arbor",fullName:"Sage Arbor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{id:"11473",title:"Social Inequality - Structure and Social Processes",coverURL:"https://cdn.intechopen.com/books/images_new/11473.jpg",hash:"cefab077e403fd1695fb2946e7914942",secondStepPassed:!0,currentStepOfPublishingProcess:3,submissionDeadline:"July 13th 2022",isOpenForSubmission:!0,editors:[{id:"313341",title:"Ph.D.",name:"Yaroslava",surname:"Robles-Bykbaev",slug:"yaroslava-robles-bykbaev",fullName:"Yaroslava Robles-Bykbaev"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},onlineFirstChapters:{paginationCount:49,paginationItems:[{id:"83087",title:"Role of Cellular Responses in Periodontal Tissue Destruction",doi:"10.5772/intechopen.106645",signatures:"Nam Cong-Nhat Huynh",slug:"role-of-cellular-responses-in-periodontal-tissue-destruction",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Periodontology - New Insights",coverURL:"https://cdn.intechopen.com/books/images_new/11566.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"83073",title:"Dental and Orofacial Trauma Impacts on Oral-Health-Related—Quality of Life in Children: Low- and Middle-Income Countries",doi:"10.5772/intechopen.105845",signatures:"Yolanda Malele-Kolisa, Nazia Khan, Mpho P. Molete, Maphefo D. Thekiso and Mzubanzi Mabongo",slug:"dental-and-orofacial-trauma-impacts-on-oral-health-related-quality-of-life-in-children-low-and-middl",totalDownloads:9,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Trauma",coverURL:"https://cdn.intechopen.com/books/images_new/11567.jpg",subseries:{id:"2",title:"Prosthodontics and Implant Dentistry"}}},{id:"82938",title:"Trauma from Occlusion: Practical Management Guidelines",doi:"10.5772/intechopen.105960",signatures:"Prashanth Shetty, Shweta Hegde, Shubham Chelkar, Rahul Chaturvedi, Shruti Pochhi, Aakanksha Shrivastava, Dudala Lakshmi, Shreya Mukherjee, Pankaj Bajaj and Shahzada Asif Raza",slug:"trauma-from-occlusion-practical-management-guidelines",totalDownloads:14,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Trauma",coverURL:"https://cdn.intechopen.com/books/images_new/11567.jpg",subseries:{id:"2",title:"Prosthodontics and Implant Dentistry"}}},{id:"82654",title:"Atraumatic Restorative Treatment: More than a Minimally Invasive Approach?",doi:"10.5772/intechopen.105623",signatures:"Manal A. Ablal",slug:"atraumatic-restorative-treatment-more-than-a-minimally-invasive-approach",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Caries - The Selection of Restoration Methods and Restorative Materials",coverURL:"https://cdn.intechopen.com/books/images_new/11565.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"82608",title:"Early Management of Dental Trauma in the Era of COVID-19",doi:"10.5772/intechopen.105992",signatures:"Khairul Bariah Chi Adam, Haszelini Hassan, Pram Kumar Subramaniam, Izzati Nabilah Ismail, Nor Adilah Harun and Naziyah Shaban Mustafa",slug:"early-management-of-dental-trauma-in-the-era-of-covid-19",totalDownloads:3,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Trauma",coverURL:"https://cdn.intechopen.com/books/images_new/11567.jpg",subseries:{id:"2",title:"Prosthodontics and Implant Dentistry"}}},{id:"82767",title:"Teeth Avulsion",doi:"10.5772/intechopen.105846",signatures:"Manal Abdalla Eltahir, Randa Fath Elrahman Ibrahim and Hanan Alharbi",slug:"teeth-avulsion",totalDownloads:21,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Trauma",coverURL:"https://cdn.intechopen.com/books/images_new/11567.jpg",subseries:{id:"2",title:"Prosthodontics and Implant Dentistry"}}},{id:"82735",title:"The Influence of Salivary pH on the Prevalence of Dental Caries",doi:"10.5772/intechopen.106154",signatures:"Laura-Cristina Rusu, Alexandra Roi, Ciprian-Ioan Roi, Codruta Victoria Tigmeanu and Lavinia Cosmina Ardelean",slug:"the-influence-of-salivary-ph-on-the-prevalence-of-dental-caries",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Caries - The Selection of Restoration Methods and Restorative Materials",coverURL:"https://cdn.intechopen.com/books/images_new/11565.jpg",subseries:{id:"1",title:"Oral Health"}}},{id:"82288",title:"Dental Emergency and Conditions",doi:"10.5772/intechopen.105495",signatures:"Navneet Kaur",slug:"dental-emergency-and-conditions",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Trauma",coverURL:"https://cdn.intechopen.com/books/images_new/11567.jpg",subseries:{id:"2",title:"Prosthodontics and Implant Dentistry"}}},{id:"81961",title:"Antioxidants as an Adjuncts to Periodontal Therapy",doi:"10.5772/intechopen.105016",signatures:"Sura Dakhil Jassim and Ali Abbas Abdulkareem",slug:"antioxidants-as-an-adjuncts-to-periodontal-therapy",totalDownloads:4,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Trauma",coverURL:"https://cdn.intechopen.com/books/images_new/11567.jpg",subseries:{id:"2",title:"Prosthodontics and Implant Dentistry"}}},{id:"82357",title:"Caries Management Aided by Fluorescence-Based Devices",doi:"10.5772/intechopen.105567",signatures:"Atena Galuscan, Daniela Jumanca and Aurora Doris Fratila",slug:"caries-management-aided-by-fluorescence-based-devices",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Dental Caries - The Selection of Restoration Methods and Restorative Materials",coverURL:"https://cdn.intechopen.com/books/images_new/11565.jpg",subseries:{id:"1",title:"Oral Health"}}}]},subseriesFiltersForOFChapters:[{caption:"Prosthodontics and Implant Dentistry",value:2,count:23,group:"subseries"},{caption:"Oral Health",value:1,count:26,group:"subseries"}],publishedBooks:{paginationCount:33,paginationItems:[{type:"book",id:"10840",title:"Benzimidazole",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10840.jpg",slug:"benzimidazole",publishedDate:"July 13th 2022",editedByType:"Edited by",bookSignature:"Pravin Kendrekar and Vinayak Adimule",hash:"e28c770013e7a8dd0fc37aea6aa9def8",volumeInSeries:34,fullTitle:"Benzimidazole",editors:[{id:"310674",title:"Dr.",name:"Pravin",middleName:null,surname:"Kendrekar",slug:"pravin-kendrekar",fullName:"Pravin Kendrekar",profilePictureURL:"https://mts.intechopen.com/storage/users/310674/images/system/310674.jpg",institutionString:"Visiting Scientist at Lipid Nanostructures Laboratory, Centre for Smart Materials, School of Natural Sciences, University of Central Lancashire",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10798",title:"Starch",subtitle:"Evolution and Recent Advances",coverURL:"https://cdn.intechopen.com/books/images_new/10798.jpg",slug:"starch-evolution-and-recent-advances",publishedDate:"June 28th 2022",editedByType:"Edited by",bookSignature:"Martins Ochubiojo Emeje",hash:"f197f6062c1574a9a90e50a369271bcf",volumeInSeries:33,fullTitle:"Starch - Evolution and Recent Advances",editors:[{id:"94311",title:"Prof.",name:"Martins",middleName:"Ochubiojo",surname:"Ochubiojo Emeje",slug:"martins-ochubiojo-emeje",fullName:"Martins Ochubiojo Emeje",profilePictureURL:"https://mts.intechopen.com/storage/users/94311/images/system/94311.jpeg",institutionString:"National Institute for Pharmaceutical Research and Development",institution:{name:"National Institute for Pharmaceutical Research and Development",institutionURL:null,country:{name:"Nigeria"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"11332",title:"Essential Oils",subtitle:"Advances in Extractions and Biological Applications",coverURL:"https://cdn.intechopen.com/books/images_new/11332.jpg",slug:"essential-oils-advances-in-extractions-and-biological-applications",publishedDate:"June 23rd 2022",editedByType:"Edited by",bookSignature:"Mozaniel Santana de Oliveira and Eloisa Helena de Aguiar Andrade",hash:"742e6cae3a35686f975edc8d7f9afa94",volumeInSeries:32,fullTitle:"Essential Oils - Advances in Extractions and Biological Applications",editors:[{id:"195290",title:"Ph.D.",name:"Mozaniel",middleName:null,surname:"Santana De Oliveira",slug:"mozaniel-santana-de-oliveira",fullName:"Mozaniel Santana De Oliveira",profilePictureURL:"https://mts.intechopen.com/storage/users/195290/images/system/195290.png",institutionString:"Museu Paraense Emílio Goeldi",institution:{name:"Museu Paraense Emílio Goeldi",institutionURL:null,country:{name:"Brazil"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10839",title:"Protein Detection",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10839.jpg",slug:"protein-detection",publishedDate:"June 23rd 2022",editedByType:"Edited by",bookSignature:"Yusuf Tutar and Lütfi Tutar",hash:"2f1c0e4e0207fc45c936e7d22a5369c4",volumeInSeries:31,fullTitle:"Protein Detection",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar",profilePictureURL:"https://mts.intechopen.com/storage/users/158492/images/system/158492.jpeg",institutionString:"University of Health Sciences",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10797",title:"Cell Culture",subtitle:"Advanced Technology and Applications in Medical and Life Sciences",coverURL:"https://cdn.intechopen.com/books/images_new/10797.jpg",slug:"cell-culture-advanced-technology-and-applications-in-medical-and-life-sciences",publishedDate:"June 15th 2022",editedByType:"Edited by",bookSignature:"Xianquan Zhan",hash:"2c628f4757f9639a4450728d839a7842",volumeInSeries:30,fullTitle:"Cell Culture - Advanced Technology and Applications in Medical and Life Sciences",editors:[{id:"223233",title:"Prof.",name:"Xianquan",middleName:null,surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan",profilePictureURL:"https://mts.intechopen.com/storage/users/223233/images/system/223233.png",institutionString:"Shandong First Medical University",institution:null}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10841",title:"Hydrolases",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10841.jpg",slug:"hydrolases",publishedDate:"June 15th 2022",editedByType:"Edited by",bookSignature:"Sajjad Haider, Adnan Haider and Angel Catalá",hash:"4e868cde273d65a7ff54b1817d640629",volumeInSeries:29,fullTitle:"Hydrolases",editors:[{id:"110708",title:"Dr.",name:"Sajjad",middleName:null,surname:"Haider",slug:"sajjad-haider",fullName:"Sajjad Haider",profilePictureURL:"https://mts.intechopen.com/storage/users/110708/images/system/110708.png",institutionString:"King Saud University",institution:{name:"King Saud University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10803",title:"Reactive Oxygen Species",subtitle:null,coverURL:"https://cdn.intechopen.com/books/images_new/10803.jpg",slug:"reactive-oxygen-species",publishedDate:"April 28th 2022",editedByType:"Edited by",bookSignature:"Rizwan Ahmad",hash:"176adcf090fdd1f93cb8ce3146e79ca1",volumeInSeries:28,fullTitle:"Reactive Oxygen Species",editors:[{id:"40482",title:null,name:"Rizwan",middleName:null,surname:"Ahmad",slug:"rizwan-ahmad",fullName:"Rizwan Ahmad",profilePictureURL:"https://mts.intechopen.com/storage/users/40482/images/system/40482.jpeg",institutionString:"Imam Abdulrahman Bin Faisal University",institution:{name:"Imam Abdulrahman Bin Faisal University",institutionURL:null,country:{name:"Saudi Arabia"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9008",title:"Vitamin K",subtitle:"Recent Topics on the Biology and Chemistry",coverURL:"https://cdn.intechopen.com/books/images_new/9008.jpg",slug:"vitamin-k-recent-topics-on-the-biology-and-chemistry",publishedDate:"March 23rd 2022",editedByType:"Edited by",bookSignature:"Hiroyuki Kagechika and Hitoshi Shirakawa",hash:"8b43add5389ba85743e0a9491e4b9943",volumeInSeries:27,fullTitle:"Vitamin K - Recent Topics on the Biology and Chemistry",editors:[{id:"180528",title:"Dr.",name:"Hiroyuki",middleName:null,surname:"Kagechika",slug:"hiroyuki-kagechika",fullName:"Hiroyuki Kagechika",profilePictureURL:"https://mts.intechopen.com/storage/users/180528/images/system/180528.jpg",institutionString:"Tokyo Medical and Dental University",institution:{name:"Tokyo Medical and Dental University",institutionURL:null,country:{name:"Japan"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"10799",title:"Phenolic Compounds",subtitle:"Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",coverURL:"https://cdn.intechopen.com/books/images_new/10799.jpg",slug:"phenolic-compounds-chemistry-synthesis-diversity-non-conventional-industrial-pharmaceutical-and-therapeutic-applications",publishedDate:"February 23rd 2022",editedByType:"Edited by",bookSignature:"Farid A. Badria",hash:"339199f254d2987ef3167eef74fb8a38",volumeInSeries:26,fullTitle:"Phenolic Compounds - Chemistry, Synthesis, Diversity, Non-Conventional Industrial, Pharmaceutical and Therapeutic Applications",editors:[{id:"41865",title:"Prof.",name:"Farid A.",middleName:null,surname:"Badria",slug:"farid-a.-badria",fullName:"Farid A. Badria",profilePictureURL:"https://mts.intechopen.com/storage/users/41865/images/system/41865.jpg",institutionString:"Mansoura University",institution:{name:"Mansoura University",institutionURL:null,country:{name:"Egypt"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"9659",title:"Fibroblasts",subtitle:"Advances in Inflammation, Autoimmunity and Cancer",coverURL:"https://cdn.intechopen.com/books/images_new/9659.jpg",slug:"fibroblasts-advances-in-inflammation-autoimmunity-and-cancer",publishedDate:"December 22nd 2021",editedByType:"Edited by",bookSignature:"Mojca Frank Bertoncelj and Katja Lakota",hash:"926fa6446f6befbd363fc74971a56de2",volumeInSeries:25,fullTitle:"Fibroblasts - Advances in Inflammation, Autoimmunity and Cancer",editors:[{id:"328755",title:"Ph.D.",name:"Mojca",middleName:null,surname:"Frank Bertoncelj",slug:"mojca-frank-bertoncelj",fullName:"Mojca Frank Bertoncelj",profilePictureURL:"https://mts.intechopen.com/storage/users/328755/images/system/328755.jpg",institutionString:"BioMed X Institute",institution:{name:"University Hospital of Zurich",institutionURL:null,country:{name:"Switzerland"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8977",title:"Protein Kinases",subtitle:"Promising Targets for Anticancer Drug Research",coverURL:"https://cdn.intechopen.com/books/images_new/8977.jpg",slug:"protein-kinases-promising-targets-for-anticancer-drug-research",publishedDate:"December 8th 2021",editedByType:"Edited by",bookSignature:"Rajesh Kumar Singh",hash:"6d200cc031706a565b554fdb1c478901",volumeInSeries:24,fullTitle:"Protein Kinases - Promising Targets for Anticancer Drug Research",editors:[{id:"329385",title:"Dr.",name:"Rajesh K.",middleName:"Kumar",surname:"Singh",slug:"rajesh-k.-singh",fullName:"Rajesh K. Singh",profilePictureURL:"https://mts.intechopen.com/storage/users/329385/images/system/329385.png",institutionString:"Punjab Technical University",institution:{name:"Punjab Technical University",institutionURL:null,country:{name:"India"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null},{type:"book",id:"8018",title:"Extracellular Matrix",subtitle:"Developments and Therapeutics",coverURL:"https://cdn.intechopen.com/books/images_new/8018.jpg",slug:"extracellular-matrix-developments-and-therapeutics",publishedDate:"October 27th 2021",editedByType:"Edited by",bookSignature:"Rama Sashank Madhurapantula, Joseph Orgel P.R.O. and Zvi Loewy",hash:"c85e82851e80b40282ff9be99ddf2046",volumeInSeries:23,fullTitle:"Extracellular Matrix - Developments and Therapeutics",editors:[{id:"212416",title:"Dr.",name:"Rama Sashank",middleName:null,surname:"Madhurapantula",slug:"rama-sashank-madhurapantula",fullName:"Rama Sashank Madhurapantula",profilePictureURL:"https://mts.intechopen.com/storage/users/212416/images/system/212416.jpg",institutionString:"Illinois Institute of Technology",institution:{name:"Illinois Institute of Technology",institutionURL:null,country:{name:"United States of America"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},subseriesFiltersForPublishedBooks:[{group:"subseries",caption:"Proteomics",value:18,count:4},{group:"subseries",caption:"Metabolism",value:17,count:6},{group:"subseries",caption:"Cell and Molecular Biology",value:14,count:9},{group:"subseries",caption:"Chemical Biology",value:15,count:14}],publicationYearFilters:[{group:"publicationYear",caption:"2022",value:2022,count:9},{group:"publicationYear",caption:"2021",value:2021,count:7},{group:"publicationYear",caption:"2020",value:2020,count:12},{group:"publicationYear",caption:"2019",value:2019,count:3},{group:"publicationYear",caption:"2018",value:2018,count:2}],authors:{paginationCount:148,paginationItems:[{id:"165328",title:"Dr.",name:"Vahid",middleName:null,surname:"Asadpour",slug:"vahid-asadpour",fullName:"Vahid Asadpour",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/165328/images/system/165328.jpg",biography:"Vahid Asadpour, MS, Ph.D., is currently with the Department of Research and Evaluation, Kaiser Permanente Southern California. He has both an MS and Ph.D. in Biomedical Engineering. He was previously a research scientist at the University of California Los Angeles (UCLA) and visiting professor and researcher at the University of North Dakota. He is currently working in artificial intelligence and its applications in medical signal processing. In addition, he is using digital signal processing in medical imaging and speech processing. Dr. Asadpour has developed brain-computer interfacing algorithms and has published books, book chapters, and several journal and conference papers in this field and other areas of intelligent signal processing. He has also designed medical devices, including a laser Doppler monitoring system.",institutionString:"Kaiser Permanente Southern California",institution:null},{id:"169608",title:"Prof.",name:"Marian",middleName:null,surname:"Găiceanu",slug:"marian-gaiceanu",fullName:"Marian Găiceanu",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/169608/images/system/169608.png",biography:"Prof. Dr. Marian Gaiceanu graduated from the Naval and Electrical Engineering Faculty, Dunarea de Jos University of Galati, Romania, in 1997. He received a Ph.D. (Magna Cum Laude) in Electrical Engineering in 2002. Since 2017, Dr. Gaiceanu has been a Ph.D. supervisor for students in Electrical Engineering. He has been employed at Dunarea de Jos University of Galati since 1996, where he is currently a professor. Dr. Gaiceanu is a member of the National Council for Attesting Titles, Diplomas and Certificates, an expert of the Executive Agency for Higher Education, Research Funding, and a member of the Senate of the Dunarea de Jos University of Galati. He has been the head of the Integrated Energy Conversion Systems and Advanced Control of Complex Processes Research Center, Romania, since 2016. He has conducted several projects in power converter systems for electrical drives, power quality, PEM and SOFC fuel cell power converters for utilities, electric vehicles, and marine applications with the Department of Regulation and Control, SIEI S.pA. (2002–2004) and the Polytechnic University of Turin, Italy (2002–2004, 2006–2007). He is a member of the Institute of Electrical and Electronics Engineers (IEEE) and cofounder-member of the IEEE Power Electronics Romanian Chapter. He is a guest editor at Energies and an academic book editor for IntechOpen. He is also a member of the editorial boards of the Journal of Electrical Engineering, Electronics, Control and Computer Science and Sustainability. Dr. Gaiceanu has been General Chairman of the IEEE International Symposium on Electrical and Electronics Engineering in the last six editions.",institutionString:'"Dunarea de Jos" University of Galati',institution:{name:'"Dunarea de Jos" University of Galati',country:{name:"Romania"}}},{id:"4519",title:"Prof.",name:"Jaydip",middleName:null,surname:"Sen",slug:"jaydip-sen",fullName:"Jaydip Sen",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/4519/images/system/4519.jpeg",biography:"Jaydip Sen is associated with Praxis Business School, Kolkata, India, as a professor in the Department of Data Science. His research areas include security and privacy issues in computing and communication, intrusion detection systems, machine learning, deep learning, and artificial intelligence in the financial domain. He has more than 200 publications in reputed international journals, refereed conference proceedings, and 20 book chapters in books published by internationally renowned publishing houses, such as Springer, CRC press, IGI Global, etc. Currently, he is serving on the editorial board of the prestigious journal Frontiers in Communications and Networks and in the technical program committees of a number of high-ranked international conferences organized by the IEEE, USA, and the ACM, USA. He has been listed among the top 2% of scientists in the world for the last three consecutive years, 2019 to 2021 as per studies conducted by the Stanford University, USA.",institutionString:"Praxis Business School",institution:null},{id:"320071",title:"Dr.",name:"Sidra",middleName:null,surname:"Mehtab",slug:"sidra-mehtab",fullName:"Sidra Mehtab",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y00002v6KHoQAM/Profile_Picture_1584512086360",biography:"Sidra Mehtab has completed her BS with honors in Physics from Calcutta University, India in 2018. She has done MS in Data Science and Analytics from Maulana Abul Kalam Azad University of Technology (MAKAUT), Kolkata, India in 2020. Her research areas include Econometrics, Time Series Analysis, Machine Learning, Deep Learning, Artificial Intelligence, and Computer and Network Security with a particular focus on Cyber Security Analytics. Ms. Mehtab has published seven papers in international conferences and one of her papers has been accepted for publication in a reputable international journal. She has won the best paper awards in two prestigious international conferences – BAICONF 2019, and ICADCML 2021, organized in the Indian Institute of Management, Bangalore, India in December 2019, and SOA University, Bhubaneswar, India in January 2021. Besides, Ms. Mehtab has also published two book chapters in two books. Seven of her book chapters will be published in a volume shortly in 2021 by Cambridge Scholars’ Press, UK. Currently, she is working as the joint editor of two edited volumes on Time Series Analysis and Forecasting to be published in the first half of 2021 by an international house. Currently, she is working as a Data Scientist with an MNC in Delhi, India.",institutionString:"NSHM College of Management and Technology",institution:{name:"Association for Computing Machinery",country:{name:"United States of America"}}},{id:"226240",title:"Dr.",name:"Andri Irfan",middleName:null,surname:"Rifai",slug:"andri-irfan-rifai",fullName:"Andri Irfan Rifai",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/226240/images/7412_n.jpg",biography:"Andri IRFAN is a Senior Lecturer of Civil Engineering and Planning. He completed the PhD at the Universitas Indonesia & Universidade do Minho with Sandwich Program Scholarship from the Directorate General of Higher Education and LPDP scholarship. He has been teaching for more than 19 years and much active to applied his knowledge in the project construction in Indonesia. His research interest ranges from pavement management system to advanced data mining techniques for transportation engineering. He has published more than 50 papers in journals and 2 books.",institutionString:null,institution:{name:"Universitas Internasional Batam",country:{name:"Indonesia"}}},{id:"314576",title:"Dr.",name:"Ibai",middleName:null,surname:"Laña",slug:"ibai-lana",fullName:"Ibai Laña",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/314576/images/system/314576.jpg",biography:"Dr. Ibai Laña works at TECNALIA as a data analyst. He received his Ph.D. in Artificial Intelligence from the University of the Basque Country (UPV/EHU), Spain, in 2018. He is currently a senior researcher at TECNALIA. His research interests fall within the intersection of intelligent transportation systems, machine learning, traffic data analysis, and data science. He has dealt with urban traffic forecasting problems, applying machine learning models and evolutionary algorithms. He has experience in origin-destination matrix estimation or point of interest and trajectory detection. Working with large volumes of data has given him a good command of big data processing tools and NoSQL databases. He has also been a visiting scholar at the Knowledge Engineering and Discovery Research Institute, Auckland University of Technology.",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"314575",title:"Dr.",name:"Jesus",middleName:null,surname:"L. Lobo",slug:"jesus-l.-lobo",fullName:"Jesus L. Lobo",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/314575/images/system/314575.png",biography:"Dr. Jesús López is currently based in Bilbao (Spain) working at TECNALIA as Artificial Intelligence Research Scientist. In most cases, a project idea or a new research line needs to be investigated to see if it is good enough to take into production or to focus on it. That is exactly what he does, diving into Machine Learning algorithms and technologies to help TECNALIA to decide whether something is great in theory or will actually impact on the product or processes of its projects. So, he is expert at framing experiments, developing hypotheses, and proving whether they’re true or not, in order to investigate fundamental problems with a longer time horizon. He is also able to design and develop PoCs and system prototypes in simulation. He has participated in several national and internacional R&D projects.\n\nAs another relevant part of his everyday research work, he usually publishes his findings in reputed scientific refereed journals and international conferences, occasionally acting as reviewer and Programme Commitee member. Concretely, since 2018 he has published 9 JCR (8 Q1) journal papers, 9 conference papers (e.g. ECML PKDD 2021), and he has co-edited a book. He is also active in popular science writing data science stories for reputed blogs (KDNuggets, TowardsDataScience, Naukas). Besides, he has recently embarked on mentoring programmes as mentor, and has also worked as data science trainer.",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"103779",title:"Prof.",name:"Yalcin",middleName:null,surname:"Isler",slug:"yalcin-isler",fullName:"Yalcin Isler",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRyQ8QAK/Profile_Picture_1628834958734",biography:"Yalcin Isler (1971 - Burdur / Turkey) received the B.Sc. degree in the Department of Electrical and Electronics Engineering from Anadolu University, Eskisehir, Turkey, in 1993, the M.Sc. degree from the Department of Electronics and Communication Engineering, Suleyman Demirel University, Isparta, Turkey, in 1996, the Ph.D. degree from the Department of Electrical and Electronics Engineering, Dokuz Eylul University, Izmir, Turkey, in 2009, and the Competence of Associate Professorship from the Turkish Interuniversity Council in 2019.\n\nHe was Lecturer at Burdur Vocational School in Suleyman Demirel University (1993-2000, Burdur / Turkey), Software Engineer (2000-2002, Izmir / Turkey), Research Assistant in Bulent Ecevit University (2002-2003, Zonguldak / Turkey), Research Assistant in Dokuz Eylul University (2003-2010, Izmir / Turkey), Assistant Professor at the Department of Electrical and Electronics Engineering in Bulent Ecevit University (2010-2012, Zonguldak / Turkey), Assistant Professor at the Department of Biomedical Engineering in Izmir Katip Celebi University (2012-2019, Izmir / Turkey). He is an Associate Professor at the Department of Biomedical Engineering at Izmir Katip Celebi University, Izmir / Turkey, since 2019. In addition to academics, he has also founded Islerya Medical and Information Technologies Company, Izmir / Turkey, since 2017.\n\nHis main research interests cover biomedical signal processing, pattern recognition, medical device design, programming, and embedded systems. He has many scientific papers and participated in several projects in these study fields. He was an IEEE Student Member (2009-2011) and IEEE Member (2011-2014) and has been IEEE Senior Member since 2014.",institutionString:null,institution:{name:"Izmir Kâtip Çelebi University",country:{name:"Turkey"}}},{id:"339677",title:"Dr.",name:"Mrinmoy",middleName:null,surname:"Roy",slug:"mrinmoy-roy",fullName:"Mrinmoy Roy",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/339677/images/16768_n.jpg",biography:"An accomplished Sales & Marketing professional with 12 years of cross-functional experience in well-known organisations such as CIPLA, LUPIN, GLENMARK, ASTRAZENECA across different segment of Sales & Marketing, International Business, Institutional Business, Product Management, Strategic Marketing of HIV, Oncology, Derma, Respiratory, Anti-Diabetic, Nutraceutical & Stomatological Product Portfolio and Generic as well as Chronic Critical Care Portfolio. A First Class MBA in International Business & Strategic Marketing, B.Pharm, D.Pharm, Google Certified Digital Marketing Professional. Qualified PhD Candidate in Operations and Management with special focus on Artificial Intelligence and Machine Learning adoption, analysis and use in Healthcare, Hospital & Pharma Domain. Seasoned with diverse therapy area of Pharmaceutical Sales & Marketing ranging from generating revenue through generating prescriptions, launching new products, and making them big brands with continuous strategy execution at the Physician and Patients level. Moved from Sales to Marketing and Business Development for 3.5 years in South East Asian Market operating from Manila, Philippines. Came back to India and handled and developed Brands such as Gluconorm, Lupisulin, Supracal, Absolut Woman, Hemozink, Fabiflu (For COVID 19), and many more. In my previous assignment I used to develop and execute strategies on Sales & Marketing, Commercialization & Business Development for Institution and Corporate Hospital Business portfolio of Oncology Therapy Area for AstraZeneca Pharma India Ltd. Being a Research Scholar and Student of ‘Operations Research & Management: Artificial Intelligence’ I published several pioneer research papers and book chapters on the same in Internationally reputed journals and Books indexed in Scopus, Springer and Ei Compendex, Google Scholar etc. Currently, I am launching PGDM Pharmaceutical Management Program in IIHMR Bangalore and spearheading the course curriculum and structure of the same. I am interested in Collaboration for Healthcare Innovation, Pharma AI Innovation, Future trend in Marketing and Management with incubation on Healthcare, Healthcare IT startups, AI-ML Modelling and Healthcare Algorithm based training module development. I am also an affiliated member of the Institute of Management Consultant of India, looking forward to Healthcare, Healthcare IT and Innovation, Pharma and Hospital Management Consulting works.",institutionString:null,institution:{name:"Lovely Professional University",country:{name:"India"}}},{id:"310576",title:"Prof.",name:"Erick Giovani",middleName:null,surname:"Sperandio Nascimento",slug:"erick-giovani-sperandio-nascimento",fullName:"Erick Giovani Sperandio Nascimento",position:null,profilePictureURL:"https://intech-files.s3.amazonaws.com/0033Y00002pDKxDQAW/ProfilePicture%202022-06-20%2019%3A57%3A24.788",biography:"Prof. Erick Sperandio is the Lead Researcher and professor of Artificial Intelligence (AI) at SENAI CIMATEC, Bahia, Brazil, also working with Computational Modeling (CM) and HPC. He holds a PhD in Environmental Engineering in the area of Atmospheric Computational Modeling, a Master in Informatics in the field of Computational Intelligence and Graduated in Computer Science from UFES. He currently coordinates, leads and participates in R&D projects in the areas of AI, computational modeling and supercomputing applied to different areas such as Oil and Gas, Health, Advanced Manufacturing, Renewable Energies and Atmospheric Sciences, advising undergraduate, master's and doctoral students. He is the Lead Researcher at SENAI CIMATEC's Reference Center on Artificial Intelligence. In addition, he is a Certified Instructor and University Ambassador of the NVIDIA Deep Learning Institute (DLI) in the areas of Deep Learning, Computer Vision, Natural Language Processing and Recommender Systems, and Principal Investigator of the NVIDIA/CIMATEC AI Joint Lab, the first in Latin America within the NVIDIA AI Technology Center (NVAITC) worldwide program. He also works as a researcher at the Supercomputing Center for Industrial Innovation (CS2i) and at the SENAI Institute of Innovation for Automation (ISI Automação), both from SENAI CIMATEC. He is a member and vice-coordinator of the Basic Board of Scientific-Technological Advice and Evaluation, in the area of Innovation, of the Foundation for Research Support of the State of Bahia (FAPESB). He serves as Technology Transfer Coordinator and one of the Principal Investigators at the National Applied Research Center in Artificial Intelligence (CPA-IA) of SENAI CIMATEC, focusing on Industry, being one of the six CPA-IA in Brazil approved by MCTI / FAPESP / CGI.br. He also participates as one of the representatives of Brazil in the BRICS Innovation Collaboration Working Group on HPC, ICT and AI. He is the coordinator of the Work Group of the Axis 5 - Workforce and Training - of the Brazilian Strategy for Artificial Intelligence (EBIA), and member of the MCTI/EMBRAPII AI Innovation Network Training Committee. He is the coordinator, by SENAI CIMATEC, of the Artificial Intelligence Reference Network of the State of Bahia (REDE BAH.IA). He leads the working group of experts representing Brazil in the Global Partnership on Artificial Intelligence (GPAI), on the theme \"AI and the Pandemic Response\".",institutionString:"Manufacturing and Technology Integrated Campus – SENAI CIMATEC",institution:null},{id:"1063",title:"Prof.",name:"Constantin",middleName:null,surname:"Volosencu",slug:"constantin-volosencu",fullName:"Constantin Volosencu",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/1063/images/system/1063.png",biography:"Prof. Dr. Constantin Voloşencu graduated as an engineer from\nPolitehnica University of Timișoara, Romania, where he also\nobtained a doctorate degree. He is currently a full professor in\nthe Department of Automation and Applied Informatics at the\nsame university. Dr. Voloşencu is the author of ten books, seven\nbook chapters, and more than 160 papers published in journals\nand conference proceedings. He has also edited twelve books and\nhas twenty-seven patents to his name. He is a manager of research grants, editor in\nchief and member of international journal editorial boards, a former plenary speaker, a member of scientific committees, and chair at international conferences. His\nresearch is in the fields of control systems, control of electric drives, fuzzy control\nsystems, neural network applications, fault detection and diagnosis, sensor network\napplications, monitoring of distributed parameter systems, and power ultrasound\napplications. He has developed automation equipment for machine tools, spooling\nmachines, high-power ultrasound processes, and more.",institutionString:'"Politechnica" University Timişoara',institution:null},{id:"221364",title:"Dr.",name:"Eneko",middleName:null,surname:"Osaba",slug:"eneko-osaba",fullName:"Eneko Osaba",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/221364/images/system/221364.jpg",biography:"Dr. Eneko Osaba works at TECNALIA as a senior researcher. He obtained his Ph.D. in Artificial Intelligence in 2015. He has participated in more than twenty-five local and European research projects, and in the publication of more than 130 papers. He has performed several stays at universities in the United Kingdom, Italy, and Malta. Dr. Osaba has served as a program committee member in more than forty international conferences and participated in organizing activities in more than ten international conferences. He is a member of the editorial board of the International Journal of Artificial Intelligence, Data in Brief, and Journal of Advanced Transportation. He is also a guest editor for the Journal of Computational Science, Neurocomputing, Swarm, and Evolutionary Computation and IEEE ITS Magazine.",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"275829",title:"Dr.",name:"Esther",middleName:null,surname:"Villar-Rodriguez",slug:"esther-villar-rodriguez",fullName:"Esther Villar-Rodriguez",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/275829/images/system/275829.jpg",biography:"Dr. Esther Villar obtained a Ph.D. in Information and Communication Technologies from the University of Alcalá, Spain, in 2015. She obtained a degree in Computer Science from the University of Deusto, Spain, in 2010, and an MSc in Computer Languages and Systems from the National University of Distance Education, Spain, in 2012. Her areas of interest and knowledge include natural language processing (NLP), detection of impersonation in social networks, semantic web, and machine learning. Dr. Esther Villar made several contributions at conferences and publishing in various journals in those fields. Currently, she is working within the OPTIMA (Optimization Modeling & Analytics) business of TECNALIA’s ICT Division as a data scientist in projects related to the prediction and optimization of management and industrial processes (resource planning, energy efficiency, etc).",institutionString:"TECNALIA Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"49813",title:"Dr.",name:"Javier",middleName:null,surname:"Del Ser",slug:"javier-del-ser",fullName:"Javier Del Ser",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/49813/images/system/49813.png",biography:"Prof. Dr. Javier Del Ser received his first PhD in Telecommunication Engineering (Cum Laude) from the University of Navarra, Spain, in 2006, and a second PhD in Computational Intelligence (Summa Cum Laude) from the University of Alcala, Spain, in 2013. He is currently a principal researcher in data analytics and optimisation at TECNALIA (Spain), a visiting fellow at the Basque Center for Applied Mathematics (BCAM) and a part-time lecturer at the University of the Basque Country (UPV/EHU). His research interests gravitate on the use of descriptive, prescriptive and predictive algorithms for data mining and optimization in a diverse range of application fields such as Energy, Transport, Telecommunications, Health and Industry, among others. In these fields he has published more than 240 articles, co-supervised 8 Ph.D. theses, edited 6 books, coauthored 7 patents and participated/led more than 40 research projects. He is a Senior Member of the IEEE, and a recipient of the Biscay Talent prize for his academic career.",institutionString:"Tecnalia Research & Innovation",institution:{name:"Tecnalia",country:{name:"Spain"}}},{id:"278948",title:"Dr.",name:"Carlos Pedro",middleName:null,surname:"Gonçalves",slug:"carlos-pedro-goncalves",fullName:"Carlos Pedro Gonçalves",position:null,profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRcmyQAC/Profile_Picture_1564224512145",biography:'Carlos Pedro Gonçalves (PhD) is an Associate Professor at Lusophone University of Humanities and Technologies and a researcher on Complexity Sciences, Quantum Technologies, Artificial Intelligence, Strategic Studies, Studies in Intelligence and Security, FinTech and Financial Risk Modeling. He is also a progammer with programming experience in:\n\nA) Quantum Computing using Qiskit Python module and IBM Quantum Experience Platform, with software developed on the simulation of Quantum Artificial Neural Networks and Quantum Cybersecurity;\n\nB) Artificial Intelligence and Machine learning programming in Python;\n\nC) Artificial Intelligence, Multiagent Systems Modeling and System Dynamics Modeling in Netlogo, with models developed in the areas of Chaos Theory, Econophysics, Artificial Intelligence, Classical and Quantum Complex Systems Science, with the Econophysics models having been cited worldwide and incorporated in PhD programs by different Universities.\n\nReceived an Arctic Code Vault Contributor status by GitHub, due to having developed open source software preserved in the \\"Arctic Code Vault\\" for future generations (https://archiveprogram.github.com/arctic-vault/), with the Strategy Analyzer A.I. module for decision making support (based on his PhD thesis, used in his Classes on Decision Making and in Strategic Intelligence Consulting Activities) and QNeural Python Quantum Neural Network simulator also preserved in the \\"Arctic Code Vault\\", for access to these software modules see: https://github.com/cpgoncalves. He is also a peer reviewer with outsanding review status from Elsevier journals, including Physica A, Neurocomputing and Engineering Applications of Artificial Intelligence. Science CV available at: https://www.cienciavitae.pt//pt/8E1C-A8B3-78C5 and ORCID: https://orcid.org/0000-0002-0298-3974',institutionString:"University of Lisbon",institution:{name:"Universidade Lusófona",country:{name:"Portugal"}}},{id:"241400",title:"Prof.",name:"Mohammed",middleName:null,surname:"Bsiss",slug:"mohammed-bsiss",fullName:"Mohammed Bsiss",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/241400/images/8062_n.jpg",biography:null,institutionString:null,institution:null},{id:"276128",title:"Dr.",name:"Hira",middleName:null,surname:"Fatima",slug:"hira-fatima",fullName:"Hira Fatima",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/276128/images/14420_n.jpg",biography:"Dr. Hira Fatima\nAssistant Professor\nDepartment of Mathematics\nInstitute of Applied Science\nMangalayatan University, Aligarh\nMobile: no : 8532041179\nhirafatima2014@gmal.com\n\nDr. Hira Fatima has received his Ph.D. degree in pure Mathematics from Aligarh Muslim University, Aligarh India. Currently working as an Assistant Professor in the Department of Mathematics, Institute of Applied Science, Mangalayatan University, Aligarh. She taught so many courses of Mathematics of UG and PG level. Her research Area of Expertise is Functional Analysis & Sequence Spaces. She has been working on Ideal Convergence of double sequence. She has published 17 research papers in National and International Journals including Cogent Mathematics, Filomat, Journal of Intelligent and Fuzzy Systems, Advances in Difference Equations, Journal of Mathematical Analysis, Journal of Mathematical & Computer Science etc. She has also reviewed few research papers for the and international journals. She is a member of Indian Mathematical Society.",institutionString:null,institution:null},{id:"414880",title:"Dr.",name:"Maryam",middleName:null,surname:"Vatankhah",slug:"maryam-vatankhah",fullName:"Maryam Vatankhah",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Borough of Manhattan Community College",country:{name:"United States of America"}}},{id:"414879",title:"Prof.",name:"Mohammad-Reza",middleName:null,surname:"Akbarzadeh-Totonchi",slug:"mohammad-reza-akbarzadeh-totonchi",fullName:"Mohammad-Reza Akbarzadeh-Totonchi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Ferdowsi University of Mashhad",country:{name:"Iran"}}},{id:"414878",title:"Prof.",name:"Reza",middleName:null,surname:"Fazel-Rezai",slug:"reza-fazel-rezai",fullName:"Reza Fazel-Rezai",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"American Public University System",country:{name:"United States of America"}}},{id:"426586",title:"Dr.",name:"Oladunni A.",middleName:null,surname:"Daramola",slug:"oladunni-a.-daramola",fullName:"Oladunni A. Daramola",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Federal University of Technology",country:{name:"Nigeria"}}},{id:"357014",title:"Prof.",name:"Leon",middleName:null,surname:"Bobrowski",slug:"leon-bobrowski",fullName:"Leon Bobrowski",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Bialystok University of Technology",country:{name:"Poland"}}},{id:"302698",title:"Dr.",name:"Yao",middleName:null,surname:"Shan",slug:"yao-shan",fullName:"Yao Shan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Dalian University of Technology",country:{name:"China"}}},{id:"354126",title:"Dr.",name:"Setiawan",middleName:null,surname:"Hadi",slug:"setiawan-hadi",fullName:"Setiawan Hadi",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Padjadjaran University",country:{name:"Indonesia"}}},{id:"125911",title:"Prof.",name:"Jia-Ching",middleName:null,surname:"Wang",slug:"jia-ching-wang",fullName:"Jia-Ching Wang",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"National Central University",country:{name:"Taiwan"}}},{id:"332603",title:"Prof.",name:"Kumar S.",middleName:null,surname:"Ray",slug:"kumar-s.-ray",fullName:"Kumar S. Ray",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Statistical Institute",country:{name:"India"}}},{id:"415409",title:"Prof.",name:"Maghsoud",middleName:null,surname:"Amiri",slug:"maghsoud-amiri",fullName:"Maghsoud Amiri",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Allameh Tabataba'i University",country:{name:"Iran"}}},{id:"357085",title:"Mr.",name:"P. Mohan",middleName:null,surname:"Anand",slug:"p.-mohan-anand",fullName:"P. Mohan Anand",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Institute of Technology Kanpur",country:{name:"India"}}},{id:"356696",title:"Ph.D. Student",name:"P.V.",middleName:null,surname:"Sai Charan",slug:"p.v.-sai-charan",fullName:"P.V. Sai Charan",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Institute of Technology Kanpur",country:{name:"India"}}},{id:"357086",title:"Prof.",name:"Sandeep K.",middleName:null,surname:"Shukla",slug:"sandeep-k.-shukla",fullName:"Sandeep K. Shukla",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Indian Institute of Technology Kanpur",country:{name:"India"}}}]}},subseries:{item:{id:"14",type:"subseries",title:"Cell and Molecular Biology",keywords:"Omics (Transcriptomics; Proteomics; Metabolomics), Molecular Biology, Cell Biology, Signal Transduction and Regulation, Cell Growth and Differentiation, Apoptosis, Necroptosis, Ferroptosis, Autophagy, Cell Cycle, Macromolecules and Complexes, Gene Expression",scope:"The Cell and Molecular Biology topic within the IntechOpen Biochemistry Series aims to rapidly publish contributions on all aspects of cell and molecular biology, including aspects related to biochemical and genetic research (not only in humans but all living beings). We encourage the submission of manuscripts that provide novel and mechanistic insights that report significant advances in the fields. Topics include, but are not limited to: Advanced techniques of cellular and molecular biology (Molecular methodologies, imaging techniques, and bioinformatics); Biological activities at the molecular level; Biological processes of cell functions, cell division, senescence, maintenance, and cell death; Biomolecules interactions; Cancer; Cell biology; Chemical biology; Computational biology; Cytochemistry; Developmental biology; Disease mechanisms and therapeutics; DNA, and RNA metabolism; Gene functions, genetics, and genomics; Genetics; Immunology; Medical microbiology; Molecular biology; Molecular genetics; Molecular processes of cell and organelle dynamics; Neuroscience; Protein biosynthesis, degradation, and functions; Regulation of molecular interactions in a cell; Signalling networks and system biology; Structural biology; Virology and microbiology.",coverUrl:"https://cdn.intechopen.com/series_topics/covers/14.jpg",hasOnlineFirst:!0,hasPublishedBooks:!0,annualVolume:11410,editor:{id:"165627",title:"Dr.",name:"Rosa María",middleName:null,surname:"Martínez-Espinosa",slug:"rosa-maria-martinez-espinosa",fullName:"Rosa María Martínez-Espinosa",profilePictureURL:"https://mts.intechopen.com/storage/users/165627/images/system/165627.jpeg",biography:"Dr. Rosa María Martínez-Espinosa has been a Spanish Full Professor since 2020 (Biochemistry and Molecular Biology) and is currently Vice-President of International Relations and Cooperation development and leader of the research group 'Applied Biochemistry” (University of Alicante, Spain). Other positions she has held at the university include Vice-Dean of Master Programs, Vice-Dean of the Degree in Biology and Vice-Dean for Mobility and Enterprise and Engagement at the Faculty of Science (University of Alicante). She received her Bachelor in Biology in 1998 (University of Alicante) and her PhD in 2003 (Biochemistry, University of Alicante). She undertook post-doctoral research at the University of East Anglia (Norwich, U.K. 2004-2005; 2007-2008).\nHer multidisciplinary research focuses on investigating archaea and their potential applications in biotechnology. She has an H-index of 21. She has authored one patent and has published more than 70 indexed papers and around 60 book chapters.\nShe has contributed to more than 150 national and international meetings during the last 15 years. Her research interests include archaea metabolism, enzymes purification and characterization, gene regulation, carotenoids and bioplastics production, antioxidant\ncompounds, waste water treatments, and brines bioremediation.\nRosa María’s other roles include editorial board member for several journals related\nto biochemistry, reviewer for more than 60 journals (biochemistry, molecular biology, biotechnology, chemistry and microbiology) and president of several organizing committees in international meetings related to the N-cycle or respiratory processes.",institutionString:null,institution:{name:"University of Alicante",institutionURL:null,country:{name:"Spain"}}},editorTwo:null,editorThree:null,series:{id:"11",title:"Biochemistry",doi:"10.5772/intechopen.72877",issn:"2632-0983"},editorialBoard:[{id:"79367",title:"Dr.",name:"Ana Isabel",middleName:null,surname:"Flores",slug:"ana-isabel-flores",fullName:"Ana Isabel Flores",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bRpIOQA0/Profile_Picture_1632418099564",institutionString:null,institution:{name:"Hospital Universitario 12 De Octubre",institutionURL:null,country:{name:"Spain"}}},{id:"328234",title:"Ph.D.",name:"Christian",middleName:null,surname:"Palavecino",slug:"christian-palavecino",fullName:"Christian Palavecino",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000030DhEhQAK/Profile_Picture_1628835318625",institutionString:null,institution:{name:"Central University of Chile",institutionURL:null,country:{name:"Chile"}}},{id:"186585",title:"Dr.",name:"Francisco Javier",middleName:null,surname:"Martin-Romero",slug:"francisco-javier-martin-romero",fullName:"Francisco Javier Martin-Romero",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0030O00002bSB3HQAW/Profile_Picture_1631258137641",institutionString:null,institution:{name:"University of Extremadura",institutionURL:null,country:{name:"Spain"}}}]},onlineFirstChapters:{paginationCount:17,paginationItems:[{id:"82751",title:"Mitochondria-Endoplasmic Reticulum Interaction in Central Neurons",doi:"10.5772/intechopen.105738",signatures:"Liliya Kushnireva and Eduard Korkotian",slug:"mitochondria-endoplasmic-reticulum-interaction-in-central-neurons",totalDownloads:6,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Updates on Endoplasmic Reticulum",coverURL:"https://cdn.intechopen.com/books/images_new/11674.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"82716",title:"Advanced glycation end product induced endothelial dysfunction through ER stress: Unravelling the role of Paraoxonase 2",doi:"10.5772/intechopen.106018",signatures:"Ramya Ravi and Bharathidevi Subramaniam Rajesh",slug:"advanced-glycation-end-product-induced-endothelial-dysfunction-through-er-stress-unravelling-the-rol",totalDownloads:15,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Updates on Endoplasmic Reticulum",coverURL:"https://cdn.intechopen.com/books/images_new/11674.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"82195",title:"Endoplasmic Reticulum: A Hub in Lipid Homeostasis",doi:"10.5772/intechopen.105450",signatures:"Raúl Ventura and María Isabel Hernández-Alvarez",slug:"endoplasmic-reticulum-a-hub-in-lipid-homeostasis",totalDownloads:17,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Updates on Endoplasmic Reticulum",coverURL:"https://cdn.intechopen.com/books/images_new/11674.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"82103",title:"The Role of Endoplasmic Reticulum Stress and Its Regulation in the Progression of Neurological and Infectious Diseases",doi:"10.5772/intechopen.105543",signatures:"Mary Dover, Michael Kishek, Miranda Eddins, Naneeta Desar, Ketema Paul and Milan Fiala",slug:"the-role-of-endoplasmic-reticulum-stress-and-its-regulation-in-the-progression-of-neurological-and-i",totalDownloads:15,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Updates on Endoplasmic Reticulum",coverURL:"https://cdn.intechopen.com/books/images_new/11674.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"80954",title:"Ion Channels and Neurodegenerative Disease Aging Related",doi:"10.5772/intechopen.103074",signatures:"Marika Cordaro, Salvatore Cuzzocrea and Rosanna Di Paola",slug:"ion-channels-and-neurodegenerative-disease-aging-related",totalDownloads:12,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"81647",title:"Diabetes and Epigenetics",doi:"10.5772/intechopen.104653",signatures:"Rasha A. Alhazzaa, Thomas Heinbockel and Antonei B. Csoka",slug:"diabetes-and-epigenetics",totalDownloads:58,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"81099",title:"SK Channels and Heart Disease",doi:"10.5772/intechopen.104115",signatures:"Katherine Zhong, Shawn Kant, Frank Sellke and Jun Feng",slug:"sk-channels-and-heart-disease",totalDownloads:26,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"80967",title:"Hot on the Trail of Skin Inflammation: Focus on TRPV1/TRPV3 Channels in Psoriasis",doi:"10.5772/intechopen.103792",signatures:"Lisa S. Martin, Emma Fraillon, Fabien P. Chevalier and Bérengère Fromy",slug:"hot-on-the-trail-of-skin-inflammation-focus-on-trpv1-trpv3-channels-in-psoriasis",totalDownloads:55,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"80952",title:"TRPV Family Ion Channels in the Mammary Epithelium: Role in Normal Tissue Homeostasis and along Breast Cancer Progression",doi:"10.5772/intechopen.103665",signatures:"Sari Susanna Tojkander",slug:"trpv-family-ion-channels-in-the-mammary-epithelium-role-in-normal-tissue-homeostasis-and-along-breas",totalDownloads:24,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"80157",title:"Structural Determinants for Ligand Accommodation in Voltage Sensors",doi:"10.5772/intechopen.102094",signatures:"Abigail García-Morales, Aylin López-Palestino and Daniel Balleza",slug:"structural-determinants-for-ligand-accommodation-in-voltage-sensors",totalDownloads:110,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"79690",title:"Mitochondrial Channels and their Role in Cardioprotection",doi:"10.5772/intechopen.101127",signatures:"Keerti Mishra and Min Luo",slug:"mitochondrial-channels-and-their-role-in-cardioprotection",totalDownloads:114,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Ion Channels - From Basic Properties to Medical Treatment",coverURL:"https://cdn.intechopen.com/books/images_new/10838.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"78415",title:"Epigenetic",doi:"10.5772/intechopen.99964",signatures:"Mehmet Ünal",slug:"epigenetic",totalDownloads:153,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"77443",title:"Cyanobacterial Phytochromes in Optogenetics",doi:"10.5772/intechopen.97522",signatures:"Sivasankari Sivaprakasam, Vinoth Mani, Nagalakshmi Balasubramaniyan and David Ravindran Abraham",slug:"cyanobacterial-phytochromes-in-optogenetics",totalDownloads:210,totalCrossrefCites:0,totalDimensionsCites:1,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"75979",title:"Spatiotemporal Regulation of Cell–Cell Adhesions",doi:"10.5772/intechopen.97009",signatures:"Brent M. Bijonowski",slug:"spatiotemporal-regulation-of-cell-cell-adhesions",totalDownloads:185,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"76646",title:"Functional Mechanism of Proton Pump-Type Rhodopsins Found in Various Microorganisms as a Potential Effective Tool in Optogenetics",doi:"10.5772/intechopen.97589",signatures:"Jun Tamogami and Takashi Kikukawa",slug:"functional-mechanism-of-proton-pump-type-rhodopsins-found-in-various-microorganisms-as-a-potential-e",totalDownloads:240,totalCrossrefCites:0,totalDimensionsCites:0,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}},{id:"76510",title:"Evolution of Epigenome as the Blueprint for Carcinogenesis",doi:"10.5772/intechopen.97379",signatures:"Zeenat Farooq, Ambreen Shah, Mohammad Tauseef, Riyaz Ahmad Rather and Mumtaz Anwar",slug:"evolution-of-epigenome-as-the-blueprint-for-carcinogenesis",totalDownloads:205,totalCrossrefCites:2,totalDimensionsCites:1,authors:null,book:{title:"Epigenetics to Optogenetics - A New Paradigm in the Study of Biology",coverURL:"https://cdn.intechopen.com/books/images_new/9672.jpg",subseries:{id:"14",title:"Cell and Molecular Biology"}}}]},publishedBooks:{paginationCount:1,paginationItems:[{type:"book",id:"11392",title:"Leadership in a Changing World",subtitle:"A Multidimensional Perspective",coverURL:"https://cdn.intechopen.com/books/images_new/11392.jpg",slug:"leadership-in-a-changing-world-a-multidimensional-perspective",publishedDate:"May 11th 2022",editedByType:"Edited by",bookSignature:"Muhammad Mohiuddin, Bilal Khalid, Md. Samim Al Azad and Slimane Ed-dafali",hash:"86a6d33cf601587e591064ce92effc02",volumeInSeries:1,fullTitle:"Leadership in a Changing World - A Multidimensional Perspective",editors:[{id:"418514",title:"Dr.",name:"Muhammad",middleName:null,surname:"Mohiuddin",slug:"muhammad-mohiuddin",fullName:"Muhammad Mohiuddin",profilePictureURL:"https://s3.us-east-1.amazonaws.com/intech-files/0033Y000038UqSfQAK/Profile_Picture_2022-05-13T10:39:03.jpg",institutionString:"Université Laval",institution:{name:"Université Laval",institutionURL:null,country:{name:"Canada"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null}]},testimonialsList:[{id:"27",text:"The opportunity to work with a prestigious publisher allows for the possibility to collaborate with more research groups interested in animal nutrition, leading to the development of new feeding strategies and food valuation while being more sustainable with the environment, allowing more readers to learn about the subject.",author:{id:"175967",name:"Manuel",surname:"Gonzalez Ronquillo",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/175967/images/system/175967.png",slug:"manuel-gonzalez-ronquillo",institution:{id:"6221",name:"Universidad Autónoma del Estado de México",country:{id:null,name:"Mexico"}}}},{id:"18",text:"It was great publishing with IntechOpen, the process was straightforward and I had support all along.",author:{id:"71579",name:"Berend",surname:"Olivier",institutionString:"Utrecht University",profilePictureURL:"https://mts.intechopen.com/storage/users/71579/images/system/71579.png",slug:"berend-olivier",institution:{id:"253",name:"Utrecht University",country:{id:null,name:"Netherlands"}}}},{id:"8",text:"I work with IntechOpen for a number of reasons: their professionalism, their mission in support of Open Access publishing, and the quality of their peer-reviewed publications, but also because they believe in equality.",author:{id:"202192",name:"Catrin",surname:"Rutland",institutionString:null,profilePictureURL:"https://mts.intechopen.com/storage/users/202192/images/system/202192.png",slug:"catrin-rutland",institution:{id:"134",name:"University of Nottingham",country:{id:null,name:"United Kingdom"}}}}]},submityourwork:{pteSeriesList:[{id:"14",title:"Artificial Intelligence",numberOfPublishedBooks:9,numberOfPublishedChapters:90,numberOfOpenTopics:6,numberOfUpcomingTopics:0,issn:"2633-1403",doi:"10.5772/intechopen.79920",isOpenForSubmission:!0},{id:"7",title:"Biomedical Engineering",numberOfPublishedBooks:12,numberOfPublishedChapters:108,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2631-5343",doi:"10.5772/intechopen.71985",isOpenForSubmission:!0}],lsSeriesList:[{id:"11",title:"Biochemistry",numberOfPublishedBooks:33,numberOfPublishedChapters:330,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2632-0983",doi:"10.5772/intechopen.72877",isOpenForSubmission:!0},{id:"25",title:"Environmental Sciences",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2754-6713",doi:"10.5772/intechopen.100362",isOpenForSubmission:!0},{id:"10",title:"Physiology",numberOfPublishedBooks:14,numberOfPublishedChapters:145,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-8261",doi:"10.5772/intechopen.72796",isOpenForSubmission:!0}],hsSeriesList:[{id:"3",title:"Dentistry",numberOfPublishedBooks:9,numberOfPublishedChapters:141,numberOfOpenTopics:2,numberOfUpcomingTopics:0,issn:"2631-6218",doi:"10.5772/intechopen.71199",isOpenForSubmission:!0},{id:"6",title:"Infectious Diseases",numberOfPublishedBooks:13,numberOfPublishedChapters:124,numberOfOpenTopics:4,numberOfUpcomingTopics:0,issn:"2631-6188",doi:"10.5772/intechopen.71852",isOpenForSubmission:!0},{id:"13",title:"Veterinary Medicine and Science",numberOfPublishedBooks:11,numberOfPublishedChapters:112,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2632-0517",doi:"10.5772/intechopen.73681",isOpenForSubmission:!0}],sshSeriesList:[{id:"22",title:"Business, Management and Economics",numberOfPublishedBooks:1,numberOfPublishedChapters:22,numberOfOpenTopics:3,numberOfUpcomingTopics:0,issn:"2753-894X",doi:"10.5772/intechopen.100359",isOpenForSubmission:!0},{id:"23",title:"Education and Human Development",numberOfPublishedBooks:0,numberOfPublishedChapters:11,numberOfOpenTopics:1,numberOfUpcomingTopics:1,issn:null,doi:"10.5772/intechopen.100360",isOpenForSubmission:!0},{id:"24",title:"Sustainable Development",numberOfPublishedBooks:1,numberOfPublishedChapters:19,numberOfOpenTopics:5,numberOfUpcomingTopics:0,issn:"2753-6580",doi:"10.5772/intechopen.100361",isOpenForSubmission:!0}],subseriesList:[{id:"3",title:"Bacterial Infectious Diseases",scope:"